

327938
STIC-EIC1600/2900

From: STIC-EIC1600/2900@uspto.gov
Sent: Sunday, April 11, 2010 6:23 PM
To: Kantamneni, Shobha
Cc: STIC-EIC1600/2900
Subject: Confirmation Receipt: 1600 Search Request - 10/675927

This is an automated email confirming that your 1600 Search Request has been received by STIC's EIC1600 <<http://uspto-a-pattn-2/siraapps/stic/npl/npl1600.htm>> .

Thank you for using STIC <<http://uspto-a-pattn-2/siraapps/stic/npl/index.html>> services.

Requester

Name: KANTAMNENI, SHOBA <<http://es.uspto.gov/emlocator/runEmployeeQry.do?action=ListEmployeeByEmpNo&empNo=80397>>
Organization: TC 1600
Art Unit: 1627
Employee Number:
Office Location: REM-4A05
Phone Number: (571)272-2930
Email: shobha.kantamneni@uspto.gov <<mailto:shobha.kantamneni@uspto.gov>>
Subject: 1600 Search Request

Request Detail

Attachment: 675927, Claims, Whole Document.pdf <<file:///\\Nsx-orgshares\\PatentsSTIC\\Attachments\\675927, Claims, Whole Document.pdf>>

Case/Application number: 10/675927 PALM <http://expoweb1:8001/cgi-bin/expo/GenInfo/snquery.pl?APPL_ID=10/675927>
Priority App. Filing Date:
Format for Search Results: SCORE & EMAIL

Identify the novelty:

Additional Comments:


Please, do structure search for compounds represented by formula (II) as in claim 75. See attached claims.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-74. (Canceled)

75. (Currently amended) A method of inhibiting Raf kinase activity in a human or animal subject suffering from a Ras/mitogen-activated protein kinase signal pathway-mediated cancer disorder selected from the group consisting of melanoma, breast cancer, prostate cancer, lung cancer, pancreatic cancer, thyroid cancer, bladder cancer, colon cancer, liver cancer, myeloid leukemia, and villous colon adenoma, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (II) effective to inhibit Raf kinase activity in the human or animal subject:



(II)

wherein Y is O [[or S]];

A₁ is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroaryl/heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;

A₂ is substituted or unsubstituted heteroaryl;

Serial#: 10/675,927
STRUCTURE SEARCH

=> FILE REG

FILE 'REGISTRY' ENTERED AT 13:21:10 ON 13 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2010 HIGHEST RN 1218902-14-7
DICTIONARY FILE UPDATES: 12 APR 2010 HIGHEST RN 1218902-14-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

Uploading LL4.str



chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 8-10

Serial#: 10/675,927

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 5-11 7-8 8-9 8-10

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

11:CLASS

Uploading LL11.str



chain nodes :

10 11 13 14

ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

15

chain bonds :

5-11 8-10 10-13 11-14 14-15

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 5-11 7-8 8-9 8-10 10-13 11-14 14-15

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

11:CLASS 13:Atom 14:Atom 15:CLASS

Serial#: 10/675,927

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 13:21:13 ON 13 APR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2010 VOL 152 ISS 16

FILE LAST UPDATED: 12 Apr 2010 (20100412/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>


This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE


=> D STAT QUE L14

L4 STR

C 12 S 13



Page 1-A



Page 1-B

Page 5 of 746

Serial#: 10/675,927

VAR G1=12/13

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS C	AT	10
NSPEC	IS C	AT	11

DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 10 12 13
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE


L7 5908 SEA FILE=REGISTRY SSS FUL L4

L11 STR

O 15 S 16



Page 1-A



Page 1-B

VAR G1=15/16

NODE ATTRIBUTES:

HCOUNT	IS M1	AT	10
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7

Page 6 of 746

Serial#: 10/675,927

NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS C AT 10
NSPEC IS C AT 11
NSPEC IS C AT 12
NSPEC IS C AT 13
NSPEC IS RC AT 14
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 10 14 15 16
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L13 1382 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L14 33 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L13

=> D L14 IBIB ABS HITSTR 1-33

L14 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2010:173773 HCAPLUS Full-text

DOCUMENT NUMBER: 152:350653

TITLE: Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination

AUTHOR(S): Mordant, Pierre; Lorient, Yohann; Leteur, Celine; Calderaro, Julien; Bourhis, Jean; Wislez, Marie; Soria, Jean-Charles; Deutsch, Eric

CORPORATE SOURCE: UPRES 2710, Univ. Paris XI, Villejuif, 94805, Fr.
SOURCE: Molecular Cancer Therapeutics (2010), 9(2), 358-368
CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Activation of phosphatidylinositol-3-kinase (PI3K)-AKT and Kirsten rat sarcoma viral oncogene homolog (KRAS) can induce cellular immortalization, proliferation, and resistance to anticancer therapeutics such as epidermal growth factor receptor inhibitors or chemotherapy. This study assessed the consequences of inhibiting these two pathways in tumor cells with activation of KRAS, PI3K-AKT, or both. We investigated whether the combination of a novel RAF/vascular endothelial growth factor receptor inhibitor, RAF265, with a mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), could lead to enhanced antitumoral effects in vitro and in vivo. To address this question, we used cell lines with different status regarding KRAS, PI3KCA, and BRAF mutations, using immunoblotting to evaluate the inhibitors, and MTT and clonogenic assays for effects on cell viability and proliferation. S.c. xenografts were used to assess the activity of the combination in vivo. RAD001 inhibited mTOR downstream signaling in all cell lines, whereas RAF265 inhibited RAF downstream signaling only in BRAF mutant cells. In vitro, addition of RAF265 to RAD001 led to decreased AKT, S6, and Eukaryotic translation initiation factor 4E binding protein 1 phosphorylation in HCT116 cells. In vitro and in vivo, RAD001 addition enhanced the antitumoral effect of RAF265 in HCT116 and H460 cells (both KRAS mut, PI3KCA mut); in contrast, the combination of RAF265 and RAD001 yielded no addnl. activity in A549 and MDAMB231 cells. The combination of RAF and mTOR inhibitors is effective for enhancing antitumoral effects in cells with deregulation of both RAS-RAF and PI3K, possibly through the cross-inhibition of 4E binding protein 1 and S6 protein. Mol Cancer Ther; 9(2); 358-68.


IT 927899-90-8

Serial#: 10/675,927

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RAF 265; dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (everolimus) in combination)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2010:50674 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 152:177081

TITLE: Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway

INVENTOR(S): Garcia-Echeverria, Carlos; Maira, Sauveur-Michel; Stuart, Darrin; Wee, Susan; Fritsch, Christine; Nagel, Tobin

PATENT ASSIGNEE(S): Novartis A.-G., Switz.

SOURCE: PCT Int. Appl., 34pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010006225	A1	20100114	WO 2009-US50192	20090710
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NM, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: EP 2008-160218 A 20080711

AB The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a com. package or product comprising such a combination as a

Serial#: 10/675,927

combined preparation for simultaneous, sep. or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.


IT 927880-90-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RAF 265; combination of (a) phosphoinositide 3-kinase inhibitor and (b) modulator of Ras/Raf/Mek pathway)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1565329 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 152:67617

TITLE: Substituted benzimidazoles for neurofibromatosis

INVENTOR(S): Stuart, Darrin

PATENT ASSIGNEE(S): Novartis AG, Switz.

SOURCE: PCT Int. Appl., 36pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009152288	A1	20091217	WO 2009-US46971	20090611
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2008-61156P P 20080613

OTHER SOURCE(S): MARPAT 152:67617

AB The present invention relates to the use of benzimidazole derivs. for the preparation of a drug for the treatment of neurofibromatosis.

IT 927880-90-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RAF-265; substituted benzimidazoles for treatment of neurofibromatosis)

Serial#: 10/675,927

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 927880-90-8D, salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(substituted benzimidazoles for treatment of neurofibromatosis)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1136438 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 151:344824

TITLE: Synergistic combination therapy for treatment of
cancer comprising Aurora kinase inhibitor, EGFR
inhibitor and optionally antiproliferative agentINVENTOR(S): Ratushny, Vladimir; Golemis, Erica A.; Astsaturon,
Igor; Serebriiskii, Ilya G.; Weiner, Louis M.

PATENT ASSIGNEE(S): Fox Chase Cancer Center, USA; Georgetown University

SOURCE: PCT Int. Appl., 26pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009114703	A2	20090917	WO 2009-US36976	20090312
WO 2009114703	A3	20100325		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

Serial#: 10/675,927

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

US 2008-36027P P 20080312


AB Comps. which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed. Thus, when HCT116 cells were treated with a combination (1:25 ratio) of C 1368 and erlotinib (1:25 ratio), the IC50 value of erlotinib decreased >3 fold (from 37.3 μ M to 12.3 μ M) and the IC50 value for C1368 decreased >4 fold (from 2.3 μ M to 0.5 μ M) as compared to treatment with either drug alone; similarly, combination treatment of a second K-Ras-mutated cell line, DLD1, with C1368 and erlotinib resulted in an even greater fold decrease of the IC50 values of the single agents, with IC50 reduced from 71.7 μ M to 13.8 μ M for erlotinib, and from 2.7 μ M to 0.5 μ M for C1368; synergy is evident for the C1368 and erlotinib combination in both cell lines under both ED 50 (ED 50) and ED 75, but not at ED 90; the lack of synergy at ED 90 is likely due to off-target kinase inhibition, which can occur when C1368 is given at high concns.

IT 927880-90-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RAF 265; synergistic combination therapy for treatment of cancer
comprising Aurora kinase inhibitor EGFR inhibitor and optionally
antiproliferative agent)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L14 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:576501 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 150:515173

TITLE: Preparation of fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors

INVENTOR(S): Di Pietro, Lucian V.; Harmange, Jean-Christophe; Askew, Benny C., Jr.; Elbaum, Daniel; Germain, Julie; Habgood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.; Potashman, Michele; Van Der Plas, Simon

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: U.S., 95pp.; Chemical Indexing Equivalent to 141:332190 (WO)
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7531553	B2	20090512	US 2004-804915	20040319
US 20040209892	A1	20041021		

Serial#: 10/675,927

AU 2004223827	A1	20041007	AU 2004-223827	20040322
CA 2004223827	B2	20080306		
CA 2518909	A1	20041007	CA 2004-2518909	20040322
WO 2004085425	A1	20041007	WO 2004-US8809	20040322



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1638954	A1	20060329	EP 2004-758050	20040322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006520805	T	20060914	JP 2006-507472	20040322
MX 2005010086	A	20060210	MX 2005-10086	20050921
			US 2003-456691P	P 20030321
			US 2004-804915	A 20040319
			WO 2004-US8809	A 20040322

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI



AB Title compds. I [W, X, Y1 and Y2 independently = O, S(O)n and NR3; ring A optionally contains a N atom at a non-fused, non-substituted ring position; n = 0-2; R = (un)substituted-aryl, -heterocyclyl, -fused heterocyclyl, etc.; R1 = (un)substituted-aryl, -arylkyl, -heterocyclyl, etc.; R2 = H, halo, alkoxy, etc.; R3 = H or alkyl] are prepared and disclosed as having kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Thus, e.g., II was prepared by cyclocondensation of 4-(pyridin-4-yloxy)benzene-1,2-diamine with 1-chloro-4-isothiocyanato-2-trifluoromethylbenzene. In human umbilical vein endothelial cell proliferation assay, selected I inhibited VEGF-stimulated proliferation at a level below 100 nM. Accordingly, I would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmol. conditions, proliferative diseases, inflammatory diseases, and other pathol. conditions as described in the specification.


IT 1055984-31-3F 1055984-36-5F 1055984-41-2F

Serial#: 10/675,927


1055984-55-8P 1055984-59-2P 1055984-78-5P
 1055984-83-2P 1055984-87-6P 1055985-14-2P
 1055985-37-9P 1055985-56-2P 1055985-58-4P
 1055985-70-0P 1055985-75-5P 1055985-77-7P
 1055985-79-9P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)


RN 1055984-34-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(3-pyrrolidinylmethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 1055984-36-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 1055984-41-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED



Serial#: 10/675,927


RN 1055984-55-8 HCAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-1-ethyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 1055984-59-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-bromo-3-(trifluoromethyl)phenyl]-6-[(3-methyl-4-pyridinyl)oxy]- (CA INDEX NAME)



RN 1055984-78-5 HCAPLUS


CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-methoxyethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 1055984-83-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Serial#: 10/675,927




RN 1055984-87-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1055985-14-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1055985-37-9 HCAPLUS
CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[1-(1-methyl-2-pyrrolidinyl)methyl]amino]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl-
(CA INDEX NAME)




RN 1055985-56-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Serial#: 10/675,927




RN 1055985-58-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1055985-70-0 HCAPLUS
CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(1-methyl-2-pyrrolidinyl)methoxy]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 1055985-75-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1055985-77-7 HCAPLUS
CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA


Serial#: 10/675,927

INDEX NAME)



RN 1055985-79-9 HCAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(pyrrolidinylmethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




IT 769960-09-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 769960-09-0 HCAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 611212-56-7P 769960-01-2P 769960-02-3P

769960-03-4P 769960-04-5P 769960-05-6P

769960-06-7P 769960-07-8P 769960-08-9P

769960-10-3P 769960-11-4P 769960-12-5P

769960-13-6P 769960-14-7P 769960-15-8P

769960-16-9P 769960-19-2P 769960-20-5P

769960-82-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


Serial#: 10/675,927

(Uses)

(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)


RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 769960-01-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(1,1,2,2,2-pentafluoroethyl)-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 769960-02-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 769960-03-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(1,1,2,2,2-pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.


Serial#: 10/675,927



RN 769960-04-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 769960-05-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethyl]-4-methoxyphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-06-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(difluoromethoxy)-4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 769960-07-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[[2-(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 769960-08-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 769960-10-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 769960-11-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(1-piperazinylmethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 769960-12-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-(dimethylamino)ethoxy)-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-13-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-14-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



Serial#: 10/675,927


RN 769960-15-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-(1-methylethyl)-1-piperazinyl]methyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 769960-16-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-(methylsulfonyl)-1-piperazinyl]methyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-19-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-5-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-20-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-methyl-1-piperazinyl]methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 769960-82-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(1-methyl-2-pyrrolidinyl)methoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



IT 769961-24-2P


RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 769961-24-2 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-2-(1,1,2,2,2-pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 769961-00-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 769961-00-4 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-chloro-5-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



—OBu-t

```
OS.CITING REF COUNT:      1      THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
                              (1 CITINGS)
REFERENCE COUNT:          18      THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
                              RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L14 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:490709 HCAPLUS Full-text
 DOCUMENT NUMBER: 150:472740
 TITLE: Preparation of quinazolines and related compounds as
 CSF-1R inhibitors
 INVENTOR(S): Sutton, James; Sendzik, Martin; Wang, Weibo
 PATENT ASSIGNEE(S): Novartis AG, Switz.
 SOURCE: PCT Int. Appl., 165pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

[illegible]



WO 2009050228	A2	20090423	WO 2008-EP63952	20081016
---------------	----	----------	-----------------	----------

WO 2009050228 A3 20090730

W:	AE	AG	AL	AM	AO	AT	AU	AE	BA	BB	BG	BH	BR	BW	BY	BZ
	CA	CH	CN	CO	CR	CU	CZ	DE	DK	DM	DO	DZ	EC	EE	EG	ES
	FI	GB	GD	GE	GH	GM	GT	HN	HR	HU	ID	IL	IN	IS	JP	KE
	KG	KM	KN	KP	KR	KZ	LA	LC	LK	LR	LS	LT	LU	LY	MA	MD
	ME	MG	MK	MP	MW	MX	MY	MZ	NA	NG	NI	NO	NZ	OM	PG	PH
RW:	PL	PT	RO	RS	RU	SC	SD	SE	SG	SK	SL	SM	ST	SV	SY	TJ
	TM	TN	TR	TT	TZ	UA	UG	US	UZ	VC	VN	ZA	ZM	ZW		
	AT	BE	BG	CH	CY	CZ	DE	DK	EE	ES	FI	FR	GB	GR	HR	HU
	IE	IS	IT	LT	LV	LM	MT	NL	NO	PL	PT	RO	SE	SI	SK	
	BF	BJ	CF	CG	CI	CM	GA	GN	GO	GW	ML	MR	NE	SN	TD	
	TG	BW	GH	GM	KE	LS	MW	MZ	NA	SD	SL	SZ	TZ	UG	ZM	ZW
	AM	AZ	BY	KG	KZ	MD	RU	TJ	TM	AP	AE	EP	OA			

PRIORITY APPLN. INFO.: US 2007-981058P P 20071018

OTHER SOURCE(S) :
GI



AB Title compds. I [ring A = 6-membered ring; Q1-Q5 = CR3 or N, provided that at least one of Q1-Q5 is N and at most three of Q1-Q5 are N; R3 = H or R3a; R3a = halo, (un)substituted alkyl, (un)substituted alkenyl, etc.; Het1 = Q, etc.; R1 R2 = H, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; Y1-Y4 = CR5 or N; R5 = H or R5a; R5a = (un)substituted alkyl, (un)substituted alkoxy, (un)substituted amino, etc.; m = 0-5; X = O, S, SO, etc.] or oxides, esters, prodrugs, pharmaceutically acceptable salts, or solvates thereof were prepared. Thus, reaction of 2,6-quinolinediol with 4-chloro-N-methylpicolinamide followed by treatment with POC13 and exposure to (1R,2R)-2-aminocyclohexanol.HCl afforded compound II, which showed 100% inhibition at 1 μ M for colony stimulating factor-1 receptor (CSF-1R). Compds. I are claimed useful for the treatment of osteoporosis, arthritis, etc.

IT 1145688-18-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines and related compds. as CSF-1R inhibitors)

RN 1145688-18-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1R,2R)-2-hydroxycyclohexyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:139541 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 150:191158

TITLE: Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof

INVENTOR(S): Miner, Jeffrey N.; Chapman, Mark S.; Quart, Barry; Adjei, Alex; Yu, Chunrong


PATENT ASSIGNEE(S): Ardea BioSciences, Inc., USA

Serial#: 10/675,927


SOURCE: PCT Int. Appl., 148pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009018238	A1	20090205	WO 2008-US71397	20080728
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080058340	A1	20080306	US 2007-830733	20070730
US 20080255133	A1	20081016	US 2008-16897	20080118
CA 2694646	A1	20090205	CA 2008-2694646	20080728
PRIORITY APPLN. INFO.:			US 2007-830733	A 20070730
			US 2008-16897	A 20080118
			US 2005-701814P	P 20050721
			US 2005-706719P	P 20050808
			US 2005-731633P	P 20051028
			WO 2006-US28326	A2 20060721
			US 2006-833886P	P 20060728
			US 2007-885849P	P 20070119
			WO 2008-US71397	W 20080728

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 150:191158; MARPAT 150:191158
 GI



I



II

AB This invention concerns combinations of inhibitors of MEK, Raf protein kinases, and other kinases including VEGFR1-3 and PDGFR- β . This invention also concerns pharmaceutical compns. comprising the compds. I [G = 1-(2,3-dihydroxypropyl)cyclopropyl, cyclopropyl, etc.; R10 = H, halo, CN, etc.; R11 = (un)substituted 5-6 membered heterocyclic containing 1-5 heteroatoms selected from O, N and S; R12 = H, halo, F, O; R13 = H, halo, OH, etc.; X, Y = F, I, Br, alkyl, etc.; A, J, L = C, CH, NH, N, O, N(Me)] and methods of use of the compds. I and compns. described herein, including the use in the treatment and/or prevention of

Serial#: 10/675,927


cancer and other hyperproliferative disorders. For example, a multi-step synthesis of II, starting from cyclopropanesulfonyl chloride, was given. Compds. I were tested in various biol. assays, alone or in combination with other therapeutic agents (data given).

IT 927880-90-8

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted cyclopropanesulfonamides as MEK kinase and Raf protein kinase inhibitors useful in prevention and combination therapy of cancer and hyperproliferative disorders)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1480550 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 150:48120

TITLE: Method to identify modulators of B-Raf protein kinase, their use for the treatment of anxiety and depression, and diagnostic and gene identification methods

INVENTOR(S): Hitz, Christiane; Hoelter, Sabine; Kuehn, Ralf; Wurst, Wolfgang; Wefers, Benedikt

PATENT ASSIGNEE(S): Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fuer Gesundheit und Umwelt (GmbH), Germany

SOURCE: PCT Int. Appl., 56pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008148522	A2	20081211	WO 2008-EP4416	20080603
WO 2008148522	A3	20090129		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,			

Serial#: 10/675,927

TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 2162746 A2 20100317 EP 2008-758979 20080603
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, AL, BA, MK, RS


PRIORITY APPLN. INFO.: US 2007-941846P P 20070604
WO 2008-EP4416 W 20080603

AB The invention discloses a method for identifying a compound capable of modulating an anxiety or depression disorder comprising (a) contacting a composition comprising a B-Raf protein or a B-Raf gene in expressible form or a transcript thereof with a compound under conditions that allow for an interaction of the B-Raf protein or the B-Raf gene or a transcript thereof and the compound; and (b) measuring whether the interaction, if any, results in (i) a change of B-Raf kinase activity compared to B-Raf kinase activity in the absence of the compound; (ii) a modulation of the expression of the B-Raf gene compared to B-Raf gene expression in the absence of the compound; or (iii) the formation of a complex between the compound and the B-Raf protein, wherein such a change in activity, modulation of expression or the formation of a complex is indicative of the compound being a modulator of an anxiety or depression disorder. Further, the invention discloses a method for treating an anxiety or depression disorder in an individual comprising administering to the individual an effective amount of a compound inhibiting B-Raf kinase activity or gene expression and to a use of a compound that inhibits B-Raf kinase activity or gene expression in the manufacture of a pharmaceutical composition for treating an anxiety or depression disorder. Moreover, the invention discloses a method for diagnosing a B-Raf-associated anxiety or depression disorder, as well as a genetically engineered mouse. Finally, the invention also discloses a method for identifying another gene contributing to the pathophysiol. of an anxiety or depression disorder apart from B-Raf.

IT 927880-90-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(CHIR 265; B-Raf protein kinase modulator identification, use for
treatment of anxiety and depression, and diagnostic and gene
identification methods)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L14 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1450757 HCAPLUS Full-text
DOCUMENT NUMBER: 150:16050
TITLE: Raf inhibitors for the treatment of thyroid cancer
INVENTOR(S): Stuart, Darrin Douglas
PATENT ASSIGNEE(S): Novartis AG, Switz.
SOURCE: PCT Int. Appl., 21pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

Serial#: 10/675,927
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008147782	A1	20081204	WO 2008-US64280	20080521
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2008256922	A1	20081204	AU 2008-256922	20080521
CA 2686787	A1	20081204	CA 2008-2686787	20080521
EP 2150252	A1	20100210	EP 2008-755991	20080521
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
KR 2010017894	A	20100216	KR 2009-726739	20080521
CN 101674828	A	20100317	CN 2008-80014174	20091030
MX 2009012626	A	20091207	MX 2009-12626	20091120
PRIORITY APPLN. INFO.:			US 2007-939625P	P 20070523
			WO 2008-US64280	W 20080521

OTHER SOURCE(S): MARPAT 150:16050


AB The invention relates to the use of an Raf inhibitor for the manufacture of pharmaceutical compns. for the treatment of thyroid cancer, more specifically papillary thyroid cancer (PTC); the use of a Raf inhibitor in the treatment of thyroid cancer, more specifically PTC; a method of treating warm-blooded animals including mammals, especially humans, suffering from thyroid cancer, more specifically PTC, by administering to a said animal in need of such treatment a dose effective against said disease of an Raf inhibitor. The invention also relates to the use of a Raf inhibitor in combination with a platin compound for the treatment of thyroid cancer, more specifically papillary thyroid cancer.

IT 927880-90-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RAF 265; raf inhibitors for treatment of thyroid cancer)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2010 ACS ON STN
 ACCESSION NUMBER: 2008:1427379 HCAPLUS Full-text

Serial#: 10/675,927

DOCUMENT NUMBER:

TITLE:

150:19084

Crystal structures of neuropilin fragments and neuropilin-antibody complexes and use of anti-neuropilin antibodies or fragments in cancer therapy

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

Appleton, Brent A.; Wiesmann, Christian; Wu, Yan

Genentech, Inc., USA

PCT Int. Appl., 88pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:


PATENT INFORMATION:

Patent

English

1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008143666	A2	20081127	WO 2007-US69185	20070517
WO 2008143666	A3	20090205		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007353779	A1	20081127	AU 2007-353779	20070517
CA 2687556	A1	20081127	CA 2007-2687556	20070517
KR 2010020967	A	20100223	KR 2009-726233	20070517
EP 2158215	A2	20100303	EP 2007-762242	20070517
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
MX 2009012282	A	20091125	MX 2009-12282	20091112
PRIORITY APPLN. INFO.:			WO 2007-US69185	A 20070517
AB	The invention provides crystal structures of neuropilin 1 (Nrp1) and neuropilin 2 (Nrp2) fragments alone and in complex with anti-neuropilin antibodies, and method for their use. The invention further provides anti-Nrp antibodies and methods for their therapeutic applications in treatment of cancer.			
IT	327880-90-8, CHIR 265			
RN	1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)			



Serial#: 10/675,927

L14 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1411316 HCAPLUS Full-text
DOCUMENT NUMBER: 150:49894
TITLE: Type-II Kinase Inhibitor Docking, Screening, and
Profiling Using Modified Structures of Active Kinase
States
AUTHOR(S): Kufareva, Irina; Abagyan, Ruben
CORPORATE SOURCE: The Scripps Research Institute, La Jolla, CA, USA
SOURCE: Journal of Medicinal Chemistry (2008), 51(24),
7921-7932
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Type-II kinase inhibitors represent a class of chems. that trap their target kinases in an inactive, so-called DFG-out state, occupying a hydrophobic pocket adjacent to the ATP binding site. These compds. are often more specific than those that target active DFG-in kinase conformations. Unfortunately, the discovery of novel type-II scaffolds presents a considerable challenge, partially because the lack of compatible kinase structures makes structure-based methods inapplicable. We present a computational protocol for converting multiple available DFG-in structures of various kinases (.apprx.70% of mammalian structural kinome) into accurate and specific models of their type-II bound state. The models, described as deletion-of-loop Asp-Phe-Gly-in (DOLPHIN) kinase models, demonstrate exceptional performance in various inhibitor discovery applications, including compound pose prediction, screening, and in silico activity profiling. Given the abundance of the DFG-in structures, the presented approach opens possibilities for kinome-wide discovery of specific mols. targeting inactive kinase states.

IT 611212-56-7

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type II inhibitor; type-II protein kinase inhibitor docking,
screening, and profiling using modified structures of active kinase
DFG-in/out states)

RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-
1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)
REFERENCE COUNT: 94 THERE ARE 94 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1398992 HCAPLUS Full-text
DOCUMENT NUMBER: 150:5734
TITLE: Preparation of Forms A-P of
1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-
yl)pyridin-4-yloxy]-N-(4-trifluoromethylphenyl)-1H-

Serial#: 10/675,927

INVENTOR(S): Hashash, Ahmad; Lin, Kangwen L.; Okhamafe, Augustus O.
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.
 SOURCE: PCT Int. Appl., 134pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008140850	A1	20081120	WO 2008-US55227	20080228
<p>W: AE, AG, AL, AM, AO, AI, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>AU 2008251764 A1 20081120 AU 2008-251764 20080228 CA 2678335 A1 20081120 CA 2008-2678335 20080228 KR 2009117833 A 20091112 KR 2009-720657 20080228 EP 2132198 A1 20091216 EP 2008-795801 20080228</p> <p>R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR</p> <p>MX 2009009344 A 20090911 MX 2009-9344 20090902 CN 101679372 A 20100324 CN 2008-80014274 20091030</p> <p>PRIORITY APPLN. INFO.: US 2007-904455P P 20070302 WO 2008-US55227 W 20080228</p>				
OTHER SOURCE(S): CASREACT 150:5734				
<p>AB Solid Forms A-P of the Raf kinase inhibitor 1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)pyridin-4-yloxy]-N-(4-(trifluoromethylphenyl)-1H-benzo[d]imidazol-2-amine (I) as characterized by XRPD, DSC, and TGA data, were prepared. Thus, I (multistep preparation from 4-amino-3-nitrophenol, tert-Bu 4-chloropyridine-2-carboxylate, Br3CCOCF3, and 4-trifluoromethylphenyl isothiocyanate given) was suspended in H2O/HOAc followed by cooling from 85° to 24° over 24 h and then standing at 4° for 24 h to give I Form A.</p>				
<p>IT 927886-90-8P 1083096-17-8P 1083096-18-9P 1083096-19-0P RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of Forms A-P of 1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)pyridin-4-yloxy]-N-(4-(trifluoromethylphenyl)-1H-benzo[d]imidazol-2-amine having specified X-ray powder diffraction patterns as Raf kinase inhibitors)</p>				
<p>RN 927880-90-8 HCAPLUS CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)</p>				

Serial#: 10/675,927



RN 1083090-17-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, hydrate (1:1) (CA INDEX NAME)




RN 1083090-18-9 HCAPLUS

CN Ethanol, compd. with 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:1) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 64-17-5

CMF C2 H6 O



RN 1083090-19-0 HCAPLUS

CN 2-Pyrrolidinone, 1-methyl-, compd. with 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-


Serial#: 10/675,927

[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:1) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 872-50-4


CMF C5 H9 N O



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1278126 HCAPLUS Full-text
DOCUMENT NUMBER: 149:556528
TITLE: Design and Synthesis of Orally Bioavailable
Benzimidazoles as Raf Kinase Inhibitors
AUTHOR(S): Ramurthy, Savithri; Subramanian, Sharadha; Aikawa,
Mina; Amiri, Payman; Costales, Abnan; Dove, Jeff;
Fong, Susan; Jansen, Johanna M.; Levine, Barry; Ma,
Sylvia; McBride, Christopher M.; Michaelian, Jonah;
Pick, Teresa; Poon, Daniel J.; Girish, Sandhya;
Shafer, Cynthia M.; Stuart, Darrin; Sung, Leonard;
Renhowe, Paul A.
CORPORATE SOURCE: Novartis Institutes for Biomedical Research,
Emeryville, CA, 94608, USA
SOURCE: Journal of Medicinal Chemistry (2008), 51(22),
7049-7052
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 149:556528
GI

Serial#: 10/675,927



I


AB A series of arylaminobenzimidazoles, e.g. I, was designed and synthesized as Raf kinase inhibitors. Exploration of the structure-activity relationship resulted in compds. that are potent in vitro and show desirable in vivo properties.

IT 611213-70-8P 1082051-94-2P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-aminobenzimidazoles as Raf kinase inhibitors)


RN 611213-70-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 1082051-94-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




IT	611212-56-7P	611212-58-9P	611212-60-3P
	611212-72-7P	611212-77-2P	611212-78-3P
	611212-79-4P	611212-85-2P	611212-96-5P
	611213-35-5P	611213-71-3P	611213-72-6P
	611213-88-9P	611213-90-2P	611214-05-2P
	611214-16-5P	611214-22-3P	611214-41-6P
	611214-42-7P	611215-09-9P	611215-15-7P
	611215-30-6P	611216-24-1P	611216-26-3P
	611216-27-4P	611216-23-2P	611216-49-0P
	1082051-95-3P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-aminobenzimidazoles as Raf kinase inhibitors)

Serial#: 10/675,927


RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-58-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-60-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-(phenylamino)-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611212-72-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611212-77-2 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-78-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-79-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-85-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611212-96-5 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-35-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-71-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-72-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611213-88-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-90-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-05-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-16-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-22-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromophenyl]amino]-1-ethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-41-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-42-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(cyclohexylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-09-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-15-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-30-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-24-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)



RN 611216-26-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611216-27-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-33-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611216-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 1082051-95-3 HCAPLUS

CN Methanone, [4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl](2-propyl-1-piperidinyl)- (CA INDEX NAME)



IT 611225-65-1P 1082051-96-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-aminobenzimidazoles as Raf kinase inhibitors)

RN 611225-65-1 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Serial#: 10/675,927




RN 1082051-98-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 611225-66-2

CMF C20 H15 Br N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 611213-06-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2-aminobenzimidazoles as Raf kinase inhibitors)

RN 611213-06-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1210491 HCAPLUS Full-text
DOCUMENT NUMBER: 149:448733
TITLE: Preparation of peptide prodrugs modified with a
1,2,3,4-cyclobutanetetracarboxylic acid derived moiety
useful in treatment and diagnosis of tumors and
inflammatory diseases
INVENTOR(S): Matthieu, Michel; Dubois, Vincent; Tranchant,
Isabelle; Kearsay, Jonathan
PATENT ASSIGNEE(S): Diatos, Fr.
SOURCE: PCT Int. Appl., 96pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008120098	A2	20081009	WO 2008-IB808	20080403
WO 2008120098	A3	20090108		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, AY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1977765	A1	20081008	EP 2007-300920	20070403
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRIORITY APPLN. INFO.:			EP 2007-300920	A 20070403
			US 2007-989486P	P 20071121

OTHER SOURCE(S): MARPAT 149:448733
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the preparation of peptide prodrugs I [L1, L2 = independently a covalent bond or a linking moiety, the linking moiety should include at least two organic functional groups, one organic functional group that can bind to the 1,2,3,4-cyclobutanetetracarboxylic acid and a second organic functional group that allows binding to the oligopeptide moiety (L1) or one functional group that can bind to the oligopeptide moiety and a second organic functional group that allows binding to D (L2); X = (CH2)n; X' = (CH2)m; X'' = (CH2)p; X''' = (CH2)q; n, m, p, q

Serial#: 10/675,927


= independently 0-10; Y = cleavable oligopeptide moiety by at least one specific and/or selective peptidase that is present in the extracellular environment of target cells; D = therapeutic agent or marker] which improve the therapeutic index and the solubility of the therapeutic agent and are intended for the treatment and/or diagnosis of tumors and/or inflammatory reactions. Thus, tetraAcid-ALAL-doxorubicin II was prepared and showed stability in human plasma after 2 h incubation. II was evaluated for its in vivo efficacy in the LS 174T tumor model and in vitro reactivation into metabolites (leucyl-doxorubicin and doxorubicin) by tumor homogenates. A coumarin analog III was prepared for use as a marker for diagnosis purposes (no data).

IT 927880-90-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide prodrugs useful in treatment and diagnosis of tumors and inflammatory diseases)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L14 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1205912 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 149:448732

TITLE: Preparation of peptide prodrugs modified with a 1,2,3,4-cyclobutanetetracarboxylic acid derived moiety useful in treatment and diagnosis of tumors and inflammatory diseases

INVENTOR(S): Matthieu, Michel; Dubois, Vincent; Tranchant, Isabelle; Kearsy, Jonathan

PATENT ASSIGNEE(S): Diatos, Fr.

SOURCE: Eur. Pat. Appl., 31pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1977765	A1	20081008	EP 2007-300920	20070403
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2008120098	A2	20081009	WO 2008-IB808	20080403
WO 2008120098	A3	20090108		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,				

Serial#: 10/675,927

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AD, EA, EP, OA
PRIORITY APPLN. INFO.: EP 2007-300920 A 20070403
US 2007-989486P P 20071121
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the preparation of peptide prodrugs I [L1, L2 = independently a covalent bond or a linking moiety; X = (CH₂)_n; X' = (CH₂)_m; X'' = (CH₂)_p; X''' = (CH₂)_q; n, m, p, q = independently 0-10; Y = cleavable oligopeptide moiety; D = therapeutic agent or marker] which improve the therapeutic index and the solubility of the therapeutic agent and are intended for the treatment and/or diagnosis of tumors and/or inflammatory reactions. Thus, tetraAcid-ALAL-doxorubicin II was prepared and showed stability in human plasma after 2 h incubation. II was evaluated for its in vivo efficacy in the LS 174T tumor model.

IT 927880-90-9
RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide prodrugs useful in treatment and diagnosis of tumors and inflammatory diseases)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:829897 HCAPLUS Full-text
DOCUMENT NUMBER: 149:143937
TITLE: Gene expression biomarkers for prediction of target modulation and efficacy of Raf inhibitors and diagnosis and/or prognosis of melanoma and other cancers
INVENTOR(S): Aziz, Natasha; Moler, Edward; Stuart, Darrin; Heise, Carla; Aardalen, Kim
PATENT ASSIGNEE(S): Novartis A.-G., Switz.
SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008082730	A2	20080710	WO 2007-US78946	20070919
WO 2008082730	A3	20090108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007340265	A1	20080710	AU 2007-340265	20070919
CA 2662508	A1	20080710	CA 2007-2662508	20070919
EP 2074226	A2	20090701	EP 2007-872305	20070919
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
KR 2009071603	A	20090701	KR 2009-707973	20070919
JP 2010504530	T	20100212	JP 2009-529376	20070919
MX 2009002936	A	20090401	MX 2009-2936	20090318
CN 101541977	A	20090923	CN 2007-80042689	20090518
US 20100004253	A1	20100107	US 2009-441888	20090527
PRIORITY APPLN. INFO.:				
			US 2006-845601P	P 20060919
			WO 2007-US78946	W 20070919


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are provided. Alterations in levels of gene expression of the biomarkers, particularly in response to Raf kinase inhibition, are measured and identifications or adjustments may be made accordingly. Transcriptional activity was assessed by measuring levels of mRNA in cells derived from xenograft tumors in mice from the B-Raf-mutant driven A375M melanoma cancer cell line using Affymetrix HG-U133-Plus-2 GeneChips. Differential expression was determined between CHIR-265 treated xenografts and the matching vehicle-only controls.

IT 927880-90-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (gene expression biomarkers for prediction of target modulation and efficacy of Raf inhibitors and diagnosis and/or prognosis of melanoma and other cancers)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



Serial#: 10/675,927

DOCUMENT NUMBER:

TITLE:

149:30417

Antibodies and inhibitory nucleic acids for targeting HIF-1 α and for diagnosing/treating tumor or metastasis

INVENTOR(S):

Huang, L. Eric

PATENT ASSIGNEE(S):

University of Utah Research Foundation, USA

SOURCE:

PCT Int. Appl., 157pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008070616	A2	20080612	WO 2007-US86264	20071203
WO 2008070616	A3	20090430		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20100074897 A1 20100325 US 2009-517132 20090710 PRIORITY APPLN. INFO.: US 2006-868188P P 20061201 WO 2007-US86264 W 20071203				


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Disclosed are compns. and methods related to HIF-1 α (hypoxia-inducible factor 1 α). The compns. and methods comprise use of HIF-1 α inhibitors for reducing tumor growth or metastatic tumor growth. The HIF-1 α inhibitor is an antibody (including monoclonal, human and humanized antibody), small mol., siRNA, shRNA, or antisense polynucleotide.

IT 927880-90-8, CHIR 265
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antibodies and inhibitory nucleic acids for targeting HIF-1 α and for diagnosing/treating tumor or metastasis)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L14 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

Serial#: 10/675,927

ACCESSION NUMBER: 2008:670875 HCAPLUS Full-text
DOCUMENT NUMBER: 149:7009
TITLE: Marker genes showing changes in levels of expression in response to antineoplastic drug therapy and their use in selection of chemotherapy
INVENTOR(S): Pratilas, Christine; Rosen, Neal
PATENT ASSIGNEE(S): Memorial Sloan Kettering Cancer Center, USA
SOURCE: U.S. Pat. Appl. Publ., 161pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080131885	A1	20080605	US 2007-732362	20070402
PRIORITY APPLN. INFO.: ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT			US 2006-788014P	P 20060331

AB A panel of 35 genes that can be used to predict the effectiveness of antitumor agents inhibiting components of the RAF/MEK/MAPK pathway is identified. These genes can be used as markers in typing the neoplasm and in monitoring the efficacy of the therapy and in the identification of new antitumor agents.

IT 927880-90-8, RAF 265
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(predicting tumor response to; marker genes responding to
antineoplastic drug therapy and their use in selection of chemotherapy)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L14 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:627172 HCAPLUS Full-text
DOCUMENT NUMBER: 149:486048
TITLE: Pseudo receptor probes: A novel pseudo receptor-based QSAR method and application into studies on a new kind of selective vascular endothelial growth factor-2 receptor inhibitors
AUTHOR(S): Ruan, Zhihua; Wang, Huiming; Ren, Yanrong; Chen, Yongwen; Han, Junfeng; Pang, Xueli; Liang, Houjie; Wu, Yuzhang
CORPORATE SOURCE: Department of Oncology, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, Peop. Rep. China
SOURCE: Chemometrics and Intelligent Laboratory Systems (2008), 92(2), 157-168
CODEN: CILSEN; ISSN: 0169-7439
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

Serial#: 10/675,927

AB In this paper, a novel pseudo receptor-based QSAR method is proposed as pseudo receptor probes (PRP), including 6 pseudo-probe types defined as empty, electrostatic, steric, hydrophobic, hydrogen bond donor and receptor probes. On that basis, pseudo probe ligand interaction is simulated by Gaussian distance-dependent function, predictability of the constructed model is taken as fitness function, and characteristic parameters and arrangements of pseudo probes are optimized by mutational particle swarm optimization (MPSO) algorithm, thereby yielding a profile imitating receptor active site. Then by applying PRP, a statistical quant. structure activity relationship (QSAR) model is constructed over 36 newly-discovered selective vascular endothelial growth factor-2 receptor (VEGFR-2) inhibitors of benzoxazole derivs. Subsequently, the distribution plot of virtual probes is contoured, interpreted from points of statistics and mol. graphics. Thereby, PRP is confirmed of competence to construct robust and predictable pseudo receptor-based QSAR model which possibly provides valuable information on receptor active sites, amenable to definite physicochem. significance.


IT 611212-56-7 769960-02-3 769960-04-5
769960-12-5 769960-13-6 769960-14-7
769960-20-5

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel pseudo receptor-based QSAR method and application to studies on a new kind of selective vascular endothelial growth factor-2 receptor (VEGFR-2) inhibitors)


RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-02-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 769960-04-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.

Serial#: 10/675,927




RN 769960-12-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-13-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-methyl-1-piperazinyl)methoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 769960-14-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 769960-20-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:286210 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 148:315348
 TITLE: Salts of benzimidazolyl pyridyl ethers and formulations thereof for cancer treatment
 INVENTOR(S): Gullapalli, Rampurna; Hashash, Ahmad; Karpinski, Piotr H.; Lin, Kangwen L.; Loeser, Eric M.; Okhamafe, Augustus O.; Sutton, Paul Allen; Sy, Eduardo
 PATENT ASSIGNEE(S): Novartis AG, Switz.
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008027523	A2	20080306	WO 2007-US19152	20070830
WO 2008027523	A3	20080410		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007290388	A1	20080306	AU 2007-290388	20070830
CA 2660376	A1	20080306	CA 2007-2660376	20070830
EP 2059518	A2	20090520	EP 2007-837588	20070830
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,			

Serial#: 10/675,927

	AL, BA, HR, MK, RS				
JP	2010502622	T	20100128	JP	2009-526734
IN	2009DN00769	A	20090522	IN	2009-DN769
MX	2009002279	A	20090320	MX	2009-2279
KR	2009043542	A	20090506	KR	2009-704220
CN	101516870	A	20090826	CN	2007-80031988
NO	2009001236	A	20090327	NO	2009-1236
PRIORITY APPLN. INFO.:				US	2006-841177P
				US	2007-954466P
				WO	2007-US19152
				P	20060830
				P	20070807
				W	20070830

AB Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of [1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H- benzoimidazol-2-yl]- (4-trifluoromethyl-phenyl)amine (I). Compns. and formulations including such salts and surfactants as well as methods of preparing such compns. and formulations for treatment of various cancers are described. Thus, the compound of Formula I was prepared and converted to various salt forms via an acid-base reaction in an organic liquid medium followed by a slow evaporation of the organic solvent or by precipitation from the organic solvent in case of mesylate, esylate, and maleate salts. The salts obtained were formulated in oral dosage forms, i.e., capsules and tablets. For example, 400 mg of granules obtained by wet granulation of I 12.5, methanesulfonic acid 9.5, Crospovidone 20.0, Poloxamer 188 10.0, and microcryst. cellulose 48% were mixed with sodium starch glycolate 20 mg, silica 10 mg, and magnesium stearate 10 mg and filled into a gelatin capsule.


IT 927880-90-8DE, salts 1009567-90-1P
 1009567-91-2P 1009567-92-3P 1009567-93-4P
 1009567-94-5P 1009567-96-7P 1009567-98-9P
 1009567-99-0P 1009568-00-6P 1009568-01-7P
 1009568-02-8P 1009568-03-9P 1009568-04-0P
 1009568-06-2P 1009568-08-4P 1009568-09-5P
 1009568-10-8P 1009568-11-9P 1009568-12-0P
 1009568-13-1P 1009568-14-2P 1009568-15-3P
 1009568-16-4P 1009568-17-5P 1009568-18-6P

RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation and oral compns. of salts of benzimidazolyl pyridyl ethers for
 treatment of cancer)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1009567-90-1 HCAPLUS


CN L-Ascorbic acid, compd. with 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O

Serial#: 10/675,927




CM 2

CRN 50-81-7

CMF C6 H8 O6

Absolute stereochemistry.




RN 1009567-91-2 HCAPLUS

CN D-erythro-Hex-2-enonic acid, γ -lactone, compd. with
1-methyl-5-[(2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl)oxy]-N-
[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O




CM 2

CRN 89-65-6

CMF C6 H8 O6

Absolute stereochemistry.




Serial#: 10/675,927

RN 1009567-92-3 HCAPLUS
CN Butanedioic acid, 2-hydroxy-, compd. with
1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-
[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)


CM 1

CRN 927880-90-8
CMF C24 H16 F6 N6 O



CM 2


CRN 6915-15-7
CMF C4 H6 O5



RN 1009567-93-4 HCAPLUS
CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-
yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-,
2-hydroxy-1,2,3-propanetricarboxylate (1:?) (CA INDEX NAME)

CM 1


CRN 927880-90-8
CMF C24 H16 F6 N6 O



CM 2

CRN 77-92-9
CMF C6 H8 O7

Serial#: 10/675,927




RN 1009567-94-5 HCAPLUS
CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 1009567-96-7 HCAPLUS
CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, ethanedioate (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O

Serial#: 10/675,927



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 1009567-98-9 HCAPLUS

CN Butanedioic acid, compd. with 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8


CMF C24 H16 F6 N6 O



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 1009567-99-0 HCAPLUS


CN Hexanedioic acid, compd. with 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

Serial#: 10/675,927

CMF C24 H16 F6 N6 O



CM 2

CRN 124-04-9

CMF C6 H10 O4




RN 1009568-00-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, (2E)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 1009568-01-7 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, acetate (1:?) (CA INDEX NAME)

Serial#: 10/675,927

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 1009568-02-8 HCAPLUS

CN Formic acid, compd. with 1-methyl-5-[(2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl)oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 64-18-6

CMF C H2 O2



RN 1009568-03-9 HCAPLUS


Serial#: 10/675,927

CN Propanoic acid, 2-hydroxy-, compd. with
1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-
[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 1009568-04-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-
yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, (2Z)-2-butenedioate
(1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.


Serial#: 10/675,927



RN 1009568-06-2 HCAPLUS
CN 1,2-Benzenedicarboxylic acid, compd. with
1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8
CMF C24 H16 F6 N6 O



CM 2


CRN 88-99-3
CMF C8 H6 O4



RN 1009568-08-4 HCAPLUS
CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, 4-methylbenzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8
CMF C24 H16 F6 N6 O




Serial#: 10/675,927

CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 1009568-09-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 1009568-10-8 HCAPLUS


CN Ethanesulfonic acid, compd. with 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O


Serial#: 10/675,927



CM 2

CRN 594-45-6

CMF C2 H6 O3 S




RN 1009568-11-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, phosphate (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 1009568-12-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-


Serial#: 10/675,927

yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, phosphonate (1:?)
(CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2


CRN 13598-36-2

CMF H3 O3 P



RN 1009568-13-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:?)
(CA INDEX NAME)



●X HCl

RN 1009568-14-2 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, sulfite (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O

Serial#: 10/675,927



CM 2

CRN 7782-99-2

CMF H2 O3 S




RN 1009568-15-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyloxy]-N-[4-(trifluoromethyl)phenyl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 1009568-16-4 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyloxy]-N-[4-(trifluoromethyl)phenyl]-, nitrate (1:?) (CA INDEX NAME)

Serial#: 10/675,927

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 7697-37-2

CMF H N O3




RN 1009568-17-5 HCAPLUS

CN Disulfurous acid, sodium salt, compd. with
1-methyl-5-([2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy)-N-
[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:2:?) (CA INDEX
NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2

CRN 7681-57-4

CMF H2 O5 S2 . 2 Na



●2 Na


Serial#: 10/675,927

RN 1009568-18-6 HCAPLUS
CN Phosphoric acid, potassium salt, compd. with
1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-
[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (1:1:?) (CA INDEX
NAME)

CM 1

CRN 927880-90-8

CMF C24 H16 F6 N6 O



CM 2


CRN 7778-77-0

CMF H3 O4 P . K



● K

IT 927880-90-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and oral compns. of salts of benzimidazolyl pyridyl ethers for
treatment of cancer)
RN 927880-90-8 HCAPLUS
CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-
yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

Serial#: 10/675,927

L14 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:126341 HCAPLUS Full-text
 DOCUMENT NUMBER: 148:212451
 TITLE: Use of melanoma inhibitory activity (MIA) protein as
 an early indicator for therapeutic response in
 melanoma
 INVENTOR(S): Tan, Nguyen; Venetsanakos, Eleni; Faure, Michel;
 Heise, Carla
 PATENT ASSIGNEE(S): Novartis AG, Switz.
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008013912	A1	20080131	WO 2007-US16848	20070726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2007277144	A1	20080131	AU 2007-277144	20070726
CA 2659270	A1	20080131	CA 2007-2659270	20070726
EP 2049904	A1	20090422	EP 2007-797034	20070726
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009544970	T	20091217	JP 2009-521842	20070726
MX 2009001070	A	20090423	MX 2009-1070	20090127
KR 2009046893	A	20090511	KR 2009-704157	20090227
CN 101512343	A	20090819	CN 2007-80033670	20090311
US 20100009392	A1	20100114	US 2009-375074	20090518
PRIORITY APPLN. INFO.:			US 2006-820756P	P 20060728
			WO 2007-US16848	W 20070726

AB The present invention relates to the use of Melanoma Inhibitory Activity (MIA) Protein as an early indicator for response to treatment with a melanoma tumor cell inhibitor in mammalian subjects suffering from melanoma. MIA is expressed and secreted by melanoma cells lines and not by colon carcinoma cell lines. MIA is secreted in vivo in mice bearing human melanoma cells and can be detected in plasma by ELISA. It has also been demonstrated that a decrease in the concentration of MIA measured after treatment with a candidate melanoma inhibitory agent, as compared to the concentration of MIA before treatment, serves as an early and accurate indicator of the efficacy of the agent for treating melanoma in a mammalian subject. Therefore, the presence or concentration of MIA measured before and after treatment may be used to determine a mammalian subject's response to treatment with a melanoma inhibitory agent. Moreover, the data described herein suggest that MIA may be useful in human clin. trials of agents that are cytostatic as well as for agents that are cytotoxic.


IT 927880-90-3
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

Serial#: 10/675,927

(use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:94822 HCAPLUS Full-text

DOCUMENT NUMBER: 148:175769

TITLE: Formulations for benzimidazolyl pyridyl ethers

INVENTOR(S): Hashash, Ahmad; Ritchie, Sean; Lin, Kangwen; Shen, Peng; Okhamafe, Augustus; Gullapalli, Rampurna

PATENT ASSIGNEE(S): Novartis AG, Switz.

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008011154	A2	20080124	WO 2007-US16469	20070720
WO 2008011154	A3	20080626		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007275634	A1	20080124	AU 2007-275634	20070720
CA 2657346	A1	20080124	CA 2007-2657346	20070720
EP 2046292	A2	20090415	EP 2007-810647	20070720
EP 2046292	B1	20100303		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009544617	T	20091217	JP 2009-520854	20070720
AT 459338	T	20100315	AT 2007-810647	20070720
KR 2009033904	A	20090406	KR 2009-703547	20090220


Serial#: 10/675,927

CN 101516335	A	20090826	CN 2007-80035017	20090320
US 20100040677	A1	20100218	US 2009-374383	20090925
PRIORITY APPLN. INFO.:			US 2006-832715P	P 20060721
			WO 2007-US16469	W 20070720

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:175769

GI



I


AB Formulations are provided, comprising: a compound of formula (I), a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture of any two or more thereof. In some embodiments, the formulations are liqs. In other embodiments, the formulations are solids. Also provided are methods of preparing such formulations.

IT 927880-90-8P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(formulations for benzimidazolyl pyridyl ethers)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L14 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2010 ACS ON STN

ACCESSION NUMBER: 2008:70351 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 148:205324

TITLE: Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. [Erratum to document cited in CA147:439495]

AUTHOR(S): Potashman, Michele H.; Bready, James; Coxon, Angela; DeMelfi, Thomas M.; DiPietro, Lucian; Doerr, Nicholas; Elbaum, Daniel; Estrada, Juan; Gallant, Paul; Germain,

Julie; Gu, Yan; Harmange, Jean-Christophe; Kaufman, Stephen A.; Kendall, Rick; Kim, Joseph L.; Kumar, Gondi N.; Long, Alexander M.; Neervannan, Seshadri; Patel, Vinod F.; Polverino, Anthony; Rose, Paul; van der Plas, Simon; Whittington, Douglas; Zanon, Roger; Zhao, Huilin

CORPORATE SOURCE: Department of Medicinal Chemistry, Amgen Inc.,
Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2008), 51(3), 699
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB On page 4351, coauthor Roger Zanon is incorrectly listed as a corresponding author with an asterisk by his name; That symbol should be an open circle indicating his affiliation with the Department of Pharmaceuticals.


IT 769960-02-3P 769960-04-5P 769960-12-5P
769960-13-6P 769960-20-5P 952490-47-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors (Erratum))

RN 769960-02-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 769960-04-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 769960-12-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethoxy]-4-


Serial#: 10/675,927

(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA
INDEX NAME)




RN 769960-13-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA
INDEX NAME)



RN 769960-20-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 952490-47-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2S)-1-methyl-2-pyrrolidinyl)methoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 611212-56-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors (Erratum))
 RN 611212-56-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L14 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:25563 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 148:298994
 TITLE: A quantitative analysis of kinase inhibitor selectivity

AUTHOR(S): Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Cicceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.

CORPORATE SOURCE: Ambit Biosciences, San Diego, CA, 92121, USA
 SOURCE: Nature Biotechnology (2008), 26(1), 127-132
 CODEN: NABIF9; ISSN: 1087-0156


PUBLISHER: Nature Publishing Group
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome. The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome. The data constitute the most comprehensive study of kinase inhibitor

Serial#: 10/675,927

selectivity to date and reveal a wide diversity of interaction patterns. To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the observed interaction patterns. The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.

IT 927880-90-8, RAF 265
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CHIR 265,RAF 265; quant. anal. of kinase inhibitor selectivity)
 RN 927880-90-8 HCAPLUS
 CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 210 THERE ARE 210 CAPLUS RECORDS THAT CITE THIS RECORD (216 CITINGS)
 REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:1333422 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:528221
 TITLE: Pharmaceutical synergistic combinations comprising an mTOR inhibitor and a Raf kinase inhibitor and its use in cancer treatment
 INVENTOR(S): Lane, Heidi
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007131869	A2	20071122	WO 2007-EP4112	20070509
WO 2007131869	A3	20081231		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007251869	A1	20071122	AU 2007-251869	20070509
CA 2650232	A1	20071122	CA 2007-2650232	20070509

Serial#: 10/675,927

EP 2023956	A2	20090218	EP 2007-725034	20070509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,				
AL, BA, HR, MK, RS				
JP 2009536632	T	20091015	JP 2009-508250	20070509
IN 2008DN09133	A	20090327	IN 2008-DN9133	20081031
US 20090105285	A1	20090423	US 2008-299819	20081106
MX 2008014343	A	20081120	MX 2008-14343	20081110
CN 101495147	A	20090729	CN 2007-80017076	20081111
KR 2009010112	A	20090128	KR 2008-730093	20081210
PRIORITY APPLN. INFO.:			GB 2006-9378	A 20060511
			WO 2007-EP4112	W 20070509

OTHER SOURCE(S): MARPAT 147:528221


AB A pharmaceutical combination is disclosed comprising an mTOR inhibitor and a Raf kinase inhibitor as a synergistic drug combination, and its use in cancer treatment.

IT 927880-90-8, CHIR 265

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical synergistic combinations comprising an mTOR inhibitor and a Raf kinase inhibitor and its use in cancer treatment)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L14 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:899544 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:439495

TITLE: Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors

AUTHOR(S): Potashman, Michele H.; Bready, James; Coxon, Angela; DeMelfi, Thomas M., Jr.; DiPietro, Lucian; Doerr, Nicholas; Elbaum, Daniel; Estrada, Juan; Gallant, Paul; Germain, Julie; Gu, Yan; Harmange, Jean-Christophe; Kaufman, Stephen A.; Kendall, Rick; Kim, Joseph L.; Kumar, Gondi N.; Long, Alexander M.; Neervannan, Seshadri; Patel, Vinod F.; Polverino, Anthony; Rose, Paul; Van der Plas, Simon; Whittington, Douglas; Zanon, Roger; Zhao, Huilin

CORPORATE SOURCE: Department of Medicinal Chemistry, Amgen Inc., Cambridge, MA, 02139, USA

SOURCE: Journal of Medicinal Chemistry (2007), 50(18), 4351-4373

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:439495


Serial#: 10/675,927

AB inhibition of the VEGF signaling pathway has become a valuable approach in the treatment of cancers. guided by X-ray crystallog. and mol. modeling, a series of 2-aminobenzimidazoles and 2-aminobenzoxazoles were identified as potent inhibitors of the vascular endothelial growth factor-2 receptor tyrosine kinase VEGFR-2 (also known as KDR, kinase insert domain receptor) in both enzymic and HUVEC cellular proliferation assays. in this report we describe the synthesis and structure-activity relationship of a series of 2-aminobenzimidazoles and benzoxazoles, culminating in the identification of a nonracemic pyrrolidinylmethoxyphenylaminobenzoxazolyloxy pyridinecarboxamide as a potent and selective VEGFR-2 inhibitor displaying a good pharmacokinetic profile. the nonracemic pyrrolidinylmethoxyphenylaminobenzoxazolyloxy pyridinecarboxamide also demonstrated efficacy in both the murine matrigel model for vascular permeability (79% inhibition observed at 100 mg/kg) and the rat corneal angiogenesis model (ED50 = 16.3 mg/kg).

IT 611212-56-7P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (design and preparation of arylamino- and aryloxy-substituted benzimidazoles and benzoxazoles as potential orally active inhibitors of VEGFR-2/KDR and of angiogenesis based on modeling from a crystal structure of a lead compound bound to VEGFR-2)

RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




IT 769960-02-3P 769960-04-5P 769960-12-5P
 769960-13-6P 769960-20-5P 952490-47-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylamino- and aryloxy-substituted benzimidazoles and benzoxazoles as potential orally active inhibitors of VEGFR-2/KDR and of angiogenesis for use as anticancer agents)

RN 769960-02-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




Serial#: 10/675,927

RN 769960-04-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 769960-12-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-13-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-20-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 952490-47-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:618350 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:52934

TITLE: Preparation of pyrrolotriazines useful for treating cancer through inhibition of aurora kinase.

INVENTOR(S): Magnuson, Steven; Dixon, Julie; Phillips, Barton; Khire, Uday; Wang, Lei; Zhang, Zhonghua; Patel, Manoj; Kumarasinghe, Ellalahewage Sathyajith; Wickens, Philip; O'laque, Alan

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 116pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007064932	A2	20070607	WO 2006-US46082	20061201
WO 2007064932	A3	20080110		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

Serial#: 10/675,927

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,	
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,	
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,	
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA	
CA 2631732 A1 20070607 CA 2006-2631732 20061201	
EP 1957078 A2 20080820 EP 2006-844737 20061201	
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,	
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR	
JP 2009518304 T 20090507 JP 2008-543507 20061201	
IN 2008DN05598 A 20080926 IN 2008-DN5598 20080627	
KR 2008083652 A 20080918 KR 2008-716159 20080702	
CN 101448506 A 20090603 CN 2006-80052186 20080801	
PRIORITY APPLN. INFO.:	
US 2005-742003P P 20051202	
WO 2006-US46082 W 20061201	


OTHER SOURCE(S): MARPAT 147:52934
GI



AB Title compds. [I; A = atoms to form 5-7 membered aryl, heteroaryl, heterocyclyl; R1 = H, halo, alkyl, CF3, OH, alkoxy, OCF3, NO2, alkylcarbonyl, CO2H, PhCO, heterocyclyl, alkylphenyl etc.; R1R5 = atoms to form 1,3-dioxolanyl, 1,4-dioxanyl; R2 = H, halo, Me; R3 = COXR31; R31 = H, alkyl, trifluoroethyl, alkoxyalkyl, cycloalkyl, dialkylaminoalkyl, heterocyclylalkyl, etc.; X = O, NH, NZ; Z = alkyl; R4, R6 = H, halo; R5 = H, halo, alkyl], were prepared Thus, 4-amino-5-(4-aminophenyl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide (preparation given) was stirred with carbonyldiimidazole in DMF overnight; 1,2-phenylenediamine was added followed by stirring for 18 h, addition of diisopropylcarbodiimide, and stirring for a further 18 h to give 41% title compound 4-amino-5-[4-(1H-benzimidazol-2-ylamino)phenyl]-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The latter and other I inhibited aurora kinase 1 and 2 with IC50 <0.1 μ M.

IT 1044945-76-7
RL: PRPH (Prophetic)
(preparation of pyrrolotriazines useful for treating cancer through inhibition of aurora kinase)

RN 1044945-76-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



L14 ANSWER 28 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:538292 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:8399
 TITLE: Anti-neuropilin 1 antagonistic antibodies for research, diagnosis and therapy of cancer and angiogenesis-associated disease
 INVENTOR(S): Watts, Ryan J.; Wu, Yan
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056470	A2	20070518	WO 2006-US43516	20061108
WO 2007056470	A3	20070809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006311590	A1	20070518	AU 2006-311590	20061108
CA 2629028	A1	20070518	CA 2006-2629028	20061108
EP 1951758	A2	20080806	EP 2006-827637	20061108
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009514972	T	20090409	JP 2008-540169	20061108
ZA 2008003811	A	20090826	ZA 2008-3811	20061108
IN 2008DN03196	A	20080815	IN 2008-DN3196	20080417
US 20080213268	A1	20080904	US 2008-107544	20080422
MX 2008005899	A	20080522	MX 2008-5899	20080507
KR 2008068105	A	20080722	KR 2008-713575	20080605
CN 101326196	A	20081217	CN 2006-80045839	20080605
NO 2008002531	A	20080609	NO 2008-2531	20080606
PRIORITY APPLN. INFO.:			US 2005-734798P	P 20051108
			US 2006-820561P	P 20060727


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.

IT 927880-90-8, CHIR 265
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-neuropilin 1 antagonistic antibodies for research, diagnosis and therapy of cancer and angiogenesis-associated disease)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L14 ANSWER 29 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:230755 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:295927

TITLE: Method for the preparation of benzimidazoles

INVENTOR(S): Dinitroff, Martin; Miller, Bridget R.; Stillwell, Brady S.; Siesel, David A.; Swiftney, Tyson; Diaz, Brian; Gu, Danlin; Van Dyck, Jonathan P.; Ryckman, David; Poon, Daniel J.; Pick, Teresa E.

PATENT ASSIGNEE(S): Novartis AG, USA

SOURCE: U.S. Pat. Appl. Publ., 50pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070049622	A1	20070301	US 2006-513745	20060830
AU 2006284666	A1	20070308	AU 2006-284666	20060830
CA 2619966	A1	20070308	CA 2006-2619966	20060830
WO 2007027950	A1	20070308	WO 2006-US34112	20060830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006287688	A1	20070315	AU 2006-287688	20060830
CA 2620472	A1	20070315	CA 2006-2620472	20060830

Serial#: 10/675,927

WO 2007030377	A1	20070315	WO 2006-US34088	20060830
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20070161680	A1	20070712	US 2006-513959	20060830
US 7482367	B2	20090127		
EP 1924577	A1	20080528	EP 2006-790127	20060830
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
EP 1926722	A1	20080604	EP 2006-824870	20060830
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009507026	T	20090219	JP 2008-529285	20060830
JP 2009507794	T	20090226	JP 2008-529291	20060830
ZA 2008000506	A	20091125	ZA 2008-506	20080117
ZA 2008000536	A	20081231	ZA 2008-536	20080118
IN 2008DN00614	A	20080711	IN 2008-DN614	20080122
IN 2008DN00731	A	20080711	IN 2008-DN731	20080125
MX 2008002876	A	20080407	MX 2008-2876	20080228
MX 2008002879	A	20080407	MX 2008-2879	20080228
KR 2008039964	A	20080507	KR 2008-705201	20080229
KR 2008039965	A	20080507	KR 2008-705202	20080229
CN 101253168	A	20080827	CN 2006-80031748	20080229
CN 101253169	A	20080827	CN 2006-80031826	20080229
NO 2008001476	A	20080326	NO 2008-1476	20080326
NO 2008001531	A	20080529	NO 2008-1531	20080328
US 20080287682	A1	20081120	US 2008-151995	20080505
US 20090170904	A1	20090702	US 2008-315779	20081205
PRIORITY APPLN. INFO.:			US 2005-712539P	P 20050830
			US 2005-713108P	P 20050830
			US 2005-731591P	P 20051027
			US 2006-774684P	P 20060217
			US 2005-713591P	P 20051027
			US 2006-513745	B1 20060830
			US 2006-513959	A3 20060830
			WO 2006-US34088	W 20060830
			WO 2006-US34112	W 20060830

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 146:295927; MARPAT 146:295927
 GI




AB A method for the preparation of 2-phenylamino-5-[[2-(imidazol-2-yl)pyridin-4-yl]oxy]benzimidazoles I [wherein R₁, R₄ = OH, halo, alkyl, etc.; R₂ = (halo)alkyl; R₃ = halo, alkyl or alkoxy; a = 1-5, b = 0-3, c = 1-2] and their tautomers, stereoisomers, esters, metabolites, prodrugs, or pharmaceutically acceptable salts thereof is disclosed. For instance, successive treatment of 4-amino-3-nitrophenol with tert-Bu 4-chloropyridine-2-carboxylate (74%), N-acylation with trifluoroacetic anhydride, N-methylation with Me₂SO₄, removal of the trifluoroacetyl group (76% for three steps), reduction of the resultant ester II (R = COOBu-t) with lithium aluminum hydride (46%), and oxidation with MnO₂ (58%) led to aldehyde II (R = CHO). This compound underwent cyclization with CF₃C(O)CHO, which was generated from CF₃C(O)CHBr₂, in NH₄OH (91%) to give imidazole II (R = 4-trifluoromethylimidazol-2-yl). The nitro was then reduced into amino with H₂ in the presence of Pd/C (96%), and subsequent addition to 4-trifluoromethylphenyl isothiocyanate followed by FeCl₃-mediated desulfurization/cyclization afforded benzimidazole III. I are useful for treating kinase mediated disorders (no data).

IT 927880-90-8P 927881-04-7P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazoles via desulfurization/cyclization of (aminophenyl)thioureas)

RN 927880-90-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 927881-04-7 HCAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[4-[[2-[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-

Serial#: 10/675,927

pyridinyl]-5-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)




IT	927880-91-9P	927880-93-1P	927880-94-2P
	927880-95-3P	927880-96-4P	927880-97-5P
	927880-98-6P	927880-99-7P	927881-00-3P
	927881-01-4P	927881-02-5P	927881-03-6P
	927881-05-9P	927881-06-9P	927881-07-0P
	927881-08-1P	927881-09-2P	927881-10-5P
	927881-11-6P	927881-12-7P	927881-13-8P
	927881-14-9P	927881-15-0P	927881-16-1P
	927881-17-2P	927881-18-3P	927881-19-4P
	927881-20-7P	927881-21-8P	927881-22-9P
	927881-23-0P	927881-24-1P	927881-25-2P
	927881-26-3P	927881-27-4P	927881-28-5P
	927881-29-6P	927881-30-3P	927881-31-0P
	927881-32-1P	927881-33-2P	927881-34-3P
	927881-35-4P	927881-36-5P	927881-37-6P
	927881-38-7P	927881-39-8P	927881-40-1P
	927881-41-2P	927881-42-3P	927881-43-4P
	927881-44-5P	927881-45-6P	927881-46-7P
	927881-47-8P	927881-48-9P	927881-49-0P
	927881-50-3P	927881-51-4P	927881-53-6P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of benzimidazoles via desulfurization/cyclization of (aminophenyl)thioureas)


RN 927880-91-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(3-pyridinyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927880-93-1 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(4-pyridinyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 927880-94-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-(1,1-dimethylethyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 927880-95-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 927880-96-4 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(3-ethylphenyl)-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927880-97-5 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-chlorophenyl)-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927880-98-6 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-ethylphenyl)-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 927880-99-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-chloro-3-(trifluoromethyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 927881-00-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-01-4 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-N-[4-(trifluoromethoxy)phenyl]-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-02-5 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-methyl-5-[[2-[4-methyl-5-[3-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 927881-03-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-methyl-5-
[[2-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]-4-
pyridinyl]oxy]- (CA INDEX NAME)




RN 927881-05-8 HCAPLUS

CN 1H-Imidazole-4-methanol, 2-[4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 927881-06-9 HCAPLUS


CN 1H-Imidazole-5-carbonitrile, 2-[4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-
(CA INDEX NAME)



RN 927881-07-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-[3-(1,1-dimethylethyl)phenyl]-1-methyl-5-[[2-(5-phenyl-1H-imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 927881-08-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(5-phenyl-1H-imidazol-2-yl)-4-pyridinyl]oxy]-N-[4-[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)




RN 927881-09-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[3-(1,1-dimethylethyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 927881-10-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-fluoro-3-(tetrahydro-3-furanyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-11-6 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 927881-12-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-fluoro-3-(1-methylethyl)phenyl]-1-methyl-5-
[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX
NAME)




RN 927881-13-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-
yl]-4-pyridinyl]oxy]-N-[4-[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)




RN 927881-14-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(1-methylethyl)phenyl]-1-methyl-5-
[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX
NAME)



RN 927881-15-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-methyl-5-
[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX
NAME)



Serial#: 10/675,927


RN 927881-16-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[5-(1,1-dimethylethyl)-2-fluorophenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 927881-17-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-methyl-5-[[2-(5-methyl-1H-imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 927881-18-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-chloro-4-(trifluoromethyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-19-4 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-[2-chloro-5-(1,1-dimethylethyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 927881-20-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-methyl-5-
[[2-[4-phenyl-5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA
INDEX NAME)




RN 927881-21-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-chloro-5-(trifluoromethyl)phenyl]-1-methyl-5-
[[2-[4-phenyl-5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA
INDEX NAME)




RN 927881-22-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[4-phenyl-5-(trifluoromethyl)-1H-
imidazol-2-yl]-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX
NAME)



RN 927881-23-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(3-ethylphenyl)-1-methyl-5-[[2-[4-phenyl-5-
(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 927881-24-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-(1,1-dimethylethyl)phenyl]-1-methyl-5-[[2-(4-phenyl-5-(trifluoromethyl)-1H-imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 927881-25-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-chloro-5-(trifluoromethyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 927881-26-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-methyl-5-[[2-(4-methyl-5-phenyl-1H-imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-27-4 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-[2-chloro-5-(trifluoromethyl)phenyl]-1-methyl-5-[[2-(4-methyl-5-phenyl-1H-imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 927881-28-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-(1,1-dimethylethyl)phenyl]-1-methyl-5-[[2-(4-methyl-5-phenyl-1H-imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 927881-29-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(4-methyl-5-phenyl-1H-imidazol-2-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 927881-30-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[5-(1,1-dimethylethyl)-2-fluorophenyl]-1-methyl-5-[[2-(4-methyl-5-phenyl-1H-imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-31-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-N-[4-(4-methyl-1-piperazinyl)phenyl]-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-32-1 HCAPLUS


CN 1H-Imidazole-5-carboxylic acid, 2-[4-[[2-[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-, methyl ester (CA INDEX NAME)

Serial#: 10/675,927




RN 927881-33-2 HCAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-5-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)




RN 927881-34-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-fluoro-4-(trifluoromethyl)phenyl]-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-35-4 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(2-chlorophenyl)-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-36-5 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(2,5-dimethoxyphenyl)-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 927881-37-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(3,5-dimethoxyphenyl)-1-methyl-5-([2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy)- (CA INDEX NAME)




RN 927881-38-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-([2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 927881-39-8 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(2-ethylphenyl)-1-methyl-5-([2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy)- (CA INDEX NAME)



RN 927881-40-1 HCAPLUS


CN Methanone, (4-ethyl-1-piperazinyl)[2-[4-([2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy)-1-methyl-1H-benzimidazol-5-yl]amino]-1-methyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 927881-41-2 HCAPLUS

CN 1H-Imidazole-5-carboxamide, 2-[4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 927881-42-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-ethyl-N-[2-fluoro-5-(trifluoromethyl)phenyl]-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-43-4 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-[2-fluoro-5-(trifluoromethyl)phenyl]-6-methoxy-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 927881-44-5 HCAPLUS


CN 1H-Benzimidazol-2-amine, 6-methoxy-1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 927881-45-6 HCAPLUS

CN Methanone, (4-ethyl-1-piperazinyl) [2-[4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 927881-46-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-ethyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 927881-47-8 HCAPLUS


CN 1H-Imidazole-5-carboxamide, N-(2-hydroxyethyl)-2-[4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)



RN 927881-48-9 HCAPLUS


CN Phenol, 2-[[1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-5-(trifluoromethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 927881-49-0 HCAPLUS

CN 1H-imidazole-5-carbonitrile, 2-[[4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)




RN 927881-50-3 HCAPLUS

CN Phenol, 5-[[1-methyl-5-[[2-[[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 927881-51-4 HCAPLUS

CN 2-Pyridinecarbonitrile, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 927881-53-6 HCAPLUS

CN 2-Pyridinecarbonitrile, 4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)


L14 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2010 ACS ON STN
ACCESSION NUMBER: 2004:857399 HCAPLUS Full-text
DOCUMENT NUMBER: 141:343478
TITLE: Use of small molecule compounds for immunopotential
INVENTOR(S): Valiante, Nicholas
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087153	A2	20041014	WO 2004-US10331	20040329
WO 2004087153	A3	20050317		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2520124	A1	20041014	CA 2004-2520124	20040329
US 20050136065	A1	20050623	US 2004-814480	20040329
EP 1608369	A2	20051228	EP 2004-758593	20040329
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRIORITY APPLN. INFO.:			US 2003-458888P	P 20030328
			WO 2004-US10331	W 20040329

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:343478

GI



I

AB The invention provides immunostimulatory compns. comprising a small mol. immunopotentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are compns. and methods of administering SMIP compds. alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. Preparation of selected compds., e.g. I, is included.


IT 611213-07-1 611214-93-8 611215-16-8
611216-17-2 611223-31-5 774196-96-2
774196-97-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(small mol. compds. for immunopotentialiation)


RN 611213-07-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611214-93-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-bicyclohexyl]-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-16-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-benzoylphenyl)amino]-1-methyl-1H-


Serial#: 10/675,927

benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-17-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(6-(1-pyrrolidinyl)-3-pyridinyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-31-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 774196-96-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[2-(trimethylsilyl)ethynyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 774196-97-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-

Serial#: 10/675,927

benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)




IT 611212-56-7P 611213-70-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(small mol. compds. for immunopotential)


RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-70-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:817883 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:332190

TITLE: Preparation of fused azoles such as 2,5-disubstituted
benzimidazoles, benzoxazoles and benzothiazoles as
kinase inhibitors

INVENTOR(S): Dipietro, Lucian V.; Harmange, Jean-Christophe; Askew,
Benny C., Jr.; Elbaum, Daniel; Germain, Julie;
Habgood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.;
Potashman, Michele; Van der Plas, Simon

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 289 pp., Chemical Indexing Equivalent

Serial#: 10/675,927

to 150:515173 (US)

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085425	A1	20041007	WO 2004-US8809	20040322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 7531553	B2	20090512	US 2004-804915	20040319
US 20040209892	A1	20041021		
AU 2004223827	A1	20041007	AU 2004-223827	20040322
AU 2004223827	B2	20080306		
CA 2518909	A1	20041007	CA 2004-2518909	20040322
EP 1638954	A1	20060329	EP 2004-758050	20040322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006520805	T	20060914	JP 2006-507472	20040322
MX 2005010086	A	20060210	MX 2005-10086	20050921
PRIORITY APPLN. INFO.:			US 2003-456691P	P 20030321
			US 2004-804915	A 20040319
			WO 2004-US8809	A 20040322

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:332190

GI



AB Title compds. I [W, X, Y1 and Y2 independently = O, S(O)n and NR3; ring A optionally contains a N atom at a non-fused, non-substituted ring position; n = 0-2; R =

Serial#: 10/675,927

(un)substituted-aryl, -heterocyclyl, -fused heterocyclyl, etc.; R1 = (un)substituted-aryl, -arylalkyl, -heterocyclyl, etc.; R2 = H, halo, alkoxy, etc.; R3 = H or alkyl are prepared and disclosed as having kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Thus, e.g., II was prepared by cyclocondensation of 4-(pyridin-4-yloxy)benzene-1,2-diamine with 1-chloro-4-isothiocyanato-2-trifluoromethylbenzene. In human umbilical vein endothelial cell proliferation assay, selected I inhibited VEGF-stimulated proliferation at a level below 100 nM. Accordingly, I would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmol. conditions, proliferative diseases, inflammatory diseases, and other pathol. conditions as described in the specification.


IT 1055984-34-2P 1055984-36-5P 1055984-41-2P
 1055984-55-9P 1055984-59-2P 1055984-78-5P
 1055984-83-2P 1055984-87-6P 1055985-14-2P
 1055985-37-9P 1055985-56-2P 1055985-58-4P
 1055985-70-0P 1055985-75-5P 1055985-77-7P
 1055985-79-9P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)


RN 1055984-34-3 HCAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(3-pyrrolidinylmethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 1055984-36-5 HCAPLUS


CN 3-Pyridinecarboxamide, 4-[[2-[[4-chlorophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 1055984-41-2 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED

Serial#: 10/675,927




RN 1055984-55-8 HCAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-1-ethyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 1055984-59-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[4-bromo-3-(trifluoromethyl)phenyl]-6-[(3-methyl-4-pyridinyl)oxy]- (CA INDEX NAME)



RN 1055984-78-5 HCAPLUS


CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-methoxyethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 1055984-83-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1055984-87-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1055985-14-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1055985-37-9 HCAPLUS


CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(1-methyl-2-pyrrolidinyl)methyl]amino]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl-
(CA INDEX NAME)



RN 1055985-56-2 HCAPLUS


Serial#: 10/675,927

CN INDEX NAME NOT YET ASSIGNED




RN 1055985-58-4 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1055985-70-0 HCAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(1-methyl-2-pyrrolidinyl)methoxy]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 1055985-75-5 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED



Serial#: 10/675,927


RN 1055985-77-7 HCAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 1055985-79-9 HCAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(3-pyrrolidinylmethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




IT	611212-56-7P	769960-01-2P	769960-02-3P
	769960-03-4P	769960-04-5P	769960-05-6P
	769960-06-7P	769960-07-8P	769960-08-9P
	769960-09-0P	769960-10-3P	769960-11-4P
	769960-12-5P	769960-13-6P	769960-14-7P
	769960-15-8P	769960-16-9P	769960-19-2P
	769960-20-5P	769960-82-9P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 769960-01-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(1,1,2,2,2-pentafluoroethyl)-3-


Serial#: 10/675,927

[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 769960-02-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[[2-(1-pyrrolidinyl)ethoxy]-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 769960-03-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(1,1,2,2,2-pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 769960-04-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[[2-(1-pyrrolidinyl)ethoxy]-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.


Serial#: 10/675,927




RN 769960-05-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethyl]-4-methoxyphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-06-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-(difluoromethoxy)-4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 769960-07-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-[[2-(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 769960-08-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 769960-09-0 HCAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 769960-10-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 769960-11-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(1-piperazinylmethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 769960-12-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-13-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-14-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



Serial#: 10/675,927


RN 769960-15-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-(1-methylethyl)-1-piperazinyl]methyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 769960-16-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-(methylsulfonyl)-1-piperazinyl]methyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-19-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-5-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 769960-20-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-methyl-1-piperazinyl]methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 769960-82-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(1-methyl-2-pyrrolidinyl)methoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




IT 769961-24-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 769961-24-2 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-2-(1,1,2,2,2-pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 769961-00-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 769961-00-4 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-chloro-5-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



—CBu-t

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 32 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:513393 HCAPLUS Full-text

DOCUMENT NUMBER: 141:71544

TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors

INVENTOR(S): Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040122237	A1	20040624	US 2003-675927	20030929
US 20040087626	A1	20040506	US 2003-405945	20030331
US 7071216	B2	20060704		
AU 2004277405	A1	20050414	AU 2004-277405	20040929
CA 2539748	A1	20050414	CA 2004-2539748	20040929
WO 2005032548	A1	20050414	WO 2004-US32161	20040929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				



Serial#: 10/675,927

SN, TD, TG				
EP 1675584	A1	20060705	EP 2004-789345	20040929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004014908	A	20061107	BR 2004-14908	20040929
CN 1913884	A	20070214	CN 2004-80032677	20040929
JP 2007507428	T	20070329	JP 2006-528331	20040929
US 20070299039	A1	20071227	US 2005-282939	20051118
MX 2006003435	A	20060620	MX 2006-3435	20060327
JP 2006193533	A	20060727	JP 2006-96143	20060330
KR 2006089232	A	20060808	KR 2006-706470	20060403
IN 2006KN0838	A	20070413	IN 2006-KN838	20060405
ZA 2006003418	A	20070725	ZA 2006-3418	20060428
PRIORITY APPLN. INFO.:			US 2002-369066P	P 20020329
			US 2003-405945	A2 20030331
			JP 2003-579810	A3 20030331
			US 2003-675927	A 20030929
			WO 2004-US32161	W 20040929

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:71544

GI



AB The title compds. I [wherein X1, X2 = N, NR4, O, S (with provisos); Y = O, S; A1 = (un)substituted alkyl, (hetero)cycloalkyl(alkyl), (hetero)aryl(alkyl), etc.; A2 = (un)substituted heteroaryl; R1 = O, H; R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted (cyclo)alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, heterocyclyl, (hetero)aryl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl; R7 = alkyl; and pharmaceutically acceptable salts, esters, or prodrugs] were prepared as Raf kinase inhibitors. Examples include synthetic methods and phys. data for 1400 compds., as well as descriptions of two Raf kinase bioassays. For instance, 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-methylcarboxamide were coupled using potassium bis(trimethylsilyl)amide and K2CO3 in DMF to give 4-[(4-amino-3-nitrophenyl)oxy]-N-methylpyridine-2-carboxamide. Pd-catalyzed hydrogenation, followed by cyclization with 4-chloro-3-(trifluoromethyl)benzenesulfonyl isothiocyanate in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide•HCl in THF provided the benzimidazole II. One thousand ninety-four compounds. inhibited Raf kinase activity with IC50 < 5 μM in a Raf/Mek filtration assay or a biotinylated Raf screen. Thus, I and their pharmaceutical compns., which may comprise at least one

Serial#: 10/675,927

addnl. agent, are useful for the treatment of Raf kinase mediated disorders, such as cancer (no data).


IT 611213-97-9P 611214-71-2P 611214-79-0P
611215-54-4P 611215-66-0P 611224-42-1P
611224-80-7P 611225-00-4P 710351-25-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)


RN 611213-97-9 HCAPLUS

CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 611214-71-2 HCAPLUS

CN Benzoic acid, 3-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)



RN 611214-79-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-54-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethynylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-68-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611224-42-1 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 611224-80-7 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 611224-79-4

CMF C20 H17 Br N4 O2




CM 2

Serial#: 10/675,927

CRN 76-05-1
CMF C2 H F3 O2




RN 611225-00-4 HCAPLUS
CN 1H-Benzimidazol-2-amine, 5-[[2-(aminomethyl)-4-pyridinyl]oxy]-N-(4-bromophenyl)-1-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
CM 1
CRN 611224-99-8
CMF C20 H18 Br N5 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 710351-25-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromo-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



IT 611212-56-7P 611212-57-8P 611212-58-9P
611212-59-0P 611212-60-3P 611212-61-4P
611212-63-6P 611212-64-7P 611212-67-0P
611212-68-1P 611212-69-2P 611212-71-6P
611212-72-7P 611212-74-9P 611212-75-0P
611212-76-1P 611212-77-2P 611212-78-3P
611212-79-4P 611212-80-7P 611212-81-8P
611212-82-9P 611212-83-0P 611212-84-1P
611212-85-2P 611212-86-3P 611212-87-4P
611212-88-5P 611212-89-6P 611212-90-9P
611212-91-0P 611212-92-1P 611212-93-2P
611212-94-3P 611212-95-4P 611212-96-5P
611212-97-6P 611212-98-7P 611212-99-8P
611213-00-9P 611213-01-5P 611213-02-6P
611213-03-7P 611213-04-8P 611213-05-9P
611213-06-0P 611213-07-1P 611213-08-2P
611213-09-3P 611213-10-6P 611213-11-7P
611213-12-8P 611213-13-9P 611213-14-0P
611213-15-1P 611213-16-2P 611213-17-3P
611213-18-4P 611213-19-5P 611213-20-8P
611213-21-9P 611213-22-0P 611213-23-1P
611213-24-2P 611213-25-3P 611213-26-4P
611213-27-5P 611213-28-6P 611213-29-7P
611213-30-0P 611213-31-1P 611213-32-2P
611213-33-3P 611213-34-4P 611213-35-5P
611213-36-6P 611213-37-7P 611213-38-8P
611213-39-9P 611213-40-2P 611213-41-3P
611213-42-4P 611213-43-5P 611213-44-6P
611213-45-7P 611213-46-8P 611213-47-9P
611213-48-0P 611213-49-1P 611213-50-4P
611213-51-5P 611213-53-7P 611213-54-8P
611213-55-9P 611213-56-0P 611213-57-1P
611213-58-2P 611213-60-6P 611213-70-8P
611213-71-9P 611213-72-0P 611213-73-1P
611213-74-2P 611213-75-3P 611213-76-4P
611213-77-5P 611213-78-6P 611213-79-7P
611213-80-0P 611213-81-1P 611213-82-2P
611213-83-3P 611213-84-4P 611213-85-5P
611213-86-6P 611213-87-7P 611213-88-8P
611213-89-9P 611213-90-2P 611213-91-3P
611213-92-4P 611213-93-5P 611213-94-6P
611213-95-7P 611213-96-8P 611213-99-1P
611214-00-7P 611214-01-8P 611214-02-9P
611214-03-0P 611214-04-1P 611214-05-2P
611214-06-3P 611214-08-5P 611214-09-6P
611214-10-9P 611214-11-0P 611214-12-1P
611214-13-2P 611214-14-3P 611214-15-4P
611214-16-5P 611214-17-6P 611214-19-7P
611214-19-8P 611214-20-1P 611214-21-2P
611214-22-3P 611214-23-4P 611214-24-5P
611214-25-6P 611214-26-7P 611214-27-8P
611214-28-9P 611214-29-0P 611214-30-3P
611214-31-4P 611214-32-5P 611214-33-6P
611214-34-7P 611214-35-8P 611214-36-9P
611214-37-0P 611214-38-1P 611214-39-2P
611214-40-5P 611214-41-6P 611214-42-7P
611214-43-8P 611214-44-9P 611214-46-1P
611214-47-2P 611214-48-3P 611214-49-4P
611214-50-7P 611214-51-8P 611214-52-9P

Serial#: 10/675,927


611214-53-8P	611214-55-2P	611214-56-3P
611214-57-4P	611214-58-5P	611214-59-6P
611214-60-9P	611214-61-0P	611214-62-1P
611214-63-2P	611214-69-8P	611214-70-1P
611214-72-3P	611214-73-4P	611214-74-5P
611214-75-6P	611214-77-8P	611214-78-9P
611214-80-3P	611214-83-6P	611214-84-7P
611214-85-8P	611214-86-9P	611214-87-0P
611214-88-1P	611214-89-2P	611214-90-5P
611214-91-6P	611214-93-3P	611214-95-0P
611214-96-1P	611214-97-2P	611214-98-3P
611214-99-4P	611215-00-0P	611215-01-1P
611215-03-3P	611215-06-6P	611215-07-7P
611215-08-8P	611215-09-9P	611215-11-3P
611215-12-4P	611215-13-5P	611215-14-6P
611215-15-7P	611215-16-8P	611215-17-9P
611215-18-0P	611215-21-5P	611215-22-6P
611215-23-7P	611215-24-8P	611215-25-9P
611215-26-0P	611215-27-1P	611215-28-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)


RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-57-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-58-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611212-59-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-60-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-(phenylamino)-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-61-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-63-6 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)-1-naphthalenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611212-64-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(4-nitrophenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-67-0 HCAPLUS

CN Benzoic acid, 4-[[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (CA INDEX NAME)



RN 611212-68-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-69-2 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-71-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-iodophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-72-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611212-74-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611212-75-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-acetylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-76-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-77-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-78-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




Serial#: 10/675,927


RN 611212-79-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2-[(3-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-80-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2-[(2-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-81-8 HCAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (CA INDEX NAME)



RN 611212-82-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[2-[(4-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.

Serial#: 10/675,927




RN 611212-83-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-84-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-85-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2-(trifluoromethyl)phenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-86-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927

yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-87-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(methylthio)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-88-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611212-89-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(2-methoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-90-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(2-fluorophenyl)amino]-1H-benzimidazol-6-


Serial#: 10/675,927

yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-91-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(aminosulfonyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-92-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611212-93-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3,4-dimethoxyphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-94-3 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-95-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,4-dichlorophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-96-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611212-97-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-methoxyphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-98-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[1,1'-biphenyl]-2-ylamino]-1H-benzimidazol-6-


Serial#: 10/675,927

yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-99-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-00-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(3,5-dimethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-01-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-(3,5-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-02-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[(2-ethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-03-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[(2,6-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-04-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-[[3,5-bis(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-05-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[(2-methoxy-5-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611213-06-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-07-1 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2-(1-methylethyl)phenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-08-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-4-nitrophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-09-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-10-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-11-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-12-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyclohexylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-13-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927

yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-14-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-15-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-16-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-butylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




Serial#: 10/675,927


RN 611213-17-3 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611213-18-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dichlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-19-5 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(4-phenoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-20-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611213-21-9 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(diethylamino)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-22-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-methylphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-23-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-chlorophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-24-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-bromo-4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-25-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-26-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromo-4-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-27-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-(trifluoromethyl)phenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-28-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-fluorophenyl)amino]-1H-


Serial#: 10/675,927

benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-29-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-30-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-31-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-32-2 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2,3,5-trifluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-33-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-34-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-35-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-36-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-37-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-38-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611213-39-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-(1,3-benzodioxol-5-ylamino)-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-40-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-41-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-42-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-43-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-44-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-45-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-(trifluoromethoxy)phenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-46-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(3-(methylthio)phenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611213-47-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-48-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-49-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611213-50-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-51-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-53-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-methyl-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-54-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-55-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-56-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611213-57-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-58-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-60-6 HCAPLUS
CN 2-Pyridinecarboxamide, N-(4-bromophenyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611213-70-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-71-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-72-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611213-73-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chlorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-74-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-iodophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-75-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611213-76-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611213-77-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611213-78-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-79-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-80-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611213-81-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611213-82-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-83-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-84-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-85-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-86-6 HCAPLUS

CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (CA INDEX NAME)


Serial#: 10/675,927




RN 611213-87-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-88-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-89-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(4-acetylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-90-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-91-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-92-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyclohexylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-93-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-94-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-95-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-96-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-99-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-00-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-01-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-02-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-03-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-04-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-4-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-05-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-06-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-08-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-09-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-10-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-11-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-12-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-13-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-14-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-15-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-cyanophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-16-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-17-6 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-18-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-19-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1,1'-biphenyl)-2-ylamino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-20-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-21-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-22-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-ethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-23-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-aminophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-24-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylamino)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-25-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-26-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-27-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-28-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-29-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-bis(trifluoromethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-30-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-31-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-32-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-33-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-34-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-35-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-2-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-36-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-37-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dimethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-38-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-39-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(5-oxazolyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-40-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-41-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-42-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(cyclohexylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-43-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-44-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-46-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1H-pyrazol-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-47-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-48-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(cyclopropylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-49-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-50-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(phenylmethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-51-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-52-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethyl-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-53-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(4-nitrophenoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-55-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-56-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-57-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[1-(acetyl-2,3-dihydro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-58-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-59-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[cycloheptylamino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-60-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-acetylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-61-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(bicyclo[2.2.1]hept-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-62-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-63-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1-hydroxyethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611214-69-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-70-1 HCAPLUS
CN Benzoic acid, 3-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 611214-72-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5-methyl-3-phenyl-4-isoxazolyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-73-4 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5-methyl-3-phenyl-4-isoxazolyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-74-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-75-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-1H-indazol-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-77-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-78-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927




RN 611214-80-3 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-83-6 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[5-(2-thienyl)-1H-pyrazol-3-yl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-84-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(1,3-benzodioxol-5-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-85-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-86-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-diethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-87-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1-hydroxyethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-88-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-89-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-90-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-91-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-93-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(1,1'-bicyclohexyl)-2-ylamino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-95-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927




RN 611214-96-1 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-97-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[5-fluoro-2-(1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-98-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5-phenyl-1H-pyrazol-3-yl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-99-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611215-07-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-08-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[2-(difluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-09-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[2-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-11-3 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-12-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-cyano-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-13-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[1-(phenylmethyl)amino]ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-14-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-(1H-indol-5-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-15-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-16-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-benzoylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-17-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-18-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromo-6-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-21-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(1-isoquinolinyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-22-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1H-pyrazol-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-23-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(1H-indol-6-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-24-8 HCAPLUS


CN Benzoic acid, 4-[[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-3-(trifluoromethoxy)-, methyl ester (CA INDEX NAME)



Serial#: 10/675,927


RN 611215-25-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-26-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(phenylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-27-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-28-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



IT 611215-29-3P 611215-30-6P 611215-31-7P
611215-32-8P 611215-33-3P 611215-34-0P
611215-35-1P 611215-36-2P 611215-37-3P
611215-38-4P 611215-40-8P 611215-41-9P
611215-42-0P 611215-43-1P 611215-44-2P
611215-45-3P 611215-46-4P 611215-47-5P
611215-48-6P 611215-49-7P 611215-50-0P
611215-51-1P 611215-52-2P 611215-53-3P
611215-56-6P 611215-57-7P 611215-58-8P
611215-60-2P 611215-61-3P 611215-62-4P
611215-63-5P 611215-66-8P 611215-69-1P
611215-70-4P 611215-71-5P 611215-72-6P
611215-74-9P 611215-75-9P 611215-77-1P
611215-78-2P 611215-80-6P 611215-81-7P
611215-82-8P 611215-83-9P 611215-84-0P
611215-85-1P 611215-86-2P 611215-87-3P
611215-88-4P 611215-89-5P 611215-90-8P
611215-91-9P 611215-92-0P 611215-93-1P
611215-94-2P 611215-95-3P 611215-96-4P
611215-98-6P 611215-99-7P 611216-00-3P
611216-01-4P 611216-02-5P 611216-03-6P
611216-04-7P 611216-05-8P 611216-06-9P
611216-07-0P 611216-08-1P 611216-09-2P
611216-10-5P 611216-11-6P 611216-12-7P
611216-13-8P 611216-14-9P 611216-15-0P
611216-16-1P 611216-17-2P 611216-18-3P
611216-19-4P 611216-20-7P 611216-22-9P
611216-23-0P 611216-25-2P 611216-26-3P
611216-27-4P 611216-28-5P 611216-29-6P
611216-30-9P 611216-31-0P 611216-32-1P
611216-33-2P 611216-34-3P 611216-35-4P
611216-36-5P 611216-37-6P 611216-39-8P
611216-40-1P 611216-41-2P 611216-42-3P
611216-43-4P 611216-44-5P 611216-45-6P
611216-46-7P 611216-47-8P 611216-48-9P
611216-49-0P 611216-50-3P 611216-51-4P
611216-52-5P 611216-53-6P 611216-54-7P
611216-55-8P 611216-56-9P 611216-57-0P
611216-58-1P 611216-59-2P 611216-60-5P
611216-61-6P 611216-62-7P 611216-63-8P
611216-64-9P 611216-65-0P 611216-66-1P
611216-67-2P 611216-68-3P 611216-69-4P
611216-70-7P 611216-71-8P 611216-72-9P
611216-73-0P 611216-74-1P 611216-75-2P
611216-76-3P 611216-77-4P 611216-78-5P
611216-79-6P 611216-80-9P 611216-81-0P
611216-82-1P 611216-84-3P 611216-85-4P
611216-86-5P 611216-87-6P 611216-89-7P
611216-89-8P 611216-91-2P 611216-92-3P
611216-93-4P 611216-94-5P 611216-95-6P
611216-96-7P 611216-97-8P 611216-98-9P
611216-99-0P 611217-00-6P 611217-02-8P
611217-03-9P 611217-43-7P 611217-44-8P
611217-46-0P 611217-47-1P 611217-48-2P
611217-50-6P 611217-51-7P 611217-52-8P
611217-54-0P 611217-55-1P 611217-56-2P
611217-57-3P 611217-58-4P 611217-59-5P
611217-60-6P 611217-62-0P 611217-64-2P
611217-66-4P 611217-67-5P 611217-68-6P

Serial#: 10/675,927


611217-69-7P	611217-70-6P	611217-71-1P
611217-73-3P	611217-75-5P	611217-77-7P
611217-79-9P	611217-81-3P	611217-83-5P
611217-85-7P	611217-86-0P	611217-90-4P
611217-92-6P	611217-94-8P	611217-96-0P
611217-98-2P	611218-00-9P	611218-02-1P
611218-04-3P	611218-07-6P	611218-09-8P
611218-11-2P	611218-13-4P	611218-15-6P
611218-17-8P	611218-19-0P	611218-21-4P
611218-23-6P	611218-25-3P	611218-27-0P
611218-29-2P	611218-30-5P	611218-33-8P
611218-35-0P	611218-37-2P	611218-40-7P
611218-42-9P	611218-44-1P	611218-46-3P
611218-48-5P	611218-50-9P	611218-52-1P
611218-54-3P	611218-56-5P	611218-58-7P
611218-60-1P	611218-63-4P	611218-65-6P
611218-67-8P	611218-69-0P	611218-71-4P
611218-73-6P	611218-75-8P	611218-77-0P
611218-79-2P	611218-81-6P	611218-83-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)


RN 611215-29-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1,7-dimethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-30-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-31-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclohexylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-32-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-33-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-34-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-35-1 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-36-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-fluoro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-37-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-aminophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-38-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-cyano-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-40-8 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-41-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-bromo-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-42-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methyl[1,1'-biphenyl]-3-yl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-43-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-44-2 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(5-cyclohexyl-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-45-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-46-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-amino-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-47-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-48-6 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylsulfonyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-49-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-50-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-51-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-biphenyl]-3-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-52-2 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-53-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-bromo-4-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-56-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(7-isoquinolinylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-57-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-58-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromo-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611215-60-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-(9H-fluoren-1-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-61-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-(9H-fluoren-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-62-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611215-63-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-66-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cycloheptylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-69-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dihydro-1-[1-oxo-3-(4-pyridinyl)propyl]-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



PAGE 1-A


PAGE 1-B



RN 611215-70-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-71-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(cyclopentylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-72-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(diethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-74-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-75-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-77-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-78-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-80-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-81-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-phenoxy-3-pyridinyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-82-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(2-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-83-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-84-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-85-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2,4,5-trimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-86-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-87-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-chloro-2-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-88-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-89-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylpropyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-90-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-91-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-92-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-93-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-94-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(3-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-95-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-96-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-98-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromo-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-99-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2,3,5-trifluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611216-00-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-01-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-02-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-[(trifluoromethyl)thio]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611216-03-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-04-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-bis(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-05-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-06-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(1-methyl-1-phenylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-07-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-08-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-(1-methylethoxy)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-09-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-10-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-11-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-methoxy-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-12-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-methyl-5-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-13-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2,5-bis(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-14-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[5-chloro-2-(difluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-15-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(phenylmethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611216-16-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-[(cyclohexylmethylamino)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-17-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[6-(1-pyrrolidinyl)-3-pyridinyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-18-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[6-(dimethylamino)-3-pyridinyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-19-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(1-methyl-4-piperidinyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611216-20-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-22-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3,3,5-trimethylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-23-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-methylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-25-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 611216-24-1

CMF C22 H20 Br N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 611216-26-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611216-27-4 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611216-28-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 611216-29-6 HCAPLUS

CN Methanone, [4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 611216-30-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-methoxy-4-[[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-2-pyridinyl]carbonyl]amino]-, ethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.

Serial#: 10/675,927




RN 611216-31-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 611216-32-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 611216-33-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611216-34-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-piperidinylmethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-35-4 HCAPLUS

CN Methanone, (3-amino-1-pyrrolidinyl)[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)



RN 611216-36-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(diphenylmethyl)-3-azetidiny]- (CA INDEX NAME)



RN 611216-37-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3S)-3-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 611216-39-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927



RN 611216-40-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-41-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)



RN 611216-42-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611216-43-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 611216-44-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidiny]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-45-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidiny)methyl]- (CA INDEX NAME)



RN 611216-46-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-3-piperidiny]- (CA INDEX NAME)



RN 611216-47-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611216-49-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 611216-50-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 611216-51-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-hydroxycyclohexyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-52-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 611216-53-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611216-54-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 611216-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




Serial#: 10/675,927


RN 611216-56-9 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 611216-57-0 HCAPLUS
CN Methanone, [4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl][4-(2-hydroxyethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 611216-58-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)




RN 611216-59-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611216-60-5 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(hexahydro-2-oxo-1H-azepin-3-yl)- (CA INDEX NAME)




RN 611216-61-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)




RN 611216-62-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-1-piperidinyl- (CA INDEX NAME)



RN 611216-63-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-methoxyphenyl)ethyl]- (CA INDEX NAME)




Serial#: 10/675,927

RN 611216-64-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Br

RN 611216-65-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Br

RN 611216-66-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-67-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-piperidiny)ethyl]- (CA INDEX NAME)




RN 611216-68-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(phenylamino)ethyl]- (CA INDEX NAME)



RN 611216-69-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-70-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611216-71-8 HCAPLUS


CN Glycine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]-, methyl ester (CA INDEX NAME)



RN 611216-72-9 HCAPLUS

CN L-Valine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 611216-73-0 HCAPLUS

CN L-Asparagine, N2-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611216-74-1 HCAPLUS

CN β -Alanine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]-, methyl ester (CA INDEX NAME)


Serial#: 10/675,927



RN 611216-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-aminopropyl]-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611216-76-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-[(2R)-2-aminopropyl]-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-77-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-pyrrolidinylmethyl)- (CA INDEX NAME)



RN 611216-78-5 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



RN 611216-79-6 HCAPLUS


CN Glycine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)



RN 611216-80-9 HCAPLUS


CN L-Valine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-81-0 HCAPLUS

CN β-Alanine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)




RN 611216-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-


Serial#: 10/675,927

benzimidazol-5-yl]oxy]-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 611216-84-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611216-85-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611216-86-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)



RN 611216-87-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (CA INDEX NAME)



RN 611216-89-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidiny)methyl]- (CA INDEX NAME)



RN 611216-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidiny]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611216-92-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-93-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)



RN 611216-94-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611216-95-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-96-7 HCAPLUS


CN L-Alanine, N-[[4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)

Serial#: 10/675,927

Absolute stereochemistry.




RN 611216-97-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2,3-dihydroxypropyl)- (CA INDEX NAME)




RN 611216-98-9 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3S)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-99-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611217-00-6 HCAPLUS

Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




PAGE 1-B



RN 611217-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




PAGE 1-B



RN 611217-03-9 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-chlorophenyl)-5-[[2-(4,5-dihydro-1H-imidazol-2-yl)-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611217-43-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidiny)ethyl]- (CA INDEX NAME)




RN 611217-44-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidiny)ethyl]- (CA INDEX NAME)



RN 611217-46-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidiny)ethyl]- (CA INDEX NAME)



RN 611217-47-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611217-48-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611217-50-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611217-51-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-(1,1-dimethylethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 611217-52-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611217-54-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 611217-55-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611217-56-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NMe₂

Serial#: 10/675,927


RN 611217-57-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)




RN 611217-58-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611217-59-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 611217-60-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611217-62-0 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611217-64-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 611217-66-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidiny)propyl]- (CA INDEX NAME)



RN 611217-67-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611217-68-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611217-69-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611217-70-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 611217-71-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611217-73-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611217-75-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611217-77-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611217-79-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611217-81-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)


Serial#: 10/675,927

NAME)




RN 611217-83-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611217-85-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611217-88-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)




RN 611217-90-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-


Serial#: 10/675,927

benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611217-92-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611217-94-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611217-96-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



Serial#: 10/675,927


RN 611217-98-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611218-00-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611218-02-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611218-04-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611218-07-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611218-09-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611218-11-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611218-13-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-ethyl-4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611218-15-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611218-17-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611218-19-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611218-21-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611218-23-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611218-25-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 611218-27-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)




RN 611218-29-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-


Serial#: 10/675,927

methyl-1H-benzimidazol-5-yl]oxy)-N-(2-(4-pyridinyl)ethyl)- (CA INDEX NAME)




RN 611218-30-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611218-33-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 611218-35-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611218-37-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 611218-40-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611218-42-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611218-44-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



Serial#: 10/675,927

RN 611218-46-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)



RN 611218-48-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611218-50-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611218-52-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




Serial#: 10/675,927


RN 611218-54-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611218-56-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611218-58-7 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)




RN 611218-60-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611218-63-4 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611218-65-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611218-67-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611218-69-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611218-71-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611218-73-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611218-75-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 611218-77-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611218-79-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




Serial#: 10/675,927

RN 611218-81-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 611218-83-8 HCAPLUS
 CN 2-Pyridinecarboxamide, N-(3-methoxypropyl)-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



IT	611218-85-0P	611218-87-2P	611218-89-4P
	611218-91-8P	611218-93-0P	611218-95-2P
	611218-97-4P	611218-98-5P	611219-00-2P
	611219-02-4P	611219-05-7P	611219-07-9P
	611219-09-1P	611219-11-5P	611219-13-7P
	611219-15-9P	611219-17-1P	611219-19-3P
	611219-21-7P	611219-23-9P	611219-25-1P
	611219-26-2P	611219-28-4P	611219-30-8P
	611219-32-0P	611219-34-2P	611219-36-4P
	611219-38-6P	611219-40-0P	611219-42-2P
	611219-44-4P	611219-46-6P	611219-48-8P
	611219-51-3P	611219-53-5P	611219-55-7P
	611219-57-9P	611219-58-0P	611219-59-1P
	611219-60-4P	611219-62-6P	611219-64-8P
	611219-66-0P	611219-68-2P	611219-70-6P
	611219-72-8P	611219-74-0P	611219-76-2P
	611219-78-4P	611219-80-8P	611219-82-0P
	611219-84-2P	611219-86-4P	611219-88-6P
	611219-90-0P	611219-93-3P	611219-95-5P
	611219-97-7P	611219-99-9P	611220-01-0P
	611220-10-1P	611220-12-3P	611220-14-5P
	611220-22-5P	611220-28-1P	611220-30-5P
	611220-32-7P	611220-34-9P	611220-36-1P
	611220-38-3P	611220-40-7P	611220-42-9P
	611220-44-1P	611220-46-3P	611220-48-5P
	611220-50-9P	611220-52-1P	611220-54-3P
	611220-56-5P	611220-58-7P	611220-60-1P
	611220-62-3P	611220-64-5P	611220-66-7P
	611220-68-9P	611220-70-3P	611220-72-5P
	611220-74-7P	611220-76-9P	611220-78-1P

Serial#: 10/675,927

611220-80-5P	611220-82-7P	611220-84-9P
611220-86-1P	611220-88-3P	611220-90-7P
611220-92-9P	611220-94-1P	611220-96-5P
611220-98-5P	611221-00-2P	611221-02-4P
611221-04-6P	611221-06-8P	611221-09-1P
611221-11-5P	611221-12-6P	611221-14-8P
611221-26-2P	611221-28-4P	611221-30-8P
611221-32-0P	611221-34-2P	611221-36-4P
611221-38-6P	611221-40-0P	611221-42-2P
611221-44-4P	611221-46-6P	611221-49-9P
611221-51-3P	611221-53-5P	611221-55-7P
611221-57-9P	611221-59-1P	611221-61-5P
611221-63-7P	611221-65-3P	611221-67-1P
611221-69-3P	611221-71-7P	611221-73-9P
611221-75-1P	611221-77-3P	611221-79-4P
611221-79-5P	611221-80-8P	611221-81-9P
611221-82-0P	611221-83-1P	611221-84-2P
611221-85-3P	611221-86-4P	611221-87-5P
611221-88-6P	611221-89-7P	611221-90-0P
611221-92-2P	611221-93-3P	611221-94-4P
611221-95-5P	611221-96-6P	611221-97-7P
611221-98-8P	611221-99-9P	611222-00-5P
611222-01-6P	611222-02-7P	611222-03-8P
611222-04-9P	611222-05-0P	611222-06-1P
611222-07-2P	611222-08-3P	611222-09-4P
611222-10-7P	611222-11-8P	611222-12-9P
611222-13-0P	611222-14-1P	611222-15-2P
611222-16-3P	611222-17-4P	611222-19-6P
611222-20-9P	611222-21-0P	611222-22-1P
611222-23-2P	611222-24-3P	611222-25-4P
611222-26-5P	611222-27-6P	611222-28-7P
611222-29-8P	611222-30-1P	611222-31-2P
611222-32-3P	611222-33-4P	611222-34-5P
611222-35-6P	611222-38-9P	611222-39-0P
611222-40-3P	611222-41-4P	611222-43-6P
611222-44-7P	611222-45-8P	611222-47-0P
611222-49-1P	611222-50-5P	611222-52-7P
611222-53-8P	611222-54-9P	611222-55-0P
611222-56-1P	611222-57-2P	611222-58-3P
611222-59-4P	611222-60-7P	611222-61-8P
611222-62-9P	611222-63-0P	611222-64-1P
611222-65-2P	611222-66-3P	611222-67-4P
611222-68-5P	611222-69-6P	611222-70-9P
611222-71-0P	611222-72-1P	611222-73-2P
611222-74-3P	611222-75-4P	611222-76-5P
611222-77-6P	611222-78-7P	611222-79-8P
611222-80-1P	611222-81-2P	611222-82-3P
611222-83-4P	611222-84-5P	611222-85-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase
inhibitors for treatment of cancer)

RN 611218-85-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-
benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611218-87-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611218-89-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611218-91-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)




RN 611218-93-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.


Serial#: 10/675,927




RN 611218-95-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 611218-97-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611218-98-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 611219-00-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611219-02-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611219-05-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611219-07-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 611219-09-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611219-11-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611219-13-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 611219-15-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidiny)propyl]- (CA INDEX NAME)



RN 611219-17-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidiny)propyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611219-19-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611219-21-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 611219-23-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611219-25-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611219-26-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-


Serial#: 10/675,927

benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611219-28-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611219-30-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611219-32-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 611219-34-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


Serial#: 10/675,927



RN 611219-36-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Bu-t


RN 611219-38-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611219-40-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611219-42-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611219-44-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611219-46-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611219-48-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611219-51-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)


Serial#: 10/675,927

(NAME)




RN 611219-53-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 611219-55-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611219-57-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611219-58-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611219-59-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611219-60-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



RN 611219-62-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)



RN 611219-64-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetlamino)ethyl]-4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611219-66-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611219-68-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 611219-70-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611219-72-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-


Serial#: 10/675,927

methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA
INDEX NAME)




RN 611219-74-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylethyl)- (CA INDEX NAME)




RN 611219-76-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611219-78-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611219-80-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)




RN 611219-82-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611219-84-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611219-86-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611219-88-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611219-90-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 611219-93-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 611219-95-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927

RN 611219-97-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 611219-99-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 611220-01-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611220-10-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611220-12-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-14-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[2-[(phenylmethyl)amino]ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-22-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-28-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[2-(dimethylamino)ethoxy]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611220-30-5 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[(methylamino)carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-32-7 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611220-34-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(4-ethyl-1-piperazinyl)carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 611220-36-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[2-(4-pyridinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611220-38-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-40-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[3-(dimethylamino)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611220-42-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-[[[1-methylethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-44-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(2,6-dimethyl-4-morpholinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-46-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-(1-piperidinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-48-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-[[[2-(1-methyl-2-

Serial#: 10/675,927

pyrrolidinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611220-50-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-[[[2-(1-piperidinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611220-52-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[[3-(1H-imidazol-1-yl)propyl]amino]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-
N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611220-54-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[[(1-ethyl-2-pyrrolidinyl)methyl]amino]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-56-5 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611220-58-7 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[2-(1-pyridinylmethyl)amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611220-60-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[(2-thiazolylamino)carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-62-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611220-64-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(1-azabicyclo[2.2.2]oct-3-ylamino)carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 611220-66-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611220-68-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-70-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611220-72-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-74-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611220-76-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611220-78-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-80-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-82-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611220-84-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

Serial#: 10/675,927



RN 611220-86-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-88-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[4-(3R)-3-(acetylamino)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 611220-90-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[1,4'-bipiperidin]-1'-yl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 611220-92-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(4-morpholinylcarbonyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-94-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[4-(3R,5S)-3,5-dimethyl-1-piperazinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 611220-96-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




Serial#: 10/675,927

RN 611220-98-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[(2R)-2-(aminocarbonyl)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611221-00-2 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[4-(1-methylethyl)-1-piperazinyl]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611221-02-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[(2R,5S)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611221-04-6 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[1-methyl-4-piperidinyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611221-06-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[2-[(dimethylamino)methyl]-4-morpholinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611221-09-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[methyl(1-methyl-3-pyrrolidinyl)amino]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611221-11-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[2-(dimethylamino)ethyl]methylamino]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-12-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[2-(4-ethyl-1-piperazinyl)ethyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611221-14-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[2-(1-piperidinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611221-26-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611221-28-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-30-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611221-32-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-chloro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611221-34-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611221-36-4 HCAPLUS


CN 3-Pyridinecarboxamide, 5-[[2-[[4-bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-38-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 611221-40-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611221-42-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611221-44-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-46-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidiny)ethyl]- (CA INDEX NAME)




RN 611221-49-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 611221-51-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611221-53-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-55-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 611221-57-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 611221-59-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611221-61-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-63-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611221-65-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



RN 611221-67-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)




RN 611221-69-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927

INDEX NAME)




RN 611221-71-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)




RN 611221-73-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611221-75-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-77-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611221-78-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 611221-79-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611221-80-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611221-81-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-82-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611221-83-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611221-84-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611221-85-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-86-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 611221-87-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611221-88-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611221-89-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-90-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611221-92-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611221-93-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)



RN 611221-94-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611221-95-5 HCAPLUS

Serial#: 10/675,927


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611221-96-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611221-97-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611221-98-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-99-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-00-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-01-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-02-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-(3-pyridinylamino)-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-03-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-6-


Serial#: 10/675,927

methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-04-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-05-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1,3-benzodioxol-5-yl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-06-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-07-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-08-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-09-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-10-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-11-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[1-methyl-5-[[2-(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]phenyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-12-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-13-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methyl-4-piperidinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-14-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-15-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-(trifluoromethyl)-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-16-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-methyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611222-17-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-19-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-methyl-1-piperazinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-20-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-chloro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-21-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-22-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-chloro-4-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-23-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-(2-methyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-24-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-(3-(trifluoromethyl)-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-25-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-chloro-4-pyridinyl)-4-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-26-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)phenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-27-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(dimethylamino)-4-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-28-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(5-pyrimidinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-29-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-30-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-fluoro-4-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-31-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611222-32-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-


Serial#: 10/675,927

quinolinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611222-33-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-34-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-35-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-38-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-fluoro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-39-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-40-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-41-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(3-fluoro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-43-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(6-fluoro-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611222-44-7 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(6-methoxy-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-45-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(6-fluoro-3-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-47-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-fluoro-4-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-48-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-


Serial#: 10/675,927

(CA INDEX NAME)




RN 611222-50-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(6-methoxy-3-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-52-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-53-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611222-54-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-55-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(phenylmethyl)sulfonyl]amino]ethyl]- (CA INDEX NAME)




PAGE 1-B

Pr-i

RN 611222-56-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(methylsulfonyl)amino]ethyl]- (CA INDEX NAME)



RN 611222-57-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(trifluoromethyl)sulfonyl]amino]ethyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


Pr-i

RN 611222-58-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(phenylsulfonyl)amino]ethyl]- (CA INDEX NAME)



RN 611222-59-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(propylsulfonyl)amino]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Pr-i


Serial#: 10/675,927

RN 611222-60-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[[4-methylphenyl]sulfonyl]amino]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611222-61-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[[2-thienylsulfonyl]amino]ethyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B





RN 611222-62-9 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[2-[[1-methylethyl]sulfonyl]amino]ethyl]-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611222-63-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[[[5-chloro-2-thienyl]sulfonyl]amino]ethyl]-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-64-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[3-[1-(phenylmethyl)-1H-1,2,3-triazol-4-yl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




Serial#: 10/675,927

RN 611222-65-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dihydro-1-(4-(4-morpholinyl)-1-oxobutyl)-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611222-66-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dihydro-1-[3-(1H-imidazol-5-yl)-1-oxopropyl]-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-67-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611222-68-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-(4-fluorophenyl)-1-methyl- (CA INDEX NAME)




RN 611222-69-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-70-9 HCAPLUS

CN 2-Pyridinecarboxamide, N,N-dimethyl-4-[[1-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-71-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-72-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-73-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-74-3 HCAPLUS

CN 2-Pyridinecarboxamide, N,N-dimethyl-4-[[1-methyl-2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-75-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-76-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-77-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-78-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-79-8 HCAPLUS


CN 2-Pyridinecarboxamide, N,N-dimethyl-4-[[1-methyl-2-[[2-(methylthio)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-80-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2,4-difluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-81-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-82-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-83-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-84-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 611222-85-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



IT	611222-86-7F	611222-87-8F	611222-88-9P
	611222-90-3P	611222-92-5F	611222-94-7P
	611222-96-9P	611222-98-1F	611223-00-8P
	611223-02-0P	611223-03-1P	611223-04-2P
	611223-05-3P	611223-06-4P	611223-07-5P
	611223-08-6P	611223-09-7P	611223-10-0P
	611223-11-1P	611223-12-2P	611223-13-3P
	611223-14-4P	611223-15-5P	611223-16-6P
	611223-17-7P	611223-18-8P	611223-19-9P
	611223-20-2P	611223-21-3P	611223-22-4P
	611223-23-5P	611223-24-6P	611223-25-7P
	611223-26-8P	611223-27-9P	611223-28-0P
	611223-29-1P	611223-30-4P	611223-31-5P
	611223-32-6P	611223-33-7P	611223-34-8P
	611223-35-9P	611223-36-0P	611223-37-1P
	611223-38-2P	611223-39-3P	611223-40-6P
	611223-41-7P	611223-42-8P	611223-43-9P
	611223-44-0P	611223-45-1P	611223-47-3P
	611223-49-5P	611223-51-9P	611223-53-1P
	611223-55-3P	611223-56-4P	611223-57-5P
	611223-58-6P	611223-59-7P	611223-60-0P
	611223-61-1P	611223-62-2P	611223-63-3P
	611223-64-4P	611223-65-5P	611223-66-6P
	611223-67-7P	611223-68-8P	611223-69-9P
	611223-70-2P	611223-71-3P	611223-72-4P
	611223-73-5P	611223-74-6P	611223-75-7P
	611223-76-8P	611223-77-9P	611223-78-0P
	611223-79-1P	611223-80-4P	611223-81-5P
	611223-82-6P	611223-83-7P	611223-84-8P
	611223-85-9P	611223-86-0P	611223-87-1P
	611223-88-2P	611223-89-3P	611223-90-6P
	611223-91-7P	611223-92-8P	611223-93-9P
	611223-94-0P	611223-95-1P	611223-96-2P
	611223-97-3P	611223-98-4P	611223-99-5P
	611224-00-1P	611224-01-2P	611224-02-3P

Serial#: 10/675,927

611224-03-4P	611224-04-5P	611224-05-6P
611224-06-7P	611224-07-8P	611224-08-9P
611224-09-0P	611224-10-3P	611224-11-4P
611224-12-5P	611224-13-6P	611224-14-7P
611224-15-8P	611224-16-9P	611224-17-0P
611224-18-1P	611224-19-2P	611224-20-5P
611224-21-6P	611224-22-7P	611224-23-8P
611224-24-9P	611224-25-0P	611224-26-1P
611224-27-2P	611224-28-3P	611224-29-4P
611224-30-7P	611224-32-9P	611224-34-1P
611224-35-2P	611224-36-3P	611224-37-4P
611224-38-5P	611224-39-6P	611224-40-9P
611224-41-0P	611224-43-2P	611224-44-3P
611224-45-4P	611224-46-5P	611224-47-6P
611224-48-7P	611224-49-8P	611224-50-1P
611224-51-2P	611224-52-3P	611224-53-4P
611224-54-5P	611224-55-6P	611224-56-7P
611224-57-8P	611224-59-9P	611224-59-0P
611224-60-3P	611224-61-4P	611224-62-5P
611224-63-6P	611224-64-7P	611224-65-8P
611224-66-9P	611224-67-0P	611224-68-1P
611224-69-2P	611224-70-5P	611224-71-6P
611224-72-7P	611224-75-0P	611224-82-9P
611224-83-0P	611224-84-1P	611224-85-2P
611224-86-3P	611224-87-4P	611224-88-5P
611224-89-6P	611224-90-9P	611224-91-0P
611224-92-1P	611224-93-2P	611224-94-3P
611224-95-4P	611224-96-5P	611224-97-6P
611224-98-7P	611225-02-6P	611225-04-8P
611225-06-0P	611225-07-1P	611225-08-2P
611225-09-3P	611225-10-6P	611225-11-7P
611225-12-8P	611225-13-9P	611225-14-0P
611225-15-1P	611225-16-2P	611225-17-3P
611225-18-4P	611225-19-5P	611225-20-8P
611225-21-9P	611225-22-0P	611225-23-1P
611225-31-1P	611225-32-2P	611225-33-3P
611225-34-4P	611225-35-5P	611225-36-6P
611225-37-7P	611225-38-8P	611225-39-9P
611225-40-2P	611225-41-3P	611225-47-9P
611225-48-0P	611225-49-1P	611225-50-4P
611225-51-5P	611225-56-0P	611225-57-1P

710351-26-1P, 4-[[2-[[2-Methoxy-5-(pyridin-4-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710351-28-3P, 4-[[2-[[3-Fluoro-2-methoxy-5-(pyridin-4-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-31-8P,
 N-Methyl-4-[[1-methyl-2-[[4-(pyridin-4-yl)-1,3-thiazol-2-yl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710351-33-0P
 710351-34-1P 710351-35-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

RN 611222-86-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-87-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-88-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-90-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-92-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-94-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611222-96-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 611222-98-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611223-00-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)

Serial#: 10/675,927



RN 611223-02-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—OMe

RN 611223-03-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)




RN 611223-04-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-05-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611223-06-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-propyl- (CA INDEX NAME)



RN 611223-07-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 611223-08-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-09-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-(3,5-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)




RN 611223-10-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)



RN 611223-11-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-12-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-13-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)




RN 611223-14-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611223-15-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 611223-16-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)


Serial#: 10/675,927




RN 611223-17-7 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611223-18-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 611223-19-9 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-N-[2-(4-pyridinyl)ethyl]-4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-20-2 HCAPLUS
CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927




RN 611223-21-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidiny)- (CA INDEX NAME)



RN 611223-22-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-propyl- (CA INDEX NAME)




RN 611223-23-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611223-24-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-25-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 611223-26-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611223-27-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-28-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-29-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611223-30-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(1H-indol-3-yl)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-31-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611223-32-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[2-[(2-methoxyphenyl)amino]-1-


Serial#: 10/675,927

methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-33-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611223-34-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611223-35-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 611223-36-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-37-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-38-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)



RN 611223-39-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611223-40-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-41-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-propyl- (CA INDEX NAME)




RN 611223-42-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 611223-43-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611223-44-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-[(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-(2-methoxyphenyl)-1-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-45-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-(2-fluorophenyl)-1-methyl- (CA INDEX NAME)




RN 611223-47-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)



RN 611223-49-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611223-51-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-53-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)




RN 611223-55-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611223-56-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611223-57-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611223-58-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611223-59-7 HCAPLUS


CN Methanone, [(2R,5R)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl][4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 611223-60-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 611223-61-1 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611223-62-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-63-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidiny)- (CA INDEX NAME)



RN 611223-64-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 611223-65-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-66-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611223-67-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 611223-68-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611223-69-9 HCAPLUS

CN Methanone, [(2R,5S)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl][4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)


Serial#: 10/675,927

Absolute stereochemistry.




RN 611223-70-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 611223-71-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 611223-72-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 611223-73-5 HCAPLUS

Serial#: 10/675,927


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611223-74-6 HCAPLUS


CN Methanone, [4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl][(2R,5R)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611223-75-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611223-76-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)



Serial#: 10/675,927


RN 611223-77-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-propyl- (CA INDEX NAME)




RN 611223-78-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)



RN 611223-79-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)




RN 611223-80-4 HCAPLUS

CN Methanone, [4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl][(2R,5S)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl]- (CA INDEX NAME)


Absolute stereochemistry.

Serial#: 10/675,927




RN 611223-81-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)




RN 611223-82-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-5-[[2-(3H-imidazo[4,5-b]pyridin-2-yl)-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)



RN 611223-83-7 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-[[2-(1H-naphth[2,3-d]imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611223-84-8 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-[[2-(6-methyl-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-85-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-[[2-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611223-86-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-[[2-(1-methyl-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611223-87-1 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-N-(4-fluorophenyl)-1-methyl- (CA INDEX NAME)



RN 611223-88-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611223-89-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611223-90-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611223-91-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611223-92-8 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-93-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)




RN 611223-94-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611223-95-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-96-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-97-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-98-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 611223-99-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 611224-00-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-01-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611224-02-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 611224-03-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-(3-methoxypropyl)-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-04-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-05-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-3-pyrrolidinyl- (CA INDEX NAME)




RN 611224-06-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611224-07-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



RN 611224-08-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-ethyl-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-09-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-10-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 611224-11-4 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(6-methyl-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-12-5 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(1H-naphth[2,3-d]imidazol-2-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-13-6 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(1-methyl-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-14-7 HCAPLUS

CN Methanone, [2-[4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-1H-benzimidazol-6-yl]phenyl- (CA INDEX NAME)




RN 611224-15-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(6-bromo-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-16-9 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(6-chloro-5-fluoro-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-17-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(6-chloro-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-18-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(6-fluoro-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-19-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-20-5 HCAPLUS


CN 1H-Benzimidazole-6-carboxylic acid, 2-[4-[[1-methyl-2-[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-, methyl ester (CA INDEX NAME)



RN 611224-21-6 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(5,6-dichloro-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-22-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-23-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(3-phenyl-1,2,4-oxadiazol-5-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)





RN 611224-24-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[7-fluoro-6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-1-methyl-N-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 611224-25-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-N-[3-(1-methylethyl)phenyl]-5-[[2-[6-[3-(1-pyrrolidinyl)propoxy]-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-26-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-27-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluoro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611224-28-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-29-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611224-30-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611224-32-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611224-34-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[4-methyl-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-35-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611224-36-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611224-37-4 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-[(7-fluoro-6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-38-5 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-[(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-[4-chloro-3-(4-pyridinyl)phenyl]-1-methyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 611224-39-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[6-(2-methoxyethoxy)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-1-methyl-N-[3-[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)




PAGE 1-A



PAGE 1-B

RN 611224-40-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[6-(4-cyclopentyl-1-piperazinyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-1-methyl-N-[3-[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)



PAGE 1-A




PAGE 1-B

RN 611224-41-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-N-[3-(4-pyridinyl)phenyl]-5-[[2-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-43-2 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)




RN 611224-44-3 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[4-(bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)



RN 611224-45-4 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[2-[[4-(ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)



RN 611224-46-5 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-47-6 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)




RN 611224-48-7 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-49-8 HCAPLUS


CN 2-Pyridinemethanol, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-50-1 HCAPLUS


CN 2-Pyridinemethanol, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-51-2 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-52-3 HCAPLUS

CN 2-Pyridinemethanol, 4-[[1-methyl-2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-53-4 HCAPLUS


CN 2-Pyridinemethanol, 4-[[2-[[3-ethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-54-5 HCAPLUS


CN 2-Pyridinemethanol, 4-[[1-methyl-2-[[4-(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-55-6 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(3-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-56-7 HCAPLUS

CN 2-Pyridinemethanol, 4-[[1-methyl-2-[[3-[(trifluoromethylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-57-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-phenyl- (CA INDEX NAME)



RN 611224-58-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-59-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3,4-dimethylphenyl)- (CA INDEX NAME)




RN 611224-60-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-61-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-chlorophenyl)- (CA INDEX NAME)



RN 611224-62-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-ethylphenyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-63-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-methylphenyl)- (CA INDEX NAME)




RN 611224-64-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1-methylethyl)phenyl]-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-65-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1,1-dimethylethyl)phenyl]-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-66-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




Serial#: 10/675,927


RN 611224-67-0 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[1,1'-biphenyl]-3-yl-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-68-1 HCAPLUS
 CN 2-Pyridinecarboxamide, N-(4-bromophenyl)-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-69-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-70-5 HCAPLUS
 CN 2-Pyridinecarboxamide, N-(3-iodophenyl)-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-71-6 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-72-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,6-bis(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611224-75-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611224-82-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[(methylamino)methyl]-4-pyridinyl]oxy]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 611224-81-8

CMF C21 H20 Br N5 O




CM 2

Serial#: 10/675,927


CRN 76-05-1
CMF C2 H F3 O2




RN 611224-83-0 HCAPLUS
CN 2-Pyrrolidinone, 1-[3-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]amino]propyl]- (CA INDEX NAME)



RN 611224-84-1 HCAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[(2-methoxyethyl)amino]methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611224-85-2 HCAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-(4-morpholinylmethyl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-86-3 HCAPLUS
CN Ethanol, 2-[[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]amino]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-87-4 HCAPLUS

CN 1-Propanol, 3-[[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]amino]- (CA INDEX NAME)




RN 611224-88-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[3-(1-pyrrolidinyl)propyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-89-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[3-(1-morpholinyl)propyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611224-90-9 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[2-(1-piperidinyl)ethyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-91-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[2-(1-pyrrolidinyl)ethyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-92-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[3-(1-piperidinyl)propyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-93-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[(dimethylamino)methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)



RN 611224-94-3 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[[[(cyclohexylmethyl)amino]methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)



RN 611224-95-4 HCAPLUS


Serial#: 10/675,927

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-
[(cyclopropylamino)methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611224-96-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-
[(propylamino)methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-97-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[(3-
pyrrolidinylamino)methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611224-98-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[[[(3-
methoxypropyl)amino]methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611225-02-6 HCAPLUS

CN Carbamic acid, [[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-
yl]oxy]-2-pyridinyl]methyl]-, methyl ester, trifluoroacetate (9CI) (CA
INDEX NAME)

CM 1

Serial#: 10/675,927

CRN 611225-01-5
CMF C22 H20 Br N5 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 611225-04-8 HCAPLUS
CN Acetamide, N-[[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 611225-03-7
CMF C22 H20 Br N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2


Serial#: 10/675,927



RN 611225-06-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 611225-05-9
CMF C29 H32 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 611225-07-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611225-08-2 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-
[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-
1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611225-09-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-
[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-
1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611225-10-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(2-methyl-4-
pyridinyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611225-11-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[3-(trifluoromethyl)-4-
pyridinyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611225-12-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)phenyl]amino]-1H-
benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-13-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-14-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611225-15-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



Serial#: 10/675,927

RN 611225-16-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




PAGE 1-B

— F


RN 611225-17-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-18-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)






RN 611225-19-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 611225-20-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 611225-21-9 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611225-22-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B



RN 611225-23-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-3-azetidiny]- (CA INDEX NAME)



RN 611225-31-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-32-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-33-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611225-34-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)-3-(2-fluoro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611225-35-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)-3-(2-fluoro-4-pyridinyl)phenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-36-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)-3-(2-fluoro-4-pyridinyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-37-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611225-38-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2,6-dimethyl-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611225-39-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2,6-dimethyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-40-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2,6-dimethyl-4-pyridinyl)phenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-41-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-methyl-3-(2-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-47-9 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[N-(4-bromophenyl)-1-methyl- (CA INDEX NAME)



RN 611225-48-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[N-[3-(1,1-dimethylethyl)phenyl]-1-methyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 611225-49-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[1-methyl-N-[3-
[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611225-50-4 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[1-methyl-N-[3-(1-methylethyl)phenyl]-
(CA INDEX NAME)



RN 611225-51-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[1-methyl-N-phenyl]- (CA INDEX NAME)



RN 611225-56-0 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1-chloroethenyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 611225-55-9

CMF C23 H20 Cl N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 611225-57-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 611216-10-5

CMF C25 H21 N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2


Serial#: 10/675,927




RN 710351-26-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710351-28-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-fluoro-2-methoxy-5-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710351-31-8 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(4-pyridinyl)-2-thiazolyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710351-33-0 HCAPLUS
 CN 2-Pyridinecarboxaldehyde, 4-[[2-[[3-ethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)

Serial#: 10/675,927




RN 710351-34-1 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)



RN 710351-35-2 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)



IT 710351-36-3P 710351-37-4P 710351-38-5P,
4-[[2-[(4-Chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-39-6P,
4-[[1-Methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-40-9P,
4-[[2-[(4-Bromo-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-41-0P,
4-[[1-Methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-42-1P,
4-[[2-[(4-Bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-43-2F,
4-[[2-[(2,4-Dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-44-3F,
4-[[2-[(3,4-Dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-45-4P,
4-[[2-[(2,3-Dihydro-1H-inden-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-47-6P,
4-[[2-[[4-Chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-48-7P,
4-[[1-Methyl-2-[[3-(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-49-8P,
4-[[2-[(4-Bromo-3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-50-1F,

4-[[2-[[2-Chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-51-2P,
4-[[1-Methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-52-3P,
4-[[2-[[4-Bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-53-4P,
4-[[2-[[3-Ethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-54-5P,
4-[[2-[[3-Methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-55-6P,
4-[[1-Methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-56-7P,
4-[[2-[[4-Ethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-57-8P,
4-[[1-Methyl-2-[[4-(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-58-9P,
4-[[2-[[3-tert-Butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-59-0P,
4-[[2-[[4-Bromo-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-60-3P,
4-[[2-[[3,4-Dichlorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-61-4P,
4-[[2-[[3-Isopropylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-62-5P,
4-[[2-[[3-Isopropoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-63-6P,
4-[[1-Methyl-2-[[3-phenoxyphenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxaldehyde oxime 710351-64-7P,
N-(3-tert-Butylphenyl)-5-[[2-(1H-imidazol-2-yl)pyridin-4-yl]oxy]-1-methyl-1H-benzimidazol-2-amine 710351-67-0P,
5-[[2-(1H-imidazol-2-yl)pyridin-4-yl]oxy]-N-(3-isopropylphenyl)-1-methyl-1H-benzimidazol-2-amine 710351-68-1P,
5-[[2-(1H-imidazol-2-yl)pyridin-4-yl]oxy]-1-methyl-N-[[4-(trifluoromethyl)thio]phenyl]-1H-benzimidazol-2-amine 710351-69-2P,
N-Methyl-4-[[1-methyl-2-[[4-methyl-3-(pyrrolidin-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710351-73-8P,
4-[[2-[[4-Chloro-3-(2-oxopyrrolidin-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-76-1P,
4-[[2-[[4-Chloro-3-(2-oxopiperidin-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-77-2P,
4-[[2-[[4-tert-Butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710351-80-7P,
N-Methyl-4-[[1-methyl-2-[[3-(2-(pyrrolidin-1-yl)ethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710351-90-9P,
4-[[2-[[4-Fluoro-3-(2-fluoropyridin-4-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-91-0P,
4-[[2-[[4-Fluoro-3-(6-methoxypyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-92-1P,
4-[[2-[[4-Fluoro-3-(4-methylpyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-93-2P,
4-[[2-[[4-Chloro-3-(5-methoxypyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-94-3P,
4-[[2-[[4-Chloro-3-(2,6-dimethylpyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-95-4P,
4-[[2-[[4-Chloro-3-(4-methylpyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-96-5P,
4-[[2-[[4-Chloro-3-(2-methylpyridin-4-yl)phenyl]amino]-1-methyl-1H-

benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710351-97-6P, 4-[[2-[[3-Fluoro-2-methoxy-5-(5-methoxypyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-98-7P,
 4-[[2-[[3-Fluoro-2-methoxy-5-(6-methoxypyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710351-99-8P, 4-[[2-[[3-Fluoro-2-methoxy-5-[6-(1H-pyrrol-1-yl)pyridin-3-yl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-00-4P,
 4-[[2-[[3-Fluoro-2-methoxy-5-(2-methylpyridin-4-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-02-6P, 4-[[2-[[5-(2,6-Dimethylpyridin-3-yl)-3-fluoro-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-04-8P,
 4-[[2-[[5-(2-Chloropyridin-3-yl)-3-fluoro-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-06-0P, 4-[[2-[[3-Fluoro-5-(2-fluoropyridin-4-yl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-08-2P,
 4-[[2-[[3-Fluoro-2-methoxy-5-(4-methylpyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-09-3P, 4-[[2-[[3-Fluoro-5-(6-fluoropyridin-3-yl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-10-6P,
 N-Methyl-4-[[1-methyl-2-[[4-(pyridin-2-yl)-1,3-thiazol-2-yl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-11-7P,
 4-[[2-[[2-Methoxy-5-(quinolin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-12-8P,
 4-[[2-[[2-Methoxy-5-(6-methoxypyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-13-9P, 4-[[2-[[5-(2,6-Dimethylpyridin-3-yl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-14-0P, 4-[[2-[[5-(3-Fluoropyridin-4-yl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-15-1P, 4-[[2-[[5-(2-Fluoropyridin-4-yl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-16-2P, 4-[[2-[[5-(Isoquinolin-4-yl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-17-3P, 4-[[2-[[4-Chloro-3-(pyridin-4-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide 710352-18-4P,
 4-[[2-[[4-Chloro-3-(pyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide
 710352-19-5P, 4-[[2-[[4-Chloro-3-(2-fluoropyridin-4-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide 710352-20-8P,
 4-[[2-[[4-Chloro-3-(6-methoxypyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide
 710352-21-9P, N-Methoxy-4-[[1-methyl-2-[[4-[[trifluoromethyl]thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-22-0P,
 4-[[2-[[3-Bromo-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710352-23-1P, 4-[[2-[[3-(6-Fluoropyridin-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-24-2P,
 N-Methyl-4-[[1-methyl-2-[[3-(pyridin-4-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-25-3P,

Serial#: 10/675,927

4-[[2-[[3-(6-Methoxypyridin-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
710352-26-4P, N-Methyl-4-[[1-methyl-2-[[3-(2-methylpyridin-4-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-27-5P,
4-[[2-[[3-(Isoquinolin-4-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
710352-28-6P, 4-[[2-[[4-Chloro-3-(thien-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide 710352-29-7P,
N-Methyl-4-[[1-methyl-2-[[3-(quinolin-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-30-0P,
N-Methyl-4-[[1-methyl-2-[[3-(4-methylpyridin-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-31-1P,
4-[[2-[[3-(5-Methoxypyridin-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
710352-32-2P, N-Methyl-4-[[1-methyl-2-[[3-(5-(1H-pyrrol-1-yl)pyridin-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-33-3P,
4-[[2-[[3-(2,6-Dimethylpyridin-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-34-4P,
N-Methyl-4-[[1-methyl-2-[[3-(5-methyl-2-furyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-35-5P,
N-Methyl-4-[[1-methyl-2-[[3-(thien-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-36-6P,
N-Methyl-4-[[1-methyl-2-[[3-(thien-2-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-37-7P,
N-Methyl-4-[[1-methyl-2-[[3-(pyridin-3-yl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-38-8P,
N-Methoxy-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-39-9P,
N-Methoxy-4-[[1-methyl-2-[[3-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-40-2P,
N-Methoxy-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-41-3P,
N-(Allyloxy)-4-[[1-methyl-2-[[3-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-42-4P,
N-(Allyloxy)-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-43-5P,
N-(Allyloxy)-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-44-6P,
N-(Allyloxy)-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-45-7P,
N-Ethoxy-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-46-8P,
N-Ethoxy-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-47-9P,
N-Ethoxy-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-48-0P,
N-(tert-Butoxy)-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-49-1P,
N-(tert-Butoxy)-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-50-4P,
N-(tert-Butoxy)-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-

Serial#: 10/675,927

benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-51-5P,
N-(Benzyloxy)-4-[[1-methyl-2-[[3-((trifluoromethyl)thio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-52-6P,
N-(Benzyloxy)-4-[[1-methyl-2-[[4-((trifluoromethyl)thio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-53-7P,
4-[[1-Methyl-2-[[3-((trifluoromethyl)thio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-phenoxy]pyridine-2-carboxamide 710352-54-8P,
4-[[1-Methyl-2-[[4-((trifluoromethyl)thio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-phenoxy]pyridine-2-carboxamide 710352-55-9P,
4-[[2-((4-Fluoro-3-isopropylphenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-56-0P,
4-[[2-((3-Cyclopentylphenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-57-1P,
N-Methoxy-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-58-2P,
4-[[2-((3-Cyclopentyl-4-fluorophenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-59-3P,
4-[[2-[[3-(2,2-Dichloro-1-methylcyclopropyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-60-6P,
1-[[2-((3-Isopropyl-4-methylphenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-61-7P,
4-[[2-((3-sec-Butylphenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-62-8P,
4-[[2-((3-tert-Butylphenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-63-9P,
4-[[2-((4-Ethyl-3-isopropylphenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-64-0P,
4-[[2-((4-tert-Butylphenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-65-1P,
4-[[2-[[2-Fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-66-2P,
4-[[2-((4-Bromophenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy]pyridine-2-carboxamide 710352-67-3P,
N-Ethoxy-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-68-4P,
N-(Allyloxy)-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-69-5P,
N-(tert-Butoxy)-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-70-6P,
4-[[1-Methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-phenoxy]pyridine-2-carboxamide 710352-71-9P,
N-(Benzyloxy)-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-72-0P,
N-Isobutoxy-4-[[1-methyl-2-[[3-((trifluoromethyl)thio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-73-1P,
N-Isobutoxy-4-[[1-methyl-2-[[4-((trifluoromethyl)thio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-74-2P,
4-[[2-[[4-Isopropoxy-3-(pyridin-4-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl]pyridine-2-carboxamide 710352-75-3P,
4-[[2-[[4-Isopropoxy-3-(pyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl]pyridine-2-carboxamide 710352-76-4P,
4-[[2-[[3-(6-Fluoropyridin-3-yl)-4-isopropoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl]pyridine-2-carboxamide 710352-77-5P,
4-[[2-[[4-Isopropoxy-3-(quinolin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl]pyridine-2-carboxamide 710352-78-6P,
4-[[2-[[4-Isopropoxy-3-(thien-2-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl]pyridine-2-carboxamide 710352-79-7P,
4-[[2-[[4-Isopropoxy-3-(thien-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl]pyridine-2-carboxamide

710352-80-8P, 4-[[2-[[4-Isopropoxy-3-(4-methylpyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-81-1P,
4-[[2-[[4-Isopropoxy-3-(5-methoxypyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
710352-82-2P, 4-[[2-[[4-Isopropoxy-3-(6-methoxypyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-83-3P,
4-[[2-[(3-Cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)pyridine-2-carboxamide 710352-84-4P,
4-[[2-[(3-Cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(methylsulfonyl)amino]ethyl]pyridine-2-carboxamide
710352-85-5P, 4-[[2-[(3-Cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-86-6P,
4-[[2-[(3-Cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-87-7P,
4-[[2-[(3-Cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-isopropylazetidin-3-yl)pyridine-2-carboxamide
710352-88-8P, 4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)pyridine-2-carboxamide
710352-89-9P, 4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(isopropylsulfonyl)amino]ethyl]pyridine-2-carboxamide 710352-90-2P,
4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-91-3P,
4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-isopropylazetidin-3-yl)pyridine-2-carboxamide
710352-92-4P, 4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxopyrrolidin-1-yl)propyl]pyridine-2-carboxamide 710352-93-5P,
4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(methylsulfonyl)amino]ethyl]pyridine-2-carboxamide
710352-94-6P, 4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]ethyl]pyridine-2-carboxamide 710352-95-7P,
4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-isopropylpiperidin-4-yl)pyridine-2-carboxamide
710352-96-8P, 4-[[2-[(3-Cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710352-97-9P,
4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710352-98-0P
, N-(1-Isopropylazetidin-3-yl)-4-[[2-[(3-isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide
710352-99-1P, 4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxopyrrolidin-1-yl)propyl]pyridine-2-carboxamide 710353-00-7P,
4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide
710353-01-8P, 4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methylpiperazin-1-yl)ethyl]pyridine-2-carboxamide 710353-02-9P,
4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(morpholin-4-yl)ethyl]pyridine-2-carboxamide
710353-03-0P, N-[2-(Acetyl amino)ethyl]-4-[[2-[(3-isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-04-1P,
4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(isopropylsulfonyl)amino]ethyl]pyridine-2-carboxamide
710353-05-2P, N-(2-Hydroxyethyl)-4-[[2-[(3-isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-06-3P,

4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)pyridine-2-carboxamide 710353-07-1P,
4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methylpiperazin-1-yl)propyl]pyridine-2-carboxamide 710353-08-5P, N-[3-(1H-Imidazol-1-yl)propyl]-4-[[2-[(3-isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-09-6P,
4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]pyridine-2-carboxamide 710353-10-9P, 4-[[2-[(3-Isopropyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-11-0P,
4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-12-1P,
4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-isopropylazetidin-3-yl)pyridine-2-carboxamide 710353-13-3P, 4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxopyrrolidin-1-yl)propyl]pyridine-2-carboxamide 710353-16-5P,
4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide 710353-18-7P, 4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methylpiperazin-1-yl)ethyl]pyridine-2-carboxamide 710353-19-8P,
4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(morpholin-4-yl)ethyl]pyridine-2-carboxamide 710353-20-1P, N-[2-(Acetylamino)ethyl]-4-[[2-[(4-ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-21-2P,
4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(isopropylsulfonyl)amino]ethyl]pyridine-2-carboxamide 710353-23-4P, 4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)pyridine-2-carboxamide 710353-24-5P, 4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)pyridine-2-carboxamide 710353-25-6P, 4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methylpiperazin-1-yl)propyl]pyridine-2-carboxamide 710353-26-7P,
4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]pyridine-2-carboxamide 710353-27-8P, 4-[[2-[(4-Ethyl-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]pyridine-2-carboxamide 710353-28-9P,
4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-29-0P,
4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-isopropylpiperidin-4-yl)pyridine-2-carboxamide 710353-30-3P, 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-isopropylazetidin-3-yl)pyridine-2-carboxamide 710353-31-4P,
4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxopyrrolidin-1-yl)propyl]pyridine-2-carboxamide 710353-32-5P, 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide 710353-33-6P,
4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methylpiperazin-1-yl)ethyl]pyridine-2-carboxamide 710353-34-7P, 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(morpholin-4-yl)ethyl]pyridine-2-carboxamide 710353-35-8P,
4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(isopropylsulfonyl)amino]ethyl]pyridine-2-carboxamide

Serial#: 10/675,927


710353-36-9P, 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)pyridine-2-carboxamide
 710353-37-9P, 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)pyridine-2-carboxamide
 710353-38-1P, 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methylpiperazin-1-yl)propyl]pyridine-2-carboxamide 710353-39-2P,
 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]pyridine-2-carboxamide
 710353-40-5P, 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]pyridine-2-carboxamide 710353-41-6P,
 4-[[2-[(4-Fluoro-3-isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-42-7P,
 4-[[2-[[3-Isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 710353-43-8P, N-(1-Isopropylazetidin-3-yl)-4-[[2-[[3-isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-44-9P,
 4-[[2-[[3-Isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxopyrrolidin-1-yl)propyl]pyridine-2-carboxamide 710353-45-0P,
 4-[[2-[[3-Isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-2-carboxamide
 710353-46-1P, 4-[[2-[[3-Isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methylpiperazin-1-yl)ethyl]pyridine-2-carboxamide 710353-47-2P
 , N-[2-(Acetyl amino)ethyl]-4-[[2-[[3-isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-48-3P,
 N-[2-[(Isopropylsulfonyl)amino]ethyl]-4-[[2-[[3-isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-49-4P,
 N-(2-Hydroxyethyl)-4-[[2-[[3-isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide
 710353-50-7P, 4-[[2-[[3-Isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)pyridine-2-carboxamide 710353-51-8P,
 4-[[2-[[3-Isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methylpiperazin-1-yl)propyl]pyridine-2-carboxamide 710353-52-9P,
 4-[[2-[[3-Isopropyl-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]pyridine-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

RN 710351-36-3 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[3-(1-methylethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, O-methyl oxime (CA INDEX NAME)



Serial#: 10/675,927


RN 710351-37-4 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[(3-phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)




RN 710351-38-5 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-39-6 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



RN 710351-40-9 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



Serial#: 10/675,927


RN 710351-41-0 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-42-1 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-43-2 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



RN 710351-44-3 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[2-[(3,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



Serial#: 10/675,927


RN 710351-45-4 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-47-6 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-48-7 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



RN 710351-49-8 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



Serial#: 10/675,927


RN 710351-50-1 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-51-2 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-52-3 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



RN 710351-53-4 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



Serial#: 10/675,927


RN 710351-54-5 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(3-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-55-6 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-56-7 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



RN 710351-57-8 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[4-(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



Serial#: 10/675,927


RN 710351-58-9 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-59-0 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[4-bromo-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-60-3 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[3,4-dichlorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



RN 710351-61-4 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)



RN 710351-62-5 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[3-(1-methylethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-63-6 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[(3-phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 710351-64-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-[3-(1,1-dimethylethyl)phenyl]-5-[[2-(1H-imidazol-2-yl)-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)



RN 710351-67-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-imidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 710351-68-1 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-imidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[4-[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710351-69-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-methyl-3-(1-pyrrolidinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710351-73-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-oxo-1-pyrrolidinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710351-76-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-oxo-1-piperidinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710351-77-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927




RN 710351-80-7 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[2-(1-pyrrolidinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710351-90-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(2-fluoro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710351-91-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(6-methoxy-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710351-92-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(4-methyl-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710351-93-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(5-methoxy-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710351-94-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2,6-dimethyl-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710351-95-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-methyl-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710351-96-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-methyl-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710351-97-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-fluoro-2-methoxy-5-(5-methoxy-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710351-98-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-fluoro-2-methoxy-5-(6-methoxy-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710351-99-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-fluoro-2-methoxy-5-[(6-(1H-pyrrol-1-yl)-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 710352-00-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-fluoro-2-methoxy-5-(2-methyl-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710352-02-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-(2,6-dimethyl-3-pyridinyl)-3-fluoro-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-04-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[5-(2-chloro-3-pyridinyl)-3-fluoro-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710352-06-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-fluoro-5-(2-fluoro-4-pyridinyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 710352-08-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-fluoro-2-methoxy-5-(4-methyl-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-09-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-fluoro-5-(6-fluoro-3-pyridinyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710352-10-6 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(2-pyridinyl)-2-thiazolyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-11-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(3-quinolinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-12-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(6-methoxy-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710352-13-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-(2,6-dimethyl-3-pyridinyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-14-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-(3-fluoro-4-pyridinyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710352-15-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-(2-fluoro-4-pyridinyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927

INDEX NAME)




RN 710352-16-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-(4-isoquinolinyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710352-17-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 710352-18-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 710352-19-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-fluoro-4-

Serial#: 10/675,927

pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 710352-20-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(6-methoxy-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 710352-21-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-methoxy-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-22-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710352-23-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(6-fluoro-3-pyridinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-24-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-pyridinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-25-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(6-methoxy-3-pyridinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-26-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-methyl-4-pyridinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-27-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(4-isoquinolinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-28-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(4-chloro-3-(3-thienyl)phenyl]amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 710352-29-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-quinolinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-30-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-methyl-3-pyridinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-31-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(5-methoxy-3-pyridinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-32-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[5-(1H-pyrrol-1-yl)-3-pyridinyl]-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-33-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2,6-dimethyl-3-pyridinyl)-4-(2,2,2-


Serial#: 10/675,927

trifluoroethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-
(CA INDEX NAME)




RN 710352-34-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(5-methyl-2-furanyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl-2-pyridinecarboxamide (CA INDEX NAME)




RN 710352-35-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-thienyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl-2-pyridinecarboxamide (CA INDEX NAME)



RN 710352-36-6 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-thienyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl-2-pyridinecarboxamide (CA INDEX NAME)



RN 710352-37-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-pyridinyl)-4-(2,2,2-trifluoroethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl-2-pyridinecarboxamide (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-38-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methoxy-4-[[1-methyl-2-[[3-
[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX
NAME)




RN 710352-39-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methoxy-4-[[1-methyl-2-[[3-
(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX
NAME)



RN 710352-40-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methoxy-4-[[1-methyl-2-[[4-
(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX
NAME)



RN 710352-41-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethoxy)phenyl]amino]-
1H-benzimidazol-5-yl]oxy]-N-(2-propen-1-yloxy)- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-42-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(2-propen-1-yloxy)- (CA INDEX NAME)




RN 710352-43-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(2-propen-1-yloxy)- (CA INDEX NAME)



RN 710352-44-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(2-propen-1-yloxy)- (CA INDEX NAME)



RN 710352-45-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-ethoxy-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-46-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethoxy-4-[[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-47-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethoxy-4-[[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-48-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-(1,1-dimethylethoxy)-4-[[[1-methyl-2-[[4-[(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-49-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-(1,1-dimethylethoxy)-4-[[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927

(NAME)




RN 710352-50-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-(1,1-dimethylethoxy)-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-51-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(phenylmethoxy)- (CA INDEX NAME)



RN 710352-52-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(phenylmethoxy)- (CA INDEX NAME)




RN 710352-53-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-


Serial#: 10/675,927

[(trifluoromethyl)thio]phenylamino]-1H-benzimidazol-5-yl]oxy]-N-phenoxy-
(CA INDEX NAME)




RN 710352-54-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-phenoxy-
(CA INDEX NAME)




RN 710352-55-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)



RN 710352-56-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(cyclopentylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)




RN 710352-57-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methoxy-4-[[1-methyl-2-[[3-(4-


Serial#: 10/675,927

pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-58-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)




RN 710352-59-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2,2-dichloro-1-methylcyclopropyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)



RN 710352-60-6 HCAPLUS


CN 2-Pyridinecarboxamide, 1,6-dihydro-N-methoxy-1-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-61-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methoxy-4-[[1-methyl-2-[[3-(1-methylpropyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-62-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)




RN 710352-63-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)



RN 710352-64-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)



RN 710352-65-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-66-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy- (CA INDEX NAME)




RN 710352-67-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethoxy-4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-68-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-(1,1-dimethylethoxy)-4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-69-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-(1,1-dimethylethoxy)-4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-70-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-phenoxy- (CA INDEX NAME)




RN 710352-71-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(phenylmethoxy)- (CA INDEX NAME)



RN 710352-72-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-methylpropoxy)-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-73-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-methylpropoxy)-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-74-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethoxy)-3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-75-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethoxy)-3-(3-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-76-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(6-fluoro-3-pyridinyl)-4-(1-methylethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-77-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethoxy)-3-(3-quinolinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-78-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethoxy)-3-(2-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-79-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethoxy)-3-(3-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-80-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethoxy)-3-(4-methyl-3-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710352-81-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(5-methoxy-3-pyridinyl)-4-(1-methylethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-82-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(6-methoxy-3-pyridinyl)-4-(1-methylethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710352-83-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 710352-84-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(methylsulfonyl)amino]ethyl]- (CA INDEX NAME)




PAGE 1-A




RN 710352-85-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-86-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-87-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-3-azetidiny]- (CA INDEX NAME)



RN 710352-88-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)

Serial#: 10/675,927



RN 710352-89-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(1-methylethyl)sulfonyl]amino]ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B



RN 710352-90-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710352-91-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-3-azetidynyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-92-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 710352-93-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(methylsulfonyl)amino]ethyl]- (CA INDEX NAME)





PAGE 1-A

PAGE 1-B




RN 710352-94-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]ethyl]- (CA INDEX NAME)



RN 710352-95-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 710352-96-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclopentyl-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-97-9 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710352-98-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[1-(1-methylethyl)-3-azetidinyl]-4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710352-99-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 710353-00-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 710353-01-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927

methylethylphenylamino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me


RN 710353-02-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 710353-03-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-04-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[[1-methylethyl)sulfonyl]amino]ethyl]-4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-05-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-06-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-07-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 710353-08-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927

INDEX NAME)




RN 710353-09-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)




RN 710353-10-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-11-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710353-12-1 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-3-azetidiny]- (CA INDEX NAME)




RN 710353-14-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (CA INDEX NAME)



RN 710353-16-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidiny)ethyl]- (CA INDEX NAME)



RN 710353-18-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




— Et


RN 710353-19-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710353-20-1 HCAPLUS
CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-21-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-[[1-(1-methylethyl)sulfonyl]amino]ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 710353-23-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 710353-24-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 710353-25-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 710353-26-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 710353-27-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethyl-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)




RN 710353-28-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710353-29-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 710353-30-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-3-azetidiny]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710353-31-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 710353-32-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 710353-33-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 710353-34-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


Serial#: 10/675,927

(NAME)




RN 710353-35-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-[(1-methylethyl)sulfonyl]amino)ethyl)- (CA INDEX NAME)




RN 710353-36-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 710353-37-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 710353-38-1 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 710353-39-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 710353-40-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 710353-41-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 710353-42-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-43-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[1-(1-methylethyl)-3-azetidinyl]-4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-44-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 710353-45-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)


Serial#: 10/675,927



RN 710353-46-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 710353-47-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-48-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[[1-(methylethyl)sulfonyl]amino]ethyl]-4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-49-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-
(CA INDEX NAME)




RN 710353-50-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-
(CA INDEX NAME)




RN 710353-51-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 710353-52-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



IT 710353-53-0P, 4-[[2-[[3-(2-Methoxypyridin-4-yl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-55-2P,
 N-Methyl-4-[[2-[[4-methyl-3-(pyridin-3-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-56-3P,
 4-[[6-Methoxy-1-methyl-2-[[4-methyl-3-(pyridin-3-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-57-4P, 4-[[2-[[3-(2-Ethylamino)pyridin-4-yl]-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-58-5P,
 4-[[2-[[3-(2-Fluoropyridin-3-yl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-59-6P, 4-[[2-[[3-(2-Fluoropyridin-3-yl)-4-

Serial#: 10/675,927

methylphenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-60-9P,
 4-[[2-[[3-(2-Fluoropyridin-3-yl)-4-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-61-0P, N-Methyl-4-[[2-[[3-(2-(pyrrolidin-1-yl)ethyl]phenyl]amino)-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-62-1P, 4-[[6-Methoxy-1-methyl-2-[[3-(2-(pyrrolidin-1-yl)ethyl]phenyl]amino)-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-63-2P,
 N-Methyl-4-[[2-[[3-(2-(morpholin-4-yl)ethyl]phenyl]amino)-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-64-3P,
 4-[[6-Methoxy-1-methyl-2-[[3-(2-(morpholin-4-yl)ethyl]phenyl]amino)-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-65-4P, N-Methyl-4-[[2-[[3-(2-(piperidin-1-yl)ethyl]phenyl]amino)-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-66-5P, N-Methyl-4-[[1-methyl-2-[[3-(2-(piperidin-1-yl)ethyl]phenyl]amino)-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-67-6P, 4-[[6-Methoxy-1-methyl-2-[[3-(2-(piperidin-1-yl)ethyl]phenyl]amino)-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-68-7P,
 N-(1-Isopropylazetidin-3-yl)-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-69-8P, N-(1-Methylpiperidin-4-yl)-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-70-9P,
 N-[2-(2,6-Dimethylpiperidin-1-yl)ethyl]-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-73-4P, 4-[[2-[[3-(tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methylpiperidin-4-yl)pyridine-2-carboxamide 710353-75-6P, 4-[[2-[[3-(tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2,6-dimethylpiperidin-1-yl)ethyl]pyridine-2-carboxamide 710353-77-8P,
 4-[[2-[[3-(tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-isopropylpiperidin-4-yl)pyridine-2-carboxamide 710353-78-9P, N-(1-Isopropylpiperidin-4-yl)-4-[[1-methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-80-3P, 4-[[2-[[4-Fluoro-3-(pyrrolidin-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-82-5P, N-Methyl-4-[[1-methyl-2-[[3-(1-methyl-1H-pyrazol-3-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-84-7P, 4-[[2-[[3-(Bromo-4-tert-butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-85-8P, N-Methyl-4-[[1-methyl-2-[[3-(1H-pyrazol-3-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-86-9P, 4-[[2-[[4-Bromo-3-tert-butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-87-0P, 4-[[2-[[4-Bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2,6-dimethylpiperidin-1-yl)ethyl]pyridine-2-carboxamide 710353-88-1P,
 N-(1-Methylpiperidin-4-yl)-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-pyridine-2-carboxamide 710353-89-2P,
 N-(1-Isopropylpiperidin-4-yl)-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-pyridine-2-carboxamide 710353-90-5P,
 N-(1-Isopropylazetidin-3-yl)-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-91-6P,
 N-[2-(2,6-Dimethylpiperidin-1-yl)ethyl]-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-92-7P,

4-[[1-Methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-93-8P,
4-[[2-[[3-(Isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-94-9P,
N-[2-(2,6-Dimethylpiperidin-1-yl)ethyl]-4-[[2-[[3-(2-fluoropyridin-4-yl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-95-0P,
4-[[2-[[3-(2-Fluoropyridin-4-yl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-96-1P,
4-[[2-[[4-Chloro-3-(2-fluoropyridin-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-97-2P, N-Methyl-4-[[1-methyl-2-[[3-(pyridin-3-yl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710353-98-3P,
4-[[2-[[3-(Acetyl amino)-4-chlorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710353-99-4P,
4-[[2-[[4-Bromo-3-tert-butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-isopropylazetidin-3-yl)pyridine-2-carboxamide 710354-01-1P, 4-[[2-[[4-Bromo-3-tert-butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methylpiperidin-4-yl)pyridine-2-carboxamide 710354-02-2P, 4-[[2-[[4-Bromo-3-tert-butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2,6-dimethylpiperidin-1-yl)ethyl]pyridine-2-carboxamide 710354-03-3P,
4-[[2-[[3-tert-Butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-04-4P,
4-[[2-[[2-Fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-05-5P,
4-[[2-[[2-Chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-06-6P,
4-[[2-[[4-Ethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-07-7P,
4-[[1-Methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-08-8P,
4-[[2-[[4-Isopropylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-09-9P,
4-[[2-[[4-Isopropyl-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-10-2P,
4-[[2-[[4-Isopropyl-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-11-3P,
4-[[2-[[3-tert-Butyl-4-chlorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-12-4P,
4-[[2-[[4-Bromo-3-tert-butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-13-5P,
4-[[1-Ethyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-14-6P,
4-[[1-Ethyl-2-[[3-(2-fluoropyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-15-7P,
4-[[1-Ethyl-2-[[3-(2-methoxypyridin-4-yl)-4-methylphenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-16-8P, 4-[[2-[[4-Chloro-3-(pyridin-4-yl)phenyl]amino]-1-ethyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-17-9P, 4-[[1-Methyl-2-[[3-(pyridin-4-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-18-0P,
4-[[2-[[4-Chloro-3-(pyridin-4-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-19-1P,
4-[[2-[[4-Chloro-3-(thien-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-20-4P,
4-[[2-[[4-Chloro-3-(thien-2-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-21-5P,
4-[[1-Methyl-2-[[4-methyl-3-(thien-2-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(1-methylpiperidin-4-yl)pyridine-2-carboxamide


Serial#: 10/675,927

710354-22-6P, N-[(2-(2,6-Dimethylpiperidin-1-yl)ethyl)-4-[[1-methyl-2-[[4-methyl-3-(thien-2-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-23-7P, 4-[[1-Methyl-2-[[4-methyl-3-(pyridin-3-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-24-8P, 4-[[2-[[4-Chloro-3-(thien-2-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-25-9P, 4-[[2-[[3-(2-Methoxy-pyridin-4-yl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-26-0P, 4-[[1-Methyl-2-[[4-methyl-3-(thien-2-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-27-1P, 4-[[2-[[4-Bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-28-2P, 4-[[2-[[3-Ethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-29-3P, N-1H-Imidazol-2-yl-4-[[2-[[3-(isopropylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-30-6P, 4-[[2-[[4-Chloro-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-31-7P, 4-[[2-[[3-(3-Furyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-32-8P, N-Methyl-4-[[1-methyl-2-[[4-methyl-3-(tetrahydrofuran-3-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-33-9P, N-Methyl-4-[[1-methyl-2-[[4-methyl-3-(tetrahydrofuran-2-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide 710354-34-0F, 4-[[2-[[3-(2-Furyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-35-1P, 4-[[2-[[4-Chloro-3-(3-furyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-36-2P, 4-[[2-[[4-Fluoro-3-(3-furyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-37-3P, 4-[[2-[[4-Fluoro-3-(tetrahydrofuran-3-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710354-38-4P, 4-[[2-[[4-Fluoro-3-(tetrahydrofuran-2-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

RN 710353-53-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-methoxy-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710353-55-2 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-methyl-3-(3-pyridinyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710353-56-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[4-methyl-3-(3-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710353-57-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-ethylamino)-4-pyridinyl]-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710353-58-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-3-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710353-59-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-3-pyridinyl)-4-methylphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710353-60-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-3-pyridinyl)-4-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710353-61-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(2-(1-pyrrolidinyl)ethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 710353-62-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-(2-(1-pyrrolidinyl)ethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710353-63-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(2-(4-


Serial#: 10/675,927

morpholinyl)ethyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 710353-64-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710353-65-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[2-(1-piperidinyl)ethyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 710353-66-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[2-(1-piperidinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-67-6 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-(2-(1-piperidinyl)ethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710353-68-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[1-(1-methylethyl)-3-azetidiny]-4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-69-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-(1-methyl-4-piperidinyl)-4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-71-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(2,6-dimethyl-1-piperidinyl)ethyl]-4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 710353-73-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 710353-75-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2,6-dimethyl-1-piperidiny)ethyl]- (CA INDEX NAME)




RN 710353-77-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-4-piperidiny]- (CA INDEX NAME)



RN 710353-78-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-[1-(1-methylethyl)-4-piperidiny]-4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-80-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(1-pyrrolidinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710353-82-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methyl-1H-pyrazol-3-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-84-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710353-85-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1H-pyrazol-3-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-86-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710353-87-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2,6-dimethyl-1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 710353-88-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-(1-methyl-4-piperidinyl)-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-89-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-[1-(1-methylethyl)-4-piperidinyl]-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-90-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-[1-(1-methylethyl)-3-azetidiny]-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710353-91-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(2,6-dimethyl-1-piperidinyl)ethyl]-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-92-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-93-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-94-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(2,6-dimethyl-1-piperidinyl)ethyl]-4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710353-95-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710353-96-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-fluoro-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710353-97-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710353-98-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(acetylamino)-4-chlorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710353-99-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-3-azetidiny]- (CA INDEX NAME)



RN 710354-01-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)



RN 710354-02-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2,6-dimethyl-1-piperidiny)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-03-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710354-04-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-05-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-06-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-ethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-07-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710354-08-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-09-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-methyl-4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-10-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-methyl-4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-11-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710354-12-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-13-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-ethyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710354-14-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-ethyl-2-[[3-(2-fluoro-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-15-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-ethyl-2-[[3-(2-methoxy-4-pyridinyl)-4-methylphenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710354-16-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-pyridinyl)phenyl]amino]-1-ethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710354-17-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710354-18-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-19-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(3-thienyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710354-20-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-thienyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710354-21-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-[[2-(2,6-dimethyl-1-piperidinyl)ethyl]-4-[[1-methyl-2-[[4-methyl-3-(2-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 710354-22-6 HCAPLUS


CN 2-Pyridinecarboxamide, N-[[2-(2,6-dimethyl-1-piperidinyl)ethyl]-4-[[1-methyl-2-[[4-methyl-3-(2-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-23-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(3-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710354-24-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-thienyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-25-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-methoxy-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-26-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-methyl-3-(2-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-27-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 710354-28-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-ethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-29-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-1H-imidazol-2-yl-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-30-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-31-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-furanyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710354-32-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-methyl-3-(tetrahydro-3-furanyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-33-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-methyl-3-(tetrahydro-2-furanyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710354-34-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-furanyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710354-35-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710354-36-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710354-37-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(tetrahydro-3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710354-38-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(tetrahydro-2-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



IT 611225-65-1P 611225-66-2P 611225-71-9P
 611225-75-3P 611225-76-4P 611225-77-5P
 611225-78-6P 611225-79-7P 611225-80-0P
 611225-81-1P 611225-82-2P 611225-95-7P
 611225-96-8P 611226-06-3P 611226-08-5P
 611226-13-2P 611226-14-3P 611226-31-4P
 710351-27-2P 710351-30-7P 710351-74-9P,
 4-[[2-[(4-Chloro-3-nitrophenyl)amino]-1-methylbenzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide 710351-75-0P,
 4-[[2-[(3-Amino-4-chlorophenyl)amino]-1-methylbenzimidazol-5-yl]oxy]-N-methylpyridine-2-carboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)


RN 611225-65-1 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 611225-66-2 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-71-9 HCAPLUS


CN 2-Pyridinecarbonitrile, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-75-3 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-76-4 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[[4-bromo-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-77-5 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-78-6 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[2-[[4-bromo-3-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-79-7 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-80-0 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-81-1 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-82-2 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-95-7 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-96-8 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611226-06-3 HCAPLUS


CN 2-Pyridinecarboxylic acid, 5-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 611226-08-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromo-4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611226-13-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 611226-14-3 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611226-31-4 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 710351-27-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-bromo-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 710351-30-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-bromo-3-fluoro-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 710351-74-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 710351-75-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-amino-4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



IT 611226-42-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

Serial#: 10/675,927

RN 611226-42-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(19 CITINGS)

L14 ANSWER 33 OF 33 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:796477 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:307759

TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors

INVENTOR(S): Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl, Wendy

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 259 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082272	A1	20031009	WO 2003-US10117	20030331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480638	A1	20031009	CA 2003-2480638	20030331
AU 2003226211	A1	20031013	AU 2003-226211	20030331
AU 2003226211	B2	20080529		
EP 1499311	A1	20050126	EP 2003-745683	20030331
EP 1499311	B1	20091104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008854	A	20050222	BR 2003-8854	20030331
CN 1655779	A	20050817	CN 2003-812193	20030331
CN 100515419	C	20090722		
JP 2005529089	T	20050929	JP 2003-579810	20030331
NZ 535985	A	20070427	NZ 2003-535985	20030331
AP 1913	A	20081031	AP 2004-3161	20030331
AT 447404	T	20091115	AT 2003-745683	20030331

Serial#: 10/675,927

IN 2004KN01433	A	20051230	IN 2004-KN1433	20040927
IN 223046	Al	20080905		
MX 2004009541	A	20050125	MX 2004-9541	20040929
NO 2004004617	A	20041228	NO 2004-4617	20041026
ZA 2004008386	A	20060531	ZA 2004-8386	20060308
JP 2006193533	A	20060727	JP 2006-96143	20060330
PRIORITY APPLN. INFO.:			US 2002-369066P	P 20020329
			JP 2003-579810	A3 20030331
			WO 2003-US10117	W 20030331


OTHER SOURCE(S): MARPAT 139:307759
GI



AB The title compds. [I; X1, X2 = N, NR4, O, S (with the provisos); Y = O, S; A1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; A2 = (un)substituted heteroaryl; R1 = O, H, and R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted alkyl, alkoxyalkyl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl], useful for inhibition of Raf kinase activity in a human or animal subject, were prepared E.g., a 3-step synthesis of the benzimidazole II (starting from 4-amino-3-nitrophenol and (4-chlorophenyl)-N-methylcarboxamide), was given. The compds. of examples 1-1094 showed a Raf kinase inhibitory activity at an IC50 of less than 5 μ M. A composition comprising the compound I is claimed. The new compds. compns. may be used either alone or in combination with at least one addnl. agent for the treatment of a Raf kinase mediated disorder, such as cancer.

IT 1066538-71-3
RL: PRPH (Prophetic)
(Preparation of substituted benzazoles as Raf kinase inhibitors)
RN 1066538-71-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




IT 611213-97-9P 611214-71-2P 611214-79-0P
611215-54-4P 611215-68-0P 611224-42-1P
611224-60-7P 611225-00-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzazoles as Raf kinase inhibitors)


RN 611213-97-9 HCAPLUS

CN Benzoic acid, 4-[[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 611214-71-2 HCAPLUS

CN Benzoic acid, 3-[[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)



RN 611214-79-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[[2-[(3-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-54-4 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethynylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-68-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611224-42-1 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, oxime (CA INDEX NAME)




RN 611224-80-7 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 611224-79-4

CMF C20 H17 Br N4 O2



Serial#: 10/675,927

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 611225-00-4 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(aminomethyl)-4-pyridinyl]oxy]-N-(4-bromophenyl)-1-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 611224-99-8

CMF C20 H18 Br N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT	611212-56-7P	611212-57-8P	611212-58-9P
	611212-59-0P	611212-60-3P	611212-61-4P
	611212-63-6P	611212-64-7P	611212-67-0P
	611212-68-1P	611212-69-2P	611212-71-6P
	611212-72-7P	611212-74-9P	611212-75-0P
	611212-76-1P	611212-77-2P	611212-78-3P
	611212-79-4P	611212-80-7P	611212-81-8P
	611212-82-9P	611212-83-0P	611212-84-1P
	611212-85-2P	611212-86-3P	611212-87-4P
	611212-88-5P	611212-89-6P	611212-90-9P

Serial#: 10/675,927

611212-91-8P 611212-92-1P 611212-93-2P
611212-94-3P 611212-95-4P 611212-96-5P
611212-97-6P 611212-98-7P 611212-99-8P
611213-00-4P 611213-01-5P 611213-02-6P
611213-03-7P 611213-04-8P 611213-05-9P
611213-06-0P 611213-07-1P 611213-08-2P
611213-09-3P 611213-10-6P 611213-11-7P
611213-12-8P 611213-13-9P 611213-14-0P
611213-15-1P 611213-16-2P 611213-17-3P
611213-18-4P 611213-19-5P 611213-20-8P
611213-21-9P 611213-22-0P 611213-23-1P
611213-24-2P 611213-25-3P 611213-26-4P
611213-27-5P 611213-28-6P 611213-29-7P
611213-30-0P 611213-31-1P 611213-32-2P
611213-33-3P 611213-34-4P 611213-35-5P
611213-36-6P 611213-37-7P 611213-38-8P
611213-39-9P 611213-40-2P 611213-41-3P
611213-42-4P 611213-43-5P 611213-44-6P
611213-45-7P 611213-46-8P 611213-47-9P
611213-48-0P 611213-49-1P 611213-50-4P
611213-51-5P 611213-53-7P 611213-54-8P
611213-55-9P 611213-56-0P 611213-57-1P
611213-58-2P 611213-60-6P 611213-70-8P
611213-71-9P 611213-72-0P 611213-73-1P
611213-74-2P 611213-75-3P 611213-76-4P
611213-77-5P 611213-78-6P 611213-79-7P
611213-80-0P 611213-81-1P 611213-82-2P
611213-83-3P 611213-84-4P 611213-85-5P
611213-86-6P 611213-87-7P 611213-88-8P
611213-89-9P 611213-90-2P 611213-91-3P
611213-92-4P 611213-93-5P 611213-94-6P
611213-95-7P 611213-96-8P 611213-99-1P
611214-00-7P 611214-01-8P 611214-02-9P
611214-03-0P 611214-04-1P 611214-05-2P
611214-06-3P 611214-08-5P 611214-09-6P
611214-10-9P 611214-11-0P 611214-12-1P
611214-13-2P 611214-14-3P 611214-15-4P
611214-16-5P 611214-17-6P 611214-18-7P
611214-19-8P 611214-20-1P 611214-21-2P
611214-22-3P 611214-23-4P 611214-24-5P
611214-25-6P 611214-26-7P 611214-27-8P
611214-28-9P 611214-29-0P 611214-30-3P
611214-31-4P 611214-32-5P 611214-33-6P
611214-34-7P 611214-35-8P 611214-36-9P
611214-37-0P 611214-38-1P 611214-39-2P
611214-40-5P 611214-41-6P 611214-42-7P
611214-43-8P 611214-44-9P 611214-46-1P
611214-47-2P 611214-48-3P 611214-49-4P
611214-50-7P 611214-51-8P 611214-52-9P
611214-53-0P 611214-55-2P 611214-56-3P
611214-57-4P 611214-58-5P 611214-59-6P
611214-60-9P 611214-61-0P 611214-62-1P
611214-63-2P 611214-69-8P 611214-70-1P
611214-72-3P 611214-73-4P 611214-74-5P
611214-75-6P 611214-77-8P 611214-78-9P
611214-80-3P 611214-83-6P 611214-84-7P
611214-85-8P 611214-86-9P 611214-87-0P
611214-88-1P 611214-89-2P 611214-90-5P
611214-91-6P 611214-93-8P 611214-95-0P
611214-96-1P 611214-97-2P 611214-98-3P
611214-99-4P 611215-00-0P 611215-01-1P

Serial#: 10/675,927


611215-03-3P	611215-06-6P	611215-07-7P
611215-08-8P	611215-09-9P	611215-11-3P
611215-12-4P	611215-13-5P	611215-14-6P
611215-15-7P	611215-16-8P	611215-17-9P
611215-18-0P	611215-21-5P	611215-22-6P
611215-23-7P	611215-24-8P	611215-25-9P
611215-26-0P	611215-27-1P	611215-28-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzazoles as Raf kinase inhibitors)


RN 611212-56-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-57-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chlorophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-58-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-59-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-fluorophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611212-60-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-(phenylamino)-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-61-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-63-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)-1-naphthalenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-64-7 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(4-nitrophenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-67-0 HCAPLUS

CN Benzoic acid, 4-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (CA INDEX NAME)




RN 611212-68-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-69-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611212-71-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-iodophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-72-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-74-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-75-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-acetylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611212-76-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-77-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-78-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-79-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611212-80-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-81-8 HCAPLUS


CN 2-Thiophenecarboxylic acid, 3-[[6-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (CA INDEX NAME)



RN 611212-82-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611212-83-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611212-84-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-85-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611212-86-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-87-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(methylthio)phenyl]amino]-1H-


Serial#: 10/675,927

benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-88-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-89-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxyphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-90-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluorophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-91-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(aminosulfonyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611212-92-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-93-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(3,4-dimethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-94-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-(2-fluoro-5-(trifluoromethyl)phenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-95-4 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dichlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-96-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611212-97-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-methoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611212-98-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(1,1'-biphenyl)-2-ylamino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611212-99-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611213-00-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-01-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-02-6 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-03-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-04-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-bis(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-05-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-5-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-06-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-07-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-08-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-4-nitrophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-09-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-10-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611213-11-7 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-12-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyclohexylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-13-9 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-difluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-14-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-15-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-16-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-butylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-17-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611213-18-4 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dichlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-19-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(4-phenoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-20-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-21-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(diethylamino)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-22-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[(4-chloro-2-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-23-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[(4-bromo-2-chlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-24-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[[2-bromo-4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-25-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-[(2-chloro-4-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-26-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromo-4-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-27-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-(trifluoromethyl)phenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-28-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-29-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-30-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-31-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-32-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2,3,5-trifluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-33-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611213-34-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-35-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-36-6 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-37-7 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-38-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-39-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1,3-benzodioxol-5-ylamino)-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-40-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-41-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1H-


Serial#: 10/675,927

benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-42-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-43-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-44-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-fluorophenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-45-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-46-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(methylthio)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611213-47-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-methoxyphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-48-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-ethylphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-49-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927

(NAME)




RN 611213-50-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-51-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611213-53-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-methyl-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)



RN 611213-54-8 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-55-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-56-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-57-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-58-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-60-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-(4-bromophenyl)-4-[[2-[[4-bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-70-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-71-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611213-72-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611213-73-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-74-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-75-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611213-76-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-77-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611213-78-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-79-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-80-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-nitrophenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-81-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611213-82-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-83-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-84-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-85-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-86-6 HCAPLUS

CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (CA INDEX NAME)



RN 611213-87-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-88-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-89-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-acetylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-90-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-(1,1-dimethylethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-91-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-92-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyclohexylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-93-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611213-94-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-95-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611213-96-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611213-99-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-00-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,5-dimethoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-01-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2,4-difluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-02-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-difluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611214-03-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-04-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-4-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-05-2 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-06-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-08-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-09-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-10-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-11-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-12-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-13-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-14-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-15-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-16-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-17-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-18-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[5-chloro-2,4-dimethoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-19-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[1,1'-biphenyl]-2-ylamino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-20-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-21-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-22-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-ethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-23-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-aminophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-24-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylamino)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-25-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-26-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-27-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-28-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-29-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-bis(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-30-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-31-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-32-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-33-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-34-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-(trifluoromethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-35-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-36-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-37-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-38-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-39-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-(5-oxazolyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-40-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-41-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-42-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(cyclohexylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-43-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-44-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-46-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1H-pyrazol-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-47-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-48-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-(cyclopropylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-49-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-50-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(phenylmethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-51-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-52-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethyl-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-53-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(4-nitrophenoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-55-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-56-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-57-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[1-acetyl-2,3-dihydro-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-58-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-59-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(cycloheptylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-60-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-acetylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-61-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(bicyclo[2.2.1]hept-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-62-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-63-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1-hydroxyethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-69-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2,4-dimethoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-70-1 HCAPLUS


CN Benzoic acid, 3-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-72-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethyl-4-isoxazolyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-73-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5-methyl-3-phenyl-4-isoxazolyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-74-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-75-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-1H-indazol-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611214-77-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-78-9 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-80-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3,4,5-trimethoxyphenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-83-6 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[5-(2-thienyl)-1H-pyrazol-3-yl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-84-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(1,3-benzodioxol-5-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-85-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-86-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-(2,6-diethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-87-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1-hydroxyethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-88-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-89-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-phenoxypyridin-2-yl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611214-90-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611214-91-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927




RN 611214-93-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-bicyclohexyl]-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611214-95-0 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(tricyclo[3.3.1.1.3,7]dec-1-ylamino)-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-96-1 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-97-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-([5-fluoro-2-(1H-imidazol-1-yl)phenyl]amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611214-98-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[(5-phenyl-1H-pyrazol-3-yl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611214-99-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-00-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-01-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[(2,3-dihydro-3-oxo-1H-isoindol-5-yl)amino]-1-


Serial#: 10/675,927

methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-03-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(2-naphthalenylamino)-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-06-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-07-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-08-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-(difluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-09-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-11-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[3-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-12-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-cyano-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-13-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-[1-(phenylmethyl)amino]ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-14-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(1H-indol-5-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-15-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-16-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-benzoylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-17-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-18-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromo-6-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-21-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1-isoquinolinylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-22-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1H-pyrazol-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-23-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1H-indol-6-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927

5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-24-8 HCAPLUS

CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-3-(trifluoromethoxy)-, methyl ester (CA INDEX NAME)




RN 611215-25-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-26-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(phenylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-27-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-

Serial#: 10/675,927
(CA INDEX NAME)



RN 611215-28-2 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



IT	611215-29-3P	611215-30-6P	611215-31-7P
	611215-32-8P	611215-33-9P	611215-34-0P
	611215-35-1P	611215-36-2P	611215-37-3P
	611215-38-4P	611215-40-8P	611215-41-9P
	611215-42-0P	611215-43-1P	611215-44-2P
	611215-45-3P	611215-46-4P	611215-47-5P
	611215-48-6P	611215-49-7P	611215-50-0P
	611215-51-1P	611215-52-2P	611215-53-3P
	611215-56-6P	611215-57-7P	611215-58-8P
	611215-60-2P	611215-61-3P	611215-62-4P
	611215-63-5P	611215-66-8P	611215-69-1P
	611215-70-4P	611215-71-5P	611215-72-6P
	611215-74-8P	611215-75-9P	611215-77-1P
	611215-78-2P	611215-80-6P	611215-81-7P
	611215-82-8P	611215-83-9P	611215-84-0P
	611215-85-1P	611215-86-2P	611215-87-3P
	611215-88-4P	611215-89-5P	611215-90-8P
	611215-91-9P	611215-92-0P	611215-93-1P
	611215-94-2P	611215-95-3P	611215-96-4P
	611215-98-6P	611215-99-7P	611216-00-3P
	611216-01-4P	611216-02-5P	611216-03-6P
	611216-04-7P	611216-05-8P	611216-06-9P
	611216-07-0P	611216-08-1P	611216-09-2P
	611216-10-5P	611216-11-6P	611216-12-7P
	611216-13-8P	611216-14-9P	611216-15-0P
	611216-16-1P	611216-17-2P	611216-18-3P
	611216-19-4P	611216-20-7P	611216-22-9P
	611216-23-0P	611216-25-2P	611216-26-3P
	611216-27-4P	611216-28-5P	611216-29-6P
	611216-30-9P	611216-31-0P	611216-32-1P

Serial#: 10/675,927

611216-33-2P	611216-34-3P	611216-35-4P
611216-36-5P	611216-37-6P	611216-39-8P
611216-40-1P	611216-41-2P	611216-42-3P
611216-43-4P	611216-44-5P	611216-45-6P
611216-46-7P	611216-47-8P	611216-48-9P
611216-49-0P	611216-50-3P	611216-51-4P
611216-52-5P	611216-53-6P	611216-54-7P
611216-55-8P	611216-56-9P	611216-57-0P
611216-58-1P	611216-59-2P	611216-60-5P
611216-61-6P	611216-62-7P	611216-63-8P
611216-64-9P	611216-65-0P	611216-66-1P
611216-67-2P	611216-68-3P	611216-69-4P
611216-70-7P	611216-71-8P	611216-72-9P
611216-73-0P	611216-74-1P	611216-75-2P
611216-76-3P	611216-77-4P	611216-78-5P
611216-79-6P	611216-80-9P	611216-81-0P
611216-82-1P	611216-84-3P	611216-85-4P
611216-86-5P	611216-87-6P	611216-88-7P
611216-89-8P	611216-91-2P	611216-92-3P
611216-93-4P	611216-94-5P	611216-95-6P
611216-96-7P	611216-97-8P	611216-98-9P
611217-00-6P	611217-00-6P	611217-02-8P
611217-03-9P	611217-43-7P	611217-44-8P
611217-46-0P	611217-47-1P	611217-48-2P
611217-50-6P	611217-51-7P	611217-52-8P
611217-54-0P	611217-55-1P	611217-56-2P
611217-57-3P	611217-58-4P	611217-59-5P
611217-60-8P	611217-62-0P	611217-64-2P
611217-66-4P	611217-67-5P	611217-68-6P
611217-69-7P	611217-70-0P	611217-71-1P
611217-73-3P	611217-75-5P	611217-77-7P
611217-79-9P	611217-81-3P	611217-83-5P
611217-85-7P	611217-88-0P	611217-90-4P
611217-92-6P	611217-94-8P	611217-96-0P
611217-98-2P	611218-00-9P	611218-02-1P
611218-04-3P	611218-07-6P	611218-09-8P
611218-11-2P	611218-13-4P	611218-15-6P
611218-17-8P	611218-19-0P	611218-21-4P
611218-23-6P	611218-25-8P	611218-27-0P
611218-29-2P	611218-30-5P	611218-33-8P
611218-35-0P	611218-37-2P	611218-40-7P
611218-42-9P	611218-44-1P	611218-46-3P
611218-48-5P	611218-50-9P	611218-52-1P
611218-54-3P	611218-56-5P	611218-58-7P
611218-60-1P	611218-63-4P	611218-65-6P
611218-67-8P	611218-69-0P	611218-71-4P
611218-73-6P	611218-75-8P	611218-77-0P
611218-79-2P	611218-81-6P	611218-83-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzazoles as Raf kinase inhibitors)

RN 611215-29-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1,7-dimethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-30-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-31-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(cyclohexyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-32-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-33-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-34-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-35-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-36-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-fluoro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-37-3 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(2-aminophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-38-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-cyano-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-40-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-41-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-bromo-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-42-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methyl[1,1'-biphenyl]-3-


Serial#: 10/675,927

yl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-43-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-44-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-45-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-amino-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-46-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-amino-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611215-47-5 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-48-6 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylsulfonyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-49-7 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-50-0 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-
[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX
NAME)




RN 611215-51-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[1,1'-biphenyl]-3-ylamino]-1-methyl-1H-
benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-52-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-4-methylphenyl]amino]-1-methyl-1H-
benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-53-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-bromo-4-(1-methylethyl)phenyl]amino]-1-
methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-56-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[7-isoquinolinylamino]-1-methyl-1H-
benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-57-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611215-58-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromo-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-60-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-(9H-fluoren-1-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611215-61-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(9H-fluoren-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-62-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-63-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[3-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-66-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cycloheptylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




Serial#: 10/675,927

RN 611215-69-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dihydro-1-(1-oxo-3-(4-pyridinyl)propyl)-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611215-70-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-71-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-(cyclopentylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-72-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(diethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-74-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-75-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-77-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-chlorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-78-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-dimethylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-80-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-81-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-phenoxy-3-pyridinyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-82-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-(2-pyridinyl)phenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-83-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-84-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-85-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2,4,5-trimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-86-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-87-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-88-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-89-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylpropyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611215-90-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-91-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-92-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-93-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-94-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(3-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-95-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611215-96-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611215-98-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromo-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611215-99-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2,3,5-trifluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611216-00-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611216-01-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-02-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-(trifluoromethylthio)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-03-6 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-04-7 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-bis(1,1-dimethylethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611216-05-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-06-9 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(1-methyl-1-phenylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-07-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2,5-dimethoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-08-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-2-(1-methylethoxy)phenyl]amino]-1-


Serial#: 10/675,927

methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-09-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-10-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-11-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-methoxy-5-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-12-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-methyl-5-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-13-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,5-bis(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611216-14-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-chloro-2-(difluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-15-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(phenylmethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-16-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-(cyclohexylmethylamino)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-17-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[6-(1-pyrrolidinyl)-3-pyridinyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611216-18-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[6-(dimethylamino)-3-pyridinyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611216-19-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[1-methyl-4-piperidinyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-20-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-methylcyclohexyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-22-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3,3,5-trimethylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-23-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(2-methylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611216-25-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 611216-24-1

CMF C22 H20 Br N5 O2



Serial#: 10/675,927

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 611216-26-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611216-27-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611216-28-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 611216-29-6 HCAPLUS

CN Methanone, [4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 611216-30-9 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-methoxy-4-[[[4-[[2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-2-pyridinyl]carbonyl]amino]-, ethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-31-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 611216-32-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611216-33-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611216-34-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 611216-35-4 HCAPLUS

CN Methanone, (3-amino-1-pyrrolidinyl)[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)



RN 611216-36-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(diphenylmethyl)-3-azetidiny]- (CA INDEX NAME)




RN 611216-37-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3S)-3-pyrrolidinyl- (CA INDEX NAME)


Serial#: 10/675,927

Absolute stereochemistry.



RN 611216-39-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-40-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-41-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)



RN 611216-42-3 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611216-43-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611216-44-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-45-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 611216-46-7 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-3-piperidinyl- (CA INDEX NAME)




RN 611216-47-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611216-48-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611216-49-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-50-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methylethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-51-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-hydroxycyclohexyl)- (CA INDEX NAME)




RN 611216-52-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611216-53-6 HCAPLUS


CN 2-Pyridinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611216-54-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-pyridinylmethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-55-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611216-56-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 611216-57-0 HCAPLUS

CN Methanone, [4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl][4-(2-hydroxyethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 611216-58-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611216-59-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611216-60-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(hexahydro-2-oxo-1H-azepin-3-yl)- (CA INDEX NAME)



RN 611216-61-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)



RN 611216-62-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-1-piperidinyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 611216-63-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 611216-64-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611216-65-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)

PAGE 1-A







RN 611216-66-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 611216-67-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-piperidinyl)ethyl]- (CA INDEX NAME)




RN 611216-68-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(phenylamino)ethyl]- (CA INDEX NAME)




RN 611216-69-4 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(acetlamino)ethyl]-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-70-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611216-71-8 HCAPLUS


CN Glycine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]-, methyl ester (CA INDEX NAME)



RN 611216-72-9 HCAPLUS

CN L-Valine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-73-0 HCAPLUS


CN L-Asparagine, N2-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)

Serial#: 10/675,927

Absolute stereochemistry.




RN 611216-74-1 HCAPLUS

CN β -Alanine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]-, methyl ester (CA INDEX NAME)

RN 611216-75-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-aminopropyl]-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611216-76-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(2R)-2-aminopropyl]-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



Serial#: 10/675,927


RN 611216-77-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-pyrrolidinylmethyl)- (CA INDEX NAME)




RN 611216-78-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



RN 611216-79-6 HCAPLUS


CN Glycine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)



RN 611216-80-9 HCAPLUS

CN L-Valine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611216-81-0 HCAPLUS


Serial#: 10/675,927

CN β -Alanine, N-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)




RN 611216-82-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 611216-84-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 611216-85-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611216-86-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611216-87-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy)-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 611216-88-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611216-89-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy)-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 611216-91-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-([2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy)-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.

Serial#: 10/675,927




RN 611216-92-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611216-93-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)



RN 611216-94-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611216-95-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.


Serial#: 10/675,927



RN 611216-96-7 HCAPLUS


CN L-Alanine, N-[[4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-97-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2,3-dihydroxypropyl)- (CA INDEX NAME)



RN 611216-98-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3S)-3-pyrrolidinyl)- (CA INDEX NAME)


Absolute stereochemistry.



Serial#: 10/675,927


RN 611216-99-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611217-00-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B



RN 611217-02-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




PAGE 1-A




RN 611217-03-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-chlorophenyl)-5-[[2-(4,5-dihydro-1H-imidazol-2-yl)-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611217-43-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611217-44-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611217-46-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611217-47-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 611217-48-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611217-50-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611217-51-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611217-52-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 611217-54-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-ethyl-2-pyrrolidinylmethyl]- (CA INDEX NAME)




RN 611217-55-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611217-56-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




PAGE 1-A




RN 611217-57-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611217-58-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611217-59-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611217-60-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611217-62-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611217-64-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 611217-66-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidiny)propyl]- (CA INDEX NAME)



RN 611217-67-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidiny)propyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611217-68-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611217-69-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611217-70-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 611217-71-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611217-73-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-


Serial#: 10/675,927

benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)




RN 611217-75-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611217-77-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611217-79-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



Serial#: 10/675,927


RN 611217-81-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611217-83-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611217-85-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[4-bromo-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611217-88-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611217-90-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611217-92-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611217-94-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611217-96-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



Serial#: 10/675,927


RN 611217-98-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611218-00-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611218-02-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611218-04-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611218-07-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611218-09-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611218-11-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611218-13-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-ethyl-4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611218-15-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611218-17-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611218-19-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611218-21-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611218-23-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611218-25-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 611218-27-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)




RN 611218-29-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-


Serial#: 10/675,927

methyl-1H-benzimidazol-5-yl]oxy)-N-(2-(4-pyridinyl)ethyl)- (CA INDEX NAME)




RN 611218-30-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611218-33-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 611218-35-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611218-37-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 611218-40-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611218-42-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611218-44-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



Serial#: 10/675,927

RN 611218-46-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)



RN 611218-48-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611218-50-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611218-52-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611218-54-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611218-56-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 611218-58-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611218-60-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611218-63-4 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611218-65-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611218-67-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611218-69-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611218-71-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611218-73-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611218-75-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 611218-77-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611218-79-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




Serial#: 10/675,927

RN 611218-81-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 611218-83-8 HCAPLUS
 CN 2-Pyridinecarboxamide, N-(3-methoxypropyl)-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



IT	611218-85-0P	611218-87-2P	611218-89-4P
	611218-91-8P	611218-93-0P	611218-95-2P
	611218-97-4P	611218-98-5P	611219-00-2P
	611219-02-4P	611219-05-7P	611219-07-9P
	611219-09-1P	611219-11-5P	611219-13-7P
	611219-15-9P	611219-17-1P	611219-19-3P
	611219-21-7P	611219-23-9P	611219-25-1P
	611219-26-2P	611219-28-4P	611219-30-8P
	611219-32-0P	611219-34-2P	611219-36-4P
	611219-38-6P	611219-40-0P	611219-42-2P
	611219-44-4P	611219-46-6P	611219-48-8P
	611219-51-3P	611219-53-5P	611219-55-7P
	611219-57-9P	611219-58-0P	611219-59-1P
	611219-60-4P	611219-62-6P	611219-64-8P
	611219-66-0P	611219-68-2P	611219-70-6P
	611219-72-8P	611219-74-0P	611219-76-2P
	611219-78-4P	611219-80-8P	611219-82-0P
	611219-84-2P	611219-86-4P	611219-88-6P
	611219-90-0P	611219-93-3P	611219-95-5P
	611219-97-7P	611219-99-9P	611220-01-0P
	611220-10-1P	611220-12-3P	611220-14-5P
	611220-22-5P	611220-28-1P	611220-30-5P
	611220-32-7P	611220-34-9P	611220-36-1P
	611220-38-3P	611220-40-7P	611220-42-9P
	611220-44-1P	611220-46-3P	611220-48-5P
	611220-50-9P	611220-52-1P	611220-54-3P
	611220-56-5P	611220-58-7P	611220-60-1P
	611220-62-3P	611220-64-5P	611220-66-7P
	611220-68-9P	611220-70-3P	611220-72-5P
	611220-74-7P	611220-76-9P	611220-78-1P

Serial#: 10/675,927

611220-80-5P	611220-82-7P	611220-84-9P
611220-86-1P	611220-88-3P	611220-90-7P
611220-92-9P	611220-94-1P	611220-96-5P
611220-98-5P	611221-00-2P	611221-02-4P
611221-04-6P	611221-06-8P	611221-09-1P
611221-11-5P	611221-12-6P	611221-14-8P
611221-26-2P	611221-28-4P	611221-30-8P
611221-32-0P	611221-34-2P	611221-36-4P
611221-38-6P	611221-40-0P	611221-42-2P
611221-44-4P	611221-46-6P	611221-49-9P
611221-51-3P	611221-53-5P	611221-55-7P
611221-57-9P	611221-59-1P	611221-61-5P
611221-63-7P	611221-65-3P	611221-67-1P
611221-69-3P	611221-71-7P	611221-73-9P
611221-75-1P	611221-77-3P	611221-79-4P
611221-79-5P	611221-80-8P	611221-81-9P
611221-82-0P	611221-83-1P	611221-84-2P
611221-85-3P	611221-86-4P	611221-87-5P
611221-88-6P	611221-89-7P	611221-90-0P
611221-92-2P	611221-93-3P	611221-94-4P
611221-95-5P	611221-96-6P	611221-97-7P
611221-98-8P	611221-99-9P	611222-00-5P
611222-01-6P	611222-02-7P	611222-03-8P
611222-04-9P	611222-05-0P	611222-06-1P
611222-07-2P	611222-08-3P	611222-09-4P
611222-10-7P	611222-11-8P	611222-12-9P
611222-13-0P	611222-14-1P	611222-15-2P
611222-16-3P	611222-17-4P	611222-19-6P
611222-20-9P	611222-21-0P	611222-22-1P
611222-23-2P	611222-24-3P	611222-25-4P
611222-26-5P	611222-27-6P	611222-28-7P
611222-29-8P	611222-30-1P	611222-31-2P
611222-32-3P	611222-33-4P	611222-34-5P
611222-35-6P	611222-38-9P	611222-39-0P
611222-40-3P	611222-41-4P	611222-43-6P
611222-44-7P	611222-45-8P	611222-47-0P
611222-49-1P	611222-50-5P	611222-52-7P
611222-53-8P	611222-54-9P	611222-55-0P
611222-56-1P	611222-57-2P	611222-58-3P
611222-59-4P	611222-60-7P	611222-61-8P
611222-62-9P	611222-63-0P	611222-64-1P
611222-65-2P	611222-66-3P	611222-67-4P
611222-68-5P	611222-69-6P	611222-70-9P
611222-71-0P	611222-72-1P	611222-73-2P
611222-74-3P	611222-75-4P	611222-76-5P
611222-77-6P	611222-78-7P	611222-79-8P
611222-80-1P	611222-81-2P	611222-82-3P
611222-83-4P	611222-84-5P	611222-85-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzazoles as Raf kinase inhibitors)

RN 611218-85-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611218-87-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611218-89-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611218-91-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)




RN 611218-93-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.


Serial#: 10/675,927




RN 611218-95-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 611218-97-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611218-98-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 611219-00-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611219-02-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611219-05-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611219-07-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 611219-09-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611219-11-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611219-13-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 611219-15-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidiny)propyl]- (CA INDEX NAME)



RN 611219-17-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611219-19-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611219-21-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 611219-23-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611219-25-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611219-26-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-


Serial#: 10/675,927

benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611219-28-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611219-30-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611219-32-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 611219-34-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


Serial#: 10/675,927



RN 611219-36-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Bu-t


RN 611219-38-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611219-40-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611219-42-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611219-44-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611219-46-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611219-48-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611219-51-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)


Serial#: 10/675,927

(NAME)




RN 611219-53-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 611219-55-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611219-57-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611219-58-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611219-59-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611219-60-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



RN 611219-62-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)



RN 611219-64-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetlamino)ethyl]-4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611219-66-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611219-68-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 611219-70-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611219-72-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-


Serial#: 10/675,927

methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA
INDEX NAME)




RN 611219-74-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-(dimethylamino)ethyl)- (CA INDEX NAME)




RN 611219-76-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611219-78-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611219-80-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)




RN 611219-82-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611219-84-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611219-86-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611219-88-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611219-90-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 611219-93-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 611219-95-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927

RN 611219-97-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 611219-99-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 611220-01-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611220-10-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611220-12-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-14-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[2-[(phenylmethyl)amino]ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-22-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-28-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[2-(dimethylamino)ethoxy]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 611220-30-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[(methylamino)carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-32-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611220-34-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[4-ethyl-1-piperazinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 611220-36-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[2-(4-pyridinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611220-38-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-40-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[3-(dimethylamino)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611220-42-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-[[[1-methylethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-44-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(2,6-dimethyl-4-morpholinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-46-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-(1-piperidinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-48-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-[[[2-(1-methyl-2-

Serial#: 10/675,927

pyrrolidinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611220-50-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-[[[2-(1-piperidinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611220-52-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[[2-[[4-[[[3-(1H-imidazol-1-yl)propyl]amino]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-
N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611220-54-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[[(1-ethyl-2-pyrrolidinyl)methyl]amino]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-56-5 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611220-58-7 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[2-(1-pyridinylmethyl)amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611220-60-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[(2-thiazolylamino)carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611220-62-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611220-64-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(1-azabicyclo[2.2.2]oct-3-ylamino)carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 611220-66-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611220-68-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-70-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927

RN 611220-72-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-74-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 611220-76-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611220-78-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-80-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-82-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611220-84-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

Serial#: 10/675,927



RN 611220-86-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611220-88-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[[(3R)-3-(acetylamino)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 611220-90-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[[(1,4'-bipiperidin)-1'-yl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 611220-92-9 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-(4-morpholinylcarbonyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611220-94-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[[3R,5S)-3,5-dimethyl-1-piperazinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 611220-96-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




Serial#: 10/675,927

RN 611220-98-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[(2R)-2-(aminocarbonyl)-1-pyrrolidinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611221-00-2 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[4-(1-methylethyl)-1-piperazinyl]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611221-02-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[(2R,5S)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611221-04-6 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[[(1-methyl-4-piperidinyl)amino]carbonyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-06-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[2-[(dimethylamino)methyl]-4-morpholinyl]carbonyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611221-09-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[4-[methyl(1-methyl-3-pyrrolidinyl)amino]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611221-11-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-[[2-[(dimethylamino)ethyl]methylamino]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-12-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(2-(4-ethyl-1-piperazinyl)ethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611221-14-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(2-(1-piperidinyl)ethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611221-26-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611221-28-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-30-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611221-32-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-chloro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611221-34-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611221-36-4 HCAPLUS


CN 3-Pyridinecarboxamide, 5-[[2-[[4-bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-38-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 611221-40-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611221-42-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611221-44-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-46-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidiny)ethyl]- (CA INDEX NAME)




RN 611221-49-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 611221-51-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611221-53-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-55-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 611221-57-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 611221-59-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611221-61-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-63-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611221-65-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)



RN 611221-67-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)




RN 611221-69-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)


Serial#: 10/675,927

INDEX NAME)




RN 611221-71-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)




RN 611221-73-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611221-75-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-77-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 611221-78-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 611221-79-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611221-80-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611221-81-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-82-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 611221-83-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611221-84-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611221-85-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611221-86-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 611221-87-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611221-88-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611221-89-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-90-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611221-92-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611221-93-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl- (CA INDEX NAME)



RN 611221-94-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611221-95-5 HCAPLUS

Serial#: 10/675,927


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 611221-96-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 611221-97-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 611221-98-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611221-99-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-00-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-01-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-02-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-(3-pyridinylamino)-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-03-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-6-


Serial#: 10/675,927

methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-04-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-05-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1,3-benzodioxol-5-yl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-06-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-2-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-07-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-08-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-09-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-10-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-11-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[3-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-12-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-13-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methyl-4-piperidinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-14-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-15-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-(trifluoromethyl)-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-16-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-methyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611222-17-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-19-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-methyl-1-piperazinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-20-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-chloro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-21-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-22-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-chloro-4-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-23-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-(2-methyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-24-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-(3-(trifluoromethyl)-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-25-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-chloro-4-pyridinyl)-4-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-26-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)phenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-27-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(dimethylamino)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-28-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(5-pyrimidinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-29-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-30-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-fluoro-4-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-31-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611222-32-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-


Serial#: 10/675,927

quinolinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611222-33-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-34-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-35-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-38-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-fluoro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-39-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(2-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-40-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-41-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(6-fluoro-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-43-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(6-fluoro-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611222-44-7 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(6-methoxy-3-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-45-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(6-fluoro-3-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-47-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-fluoro-4-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-48-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-


Serial#: 10/675,927

(CA INDEX NAME)




RN 611222-50-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(6-methoxy-3-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611222-52-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-53-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(3-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611222-54-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-pyridinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-55-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(phenylmethyl)sulfonyl]amino]ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

Pr-i

RN 611222-56-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(methylsulfonyl)amino]ethyl]- (CA INDEX NAME)



RN 611222-57-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(trifluoromethyl)sulfonyl]amino]ethyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


Pr-i

RN 611222-58-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(phenylsulfonyl)amino]ethyl]- (CA INDEX NAME)



RN 611222-59-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(propylsulfonyl)amino]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Pr-i


Serial#: 10/675,927

RN 611222-60-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[[4-methylphenyl)sulfonyl]amino]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 611222-61-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-[(2-thienylsulfonyl)amino]ethyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B





RN 611222-62-9 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[2-[[4-methylphenyl)sulfonyl]amino]ethyl]-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




Pr-i

RN 611222-63-0 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[2-[[[5-chloro-2-thienyl]sulfonyl]amino]ethyl]-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-64-1 HCAPLUS
 CN 2-Pyridinecarboxamide, N-methyl-4-[[[1-methyl-2-[[3-[1-(phenylmethyl)-1H-1,2,3-triazol-4-yl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




Serial#: 10/675,927

RN 611222-65-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dihydro-1-(4-(4-morpholinyl)-1-oxobutyl)-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611222-66-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dihydro-1-[3-(1H-imidazol-5-yl)-1-oxopropyl]-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611222-67-4 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611222-68-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-(4-fluorophenyl)-1-methyl- (CA INDEX NAME)




RN 611222-69-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-70-9 HCAPLUS

CN 2-Pyridinecarboxamide, N,N-dimethyl-4-[[1-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-71-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-72-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-73-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-74-3 HCAPLUS

CN 2-Pyridinecarboxamide, N,N-dimethyl-4-[[1-methyl-2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611222-75-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-76-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-77-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-78-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-79-8 HCAPLUS


CN 2-Pyridinecarboxamide, N,N-dimethyl-4-[[1-methyl-2-[[2-(methylthio)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-80-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2,4-difluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611222-81-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-82-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-83-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-84-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)

Serial#: 10/675,927



RN 611222-85-6 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



IT	611222-86-7F	611222-87-8F	611222-88-9P
	611222-90-3P	611222-92-5F	611222-94-7P
	611222-96-9P	611222-98-1F	611223-00-8F
	611223-02-0P	611223-03-1F	611223-04-2P
	611223-05-3P	611223-06-4P	611223-07-5P
	611223-08-6P	611223-09-7P	611223-10-0P
	611223-11-1P	611223-12-2P	611223-13-3P
	611223-14-4P	611223-15-5P	611223-16-6P
	611223-17-7P	611223-18-8P	611223-19-9P
	611223-20-2P	611223-21-3P	611223-22-4P
	611223-23-5P	611223-24-6P	611223-25-7P
	611223-26-8P	611223-27-9P	611223-28-0P
	611223-29-1P	611223-30-4P	611223-31-5P
	611223-32-6P	611223-33-7P	611223-34-8P
	611223-35-9P	611223-36-0P	611223-37-1P
	611223-38-2P	611223-39-3P	611223-40-6P
	611223-41-7P	611223-42-8P	611223-43-9P
	611223-44-0P	611223-45-1P	611223-47-3P
	611223-49-5P	611223-51-9P	611223-53-1P
	611223-55-3P	611223-56-4P	611223-57-5P
	611223-58-6P	611223-59-7P	611223-60-0P
	611223-61-1P	611223-62-2P	611223-63-3P
	611223-64-4P	611223-65-5P	611223-66-6P
	611223-67-7P	611223-68-8P	611223-69-9P
	611223-70-2P	611223-71-3P	611223-72-4P
	611223-73-5P	611223-74-6P	611223-75-7P
	611223-76-8P	611223-77-9P	611223-78-0P
	611223-79-1P	611223-80-4P	611223-81-5P
	611223-82-6P	611223-83-7P	611223-84-8P
	611223-85-9P	611223-86-0P	611223-87-1P
	611223-88-2P	611223-89-3P	611223-90-6P
	611223-91-7P	611223-92-8P	611223-93-9P
	611223-94-0P	611223-95-1P	611223-96-2P
	611223-97-3P	611223-98-4P	611223-99-5P
	611224-00-1P	611224-01-2P	611224-02-3P


Serial#: 10/675,927

611224-03-4P	611224-04-5P	611224-05-6P
611224-06-7P	611224-07-8P	611224-08-9P
611224-09-0P	611224-10-3P	611224-11-4P
611224-12-5P	611224-13-6P	611224-14-7P
611224-15-8P	611224-16-9P	611224-17-0P
611224-18-1P	611224-19-2P	611224-20-5P
611224-21-6P	611224-22-7P	611224-23-8P
611224-24-9P	611224-25-0P	611224-26-1P
611224-27-2P	611224-28-3P	611224-29-4P
611224-30-7P	611224-32-9P	611224-34-1P
611224-35-2P	611224-36-3P	611224-37-4P
611224-38-5P	611224-39-6P	611224-40-9P
611224-41-0P	611224-43-2P	611224-44-3P
611224-45-4P	611224-46-5P	611224-47-6P
611224-48-7P	611224-49-8P	611224-50-1P
611224-51-2P	611224-52-3P	611224-53-4P
611224-54-5P	611224-55-6P	611224-56-7P
611224-57-8P	611224-59-9P	611224-59-0P
611224-60-3P	611224-61-4P	611224-62-5P
611224-63-6P	611224-64-7P	611224-65-8P
611224-66-9P	611224-67-0P	611224-68-1P
611224-69-2P	611224-70-5P	611224-71-6P
611224-72-7P	611224-75-0P	611224-82-9P
611224-83-0P	611224-84-1P	611224-85-2P
611224-86-3P	611224-87-4P	611224-88-5P
611224-89-6P	611224-90-9P	611224-91-0P
611224-92-1P	611224-93-2P	611224-94-3P
611224-95-4P	611224-96-5P	611224-97-6P
611224-98-7P	611225-02-6P	611225-04-8P
611225-06-0P	611225-07-1P	611225-08-2P
611225-09-3P	611225-10-6P	611225-11-7P
611225-12-8P	611225-13-9P	611225-14-0P
611225-15-1P	611225-16-2P	611225-17-3P
611225-18-4P	611225-19-5P	611225-20-8P
611225-21-9P	611225-22-0P	611225-23-1P
611225-31-1P	611225-32-2P	611225-33-3P
611225-34-4P	611225-35-5P	611225-36-6P
611225-37-7P	611225-38-8P	611225-39-9P
611225-40-2P	611225-41-3P	611225-47-9P
611225-48-0P	611225-49-1P	611225-50-4P
611225-51-5P	611225-56-0P	611225-57-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzazoles as Raf kinase inhibitors)


RN 611222-86-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



Serial#: 10/675,927


RN 611222-87-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-88-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 611222-90-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-92-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 611222-94-7 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611222-96-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 611222-98-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611223-00-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




Serial#: 10/675,927

RN 611223-02-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe


RN 611223-03-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 611223-04-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)



RN 611223-05-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-06-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-propyl- (CA INDEX NAME)




RN 611223-07-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 611223-08-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)



RN 611223-09-7 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-[(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-(3,5-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-10-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)




RN 611223-11-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-12-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 611223-13-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-14-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611223-15-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611223-16-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611223-17-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-18-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 611223-19-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611223-20-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-21-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-22-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-propyl- (CA INDEX NAME)




RN 611223-23-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611223-24-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 611223-25-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-26-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611223-27-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-28-0 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-29-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-30-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(1H-indol-3-yl)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-31-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 611223-32-6 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-33-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)


Serial#: 10/675,927




RN 611223-34-8 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 611223-35-9 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 611223-36-0 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-N-[2-(4-pyridinyl)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-37-1 HCAPLUS
CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-38-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)




RN 611223-39-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611223-40-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611223-41-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-propyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-42-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 611223-43-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611223-44-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-[(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-(2-methoxyphenyl)-1-methyl- (CA INDEX NAME)




RN 611223-45-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-(2-fluorophenyl)-1-methyl- (CA INDEX NAME)


Serial#: 10/675,927




RN 611223-47-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)



RN 611223-49-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611223-51-9 HCAPLUS
CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-53-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-55-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 611223-56-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 611223-57-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611223-58-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)


Serial#: 10/675,927



RN 611223-59-7 HCAPLUS


CN Methanone, [(2R,5R)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl][4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611223-60-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 611223-61-1 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 611223-62-2 HCAPLUS


Serial#: 10/675,927

CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611223-63-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)




RN 611223-64-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 611223-65-5 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 611223-66-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-67-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)



RN 611223-68-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611223-69-9 HCAPLUS

CN Methanone, [(2R,5S)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl][4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



Serial#: 10/675,927


RN 611223-70-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 611223-71-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(2-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 611223-72-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 611223-73-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611223-74-6 HCAPLUS

CN Methanone, [4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-

Serial#: 10/675,927


yl]oxy]-2-pyridinyl]][(2R,5R)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611223-75-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 611223-76-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)




RN 611223-77-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-propyl- (CA INDEX NAME)




Serial#: 10/675,927

RN 611223-78-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)




RN 611223-79-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)




RN 611223-80-4 HCAPLUS
CN Methanone, [4-[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]] [(2R,5S)-2-[(dimethylamino)methyl]-5-methyl-4-morpholinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611223-81-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-82-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-5-[[2-(3H-imidazo[4,5-b]pyridin-2-yl)-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611223-83-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-[[2-(1H-naphth[2,3-d]imidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611223-84-8 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-[[2-(6-methyl-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611223-85-9 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-[[2-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-86-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-[[2-(1-methyl-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611223-87-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-N-(4-fluorophenyl)-1-methyl- (CA INDEX NAME)



RN 611223-88-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-89-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


Serial#: 10/675,927



RN 611223-90-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[1-methyl-2-
[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX
NAME)

PAGE 1-A




PAGE 1-B




RN 611223-91-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-
1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (CA INDEX NAME)



RN 611223-92-8 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-[[1-methyl-2-
[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX
NAME)



Serial#: 10/675,927


RN 611223-93-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)




RN 611223-94-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 611223-95-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-96-2 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611223-97-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611223-98-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 611223-99-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(1-piperidiny)propyl]- (CA INDEX NAME)




RN 611224-00-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidiny)propyl]- (CA INDEX NAME)



RN 611224-01-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridiny)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-02-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 611224-03-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-(3-methoxypropyl)-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-04-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-05-6 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-3-pyrrolidinyl- (CA INDEX NAME)




RN 611224-06-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-


Serial#: 10/675,927

1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 611224-07-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-propyl- (CA INDEX NAME)




RN 611224-08-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-ethyl-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-09-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-10-3 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-11-4 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(6-methyl-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-12-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(1H-naphth[2,3-d]imidazol-2-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-13-6 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(1-methyl-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-14-7 HCAPLUS


CN Methanone, [2-[4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-1H-benzimidazol-6-yl]phenyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-15-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(6-bromo-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-16-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(6-chloro-5-fluoro-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-17-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(6-chloro-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-18-1 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(6-fluoro-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-19-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-20-5 HCAPLUS

CN 1H-Benzimidazole-6-carboxylic acid, 2-[4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-, methyl ester (CA INDEX NAME)



RN 611224-21-6 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(5,6-dichloro-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-22-7 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-23-8 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-(3-phenyl-1,2,4-oxadiazol-5-yl)-4-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 611224-24-9 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-(7-fluoro-6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-1-methyl-N-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 611224-25-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-N-[3-(1-methylethyl)phenyl]-5-[[2-[6-[3-(1-pyrrolidinyl)propoxy]-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



Serial#: 10/675,927


RN 611224-26-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-27-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluoro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611224-28-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611224-29-4 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-30-7 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611224-32-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611224-34-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxyethyl)-4-[[1-methyl-2-[[4-methyl-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-35-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-36-3 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 611224-37-4 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-[7-fluoro-6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-38-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5-[[2-(1H-benzimidazol-2-yl)-4-pyridinyl]oxy]-N-[4-chloro-3-(4-pyridinyl)phenyl]-1-methyl- (CA INDEX NAME)



RN 611224-39-6 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5-[[2-[6-(2-methoxyethoxy)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-1-methyl-N-[3-[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)




PAGE 1-A




RN 611224-40-9 HCAPLUS
 CN 1H-Benzimidazol-2-amine, 5-[[2-[6-(4-cyclopentyl-1-piperazinyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]-1-methyl-N-[3-(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)



RN 611224-41-0 HCAPLUS
 CN 1H-Benzimidazol-2-amine, 1-methyl-N-[3-(4-pyridinyl)phenyl]-5-[[2-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-43-2 HCAPLUS
 CN 2-Pyridinecarboxaldehyde, 4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-44-3 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)




RN 611224-45-4 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)




RN 611224-46-5 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)



RN 611224-47-6 HCAPLUS


CN 2-Pyridinecarboxaldehyde, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, O-methyloxime (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-48-7 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-49-8 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-50-1 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-51-2 HCAPLUS


CN 2-Pyridinemethanol, 4-[[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-52-3 HCAPLUS

CN 2-Pyridinemethanol, 4-[[1-methyl-2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-53-4 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-54-5 HCAPLUS

CN 2-Pyridinemethanol, 4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-55-6 HCAPLUS

CN 2-Pyridinemethanol, 4-[[2-[(3-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-56-7 HCAPLUS

CN 2-Pyridinemethanol, 4-[[1-methyl-2-[[3-


Serial#: 10/675,927

[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy)- (CA INDEX NAME)




RN 611224-57-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-phenyl- (CA INDEX NAME)




RN 611224-58-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methoxy-N-methyl- (CA INDEX NAME)



RN 611224-59-0 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3,4-dimethylphenyl)- (CA INDEX NAME)



RN 611224-60-3 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-61-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-chlorophenyl)- (CA INDEX NAME)




RN 611224-62-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-ethylphenyl)- (CA INDEX NAME)



RN 611224-63-6 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-methylphenyl)- (CA INDEX NAME)



RN 611224-64-7 HCAPLUS


CN 2-Pyridinecarboxamide, N-[3-(1-methylethyl)phenyl]-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-65-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-(1,1-dimethylethyl)phenyl]-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-66-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 611224-67-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[1,1'-biphenyl]-3-yl-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-68-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-(4-bromophenyl)-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-69-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 611224-70-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-(3-iodophenyl)-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611224-71-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611224-72-7 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2,6-bis(1-methylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611224-75-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-82-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-
[(methylamino)methyl]-4-pyridinyl]oxy]-, 2,2,2-trifluoroacetate (1:?) (CA
INDEX NAME)

CM 1

CRN 611224-81-8

CMF C21 H20 Br N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 611224-83-0 HCAPLUS


CN 2-Pyrrolidinone, 1-[3-[[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-
benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]amino]propyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-84-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[[2-methoxyethyl)amino)methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611224-85-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-(4-morpholinylmethyl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-86-3 HCAPLUS

CN Ethanol, 2-[[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]amino]- (CA INDEX NAME)



RN 611224-87-4 HCAPLUS


CN 1-Propanol, 3-[[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]amino]- (CA INDEX NAME)



RN 611224-88-5 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[3-(1-pyrrolidinyl)propyl]amino)methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611224-89-6 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[3-(4-morpholinyl)propyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-90-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[3-(1-piperidinyl)ethyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 611224-91-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[2-(1-pyrrolidinyl)ethyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611224-92-1 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[[[3-(1-piperidinyl)propyl]amino]methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611224-93-2 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[(dimethylamino)methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611224-94-3 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[(cyclohexylmethyl)amino]methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611224-95-4 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[(cyclopropylamino)methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)



RN 611224-96-5 HCAPLUS


CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[(propylamino)methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611224-97-6 HCAPLUS


Serial#: 10/675,927

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-[[2-[(3-pyrrolidinylamino)methyl]-4-pyridinyl]oxy]- (CA INDEX NAME)



RN 611224-98-7 HCAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-bromophenyl)-5-[[2-[(3-methoxypropyl)amino]methyl]-4-pyridinyl]oxy]-1-methyl- (CA INDEX NAME)




RN 611225-02-6 HCAPLUS

CN Carbamic acid, [[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 611225-01-5

CMF C22 H20 Br N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




Serial#: 10/675,927

RN 611225-04-8 HCAPLUS
CN Acetamide, N-[[4-[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 611225-03-7

CMF C22 H20 Br N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 611225-06-0 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 611225-05-9

CMF C29 H32 N6 O3




CM 2

Serial#: 10/675,927


CRN 76-05-1
CMF C2 H F3 O2




RN 611225-07-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (CA INDEX NAME)



RN 611225-08-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (CA INDEX NAME)




RN 611225-09-3 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[1-methyl-2-[[3-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (CA INDEX NAME)




RN 611225-10-6 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(2-methyl-4-pyridiny)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-11-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(trifluoromethyl)-4-pyridinyl]phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




RN 611225-12-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611225-13-9 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-14-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)


Serial#: 10/675,927



RN 611225-15-1 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 611225-16-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


RN 611225-17-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927



RN 611225-18-4 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




RN 611225-19-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 611225-20-8 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 611225-21-9 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(acetylamino)ethyl]-4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-22-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611225-23-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(1-methylethyl)-3-azetidiny]- (CA INDEX NAME)




RN 611225-31-1 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-32-2 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[6-methoxy-1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-33-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]- (CA INDEX NAME)




Serial#: 10/675,927


RN 611225-34-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)-3-(2-fluoro-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611225-35-5 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)-3-(2-fluoro-4-pyridinyl)phenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-36-6 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)-3-(2-fluoro-4-pyridinyl)phenyl]amino]-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-37-7 HCAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2-fluoro-4-pyridinyl)-4-methylphenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-38-8 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2,6-dimethyl-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 611225-39-9 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2,6-dimethyl-4-pyridinyl)phenyl]amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611225-40-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3-(2,6-dimethyl-4-pyridinyl)phenyl]amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611225-41-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-methyl-3-(2-thienyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)

Serial#: 10/675,927




RN 611225-47-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[N-(4-bromophenyl)-1-methyl-] (CA INDEX NAME)



RN 611225-48-0 HCAPLUS


CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[N-(3-(1,1-dimethylethyl)phenyl)-1-methyl-] (CA INDEX NAME)



RN 611225-49-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[1-methyl-N-[3-(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃

Serial#: 10/675,927


RN 611225-50-4 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[1-methyl-N-[3-(1-methylethyl)phenyl]-
(CA INDEX NAME)



RN 611225-51-5 HCAPLUS

CN 1H-Benzimidazol-2-amine, 5,5'-oxybis[1-methyl-N-phenyl]- (CA INDEX NAME)




RN 611225-56-0 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[2-[[3-(1-chloroethyl)phenyl]amino]-1-methyl-
1H-benzimidazol-5-yl]oxy]-N-methyl-, 2,2,2-trifluoroacetate (1:1) (CA
INDEX NAME)

CM 1

CRN 611225-55-9

CMF C23 H20 Cl N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




Serial#: 10/675,927

RN 611225-57-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 611216-10-5
 CMF C25 H21 N5 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



IT 611226-42-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted benzazoles as Raf kinase inhibitors)
 RN 611226-42-7 HCAPLUS
 CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



IT	611225-65-1P	611225-66-2P	611225-71-9P
	611225-75-3P	611225-76-4P	611225-77-5P
	611225-78-6P	611225-79-7P	611225-80-0P
	611225-81-1P	611225-82-2P	611225-85-7P
	611225-96-8P	611226-06-8P	611226-08-5P

Serial#: 10/675,927


611226-13-2P 611226-14-3P 611226-31-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of substituted benzazoles as Raf kinase inhibitors)


RN 611225-65-1 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-
benzimidazol-5-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 611225-66-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-
benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-71-9 HCAPLUS

CN 2-Pyridinecarbonitrile, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-
benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-75-3 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-
1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611225-76-4 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-77-5 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-78-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-79-7 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[1-methyl-2-[(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611225-80-0 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-81-1 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611225-82-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611225-95-7 HCAPLUS


CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-chlorophenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



Serial#: 10/675,927


RN 611225-96-8 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-bromo-3-methylphenyl)amino]-6-methoxy-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)




RN 611226-06-3 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 611226-08-5 HCAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromo-4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 611226-13-2 HCAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



Serial#: 10/675,927


RN 611226-14-3 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



RN 611226-31-4 HCAPLUS

CN 2-Pyridinecarboxaldehyde, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Serial#: 10/675,927
INVENTOR SEARCH

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 13:23:59 ON 13 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2010 VOL 152 ISS 16
FILE LAST UPDATED: 12 Apr 2010 (20100412/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE


=> D STAT QUE L31

L4 STR

O 12 S 13



Page 1-A



Serial#: 10/675,927

Page 1-B

VAR G1=12/13

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS C	AT	10
NSPEC	IS C	AT	11

DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 10 12 13
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE


L7 5908 SEA FILE=REGISTRY SSS FUL L4

L11 STR

o15 s16



Page 1-A



Page 1-B

VAR G1=15/16

NODE ATTRIBUTES:

HCOUNT	IS M1	AT	10
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4

Serial#: 10/675,927

NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS C AT 10
NSPEC IS C AT 11
NSPEC IS C AT 12
NSPEC IS C AT 13
NSPEC IS RC AT 14
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 10 14 15 16
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L13 1382 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L14 33 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L13
L15 32 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON AMIRI P?/AU
L16 40 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON FANTL W?/AU
L17 1048 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON LEVINE B?/AU
L18 88 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON POON D?/AU
L19 26 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON RAMURTHY S?/AU
L20 42 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON RENHOWE P?/AU
L21 1408 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SUBRAMANIAN S?/AU
L22 286 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SUNG L?/AU
L23 5 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L15 AND ((L16 OR L17
OR L18 OR L19 OR L20 OR L21 OR L22))
L24 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L16 AND ((L17 OR L18
OR L19 OR L20 OR L21 OR L22))
L25 7 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L17 AND ((L18 OR L19
OR L20 OR L21 OR L22))
L26 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L18 AND ((L19 OR L20
OR L21 OR L22))
L27 15 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L19 AND ((L20 OR L21
OR L22))
L28 9 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L20 AND ((L21 OR
L22))
L29 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L21 AND L22
L30 23 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L23 OR L24 OR L25 OR
L26 OR L27 OR L28 OR L29)
L31 20 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L30 NOT L14

=> D L31 IBIB ABS HITIND HITSTR 1-20

L31 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1589837 HCAPLUS Full-text
DOCUMENT NUMBER: 152:97484
TITLE: 2-Arylaminoquinazolines as PDK1 inhibitors and their
preparation and use in the treatment of proliferative
diseases
INVENTOR(S): Jain, Rama; Lin, Xiaodong; Ng, Simon C.; Pfister,
Keith B.; Ramurthy, Savithra; Rico, Alice;
Subramanian, Sharadha; Wang, Xiaojing Michael
PATENT ASSIGNEE(S): Novartis AG, Switz.
SOURCE: PCT Int. Appl., 619pp.
CODEN: PIXXD2

Serial#: 10/675,927


DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009153313	A1	20091223	WO 2009-EP57606	20090618
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: MARPAT 152:97484 US 2008-74556P P 20080620

OTHER SOURCE(S):

GI



AB The invention provides quinazoline compds. of formula I that are inhibitors of PDK1. Also provided are pharmaceutical compns. including the compds., and methods of treating proliferative diseases, such as cancers, with the compds. or composition Compds. of formula I wherein R1a is H and halo; R3a is (un)substituted C2-6 heterocycloalkoxy and (un)substituted C1-6 heteroaryl-C1-4 alkoxy; R4a is H, thiazole, pyrazole, triazole, tetrazole, pyridine, CN, halo, etc.; R1a is (un)substituted phenyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their PDK1 inhibitory activity (some data given).

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1166203 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 151:403302

TITLE: Preparation of substituted imidazoles and oxazoles as Raf kinase inhibitors

INVENTOR(S): Huang, Zilin; Jin, Jeff; Machajewski, Timothy D.; Antonios-McCrea, William R.; McKenna, Maureen;

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

Poon, Daniel; Renhowe, Paul A.;
Sendzik, Martin; Shafer, Cynthia M.; Smith, Aaron; Xu,
Yongjin; Zhang, Qiong
Novartis AG, Switz.
PCT Int. Appl., 209 pp.
CODEN: PIXXD2

Patent
English

1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009115572	A2	20090924	WO 2009-EP53245	20090319
WO 2009115572	A3	20091203		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20100003246 A1 20100107 2009-383035 20090319



PRIORITY APPLN. INFO.: US 2008-38723P P 20080321

US 2009-208458P P 20090224

OTHER SOURCE(S):

MARPAT 151:403302

GI



AB The title compds. I [X = N and Y = NR₄, O or S; or X = NR₄, O, S and Y = N; R₁, R₂ = (un)substituted heteroaryl, heterocyclyl; R₃ = (un)substituted alkyl, aryl, heteroaryl, etc.; R₄ = H, alkyl; including tautomers of the central imidazole ring when X or Y = NH], useful for inhibition of Raf kinase, were prepared E.g., a multi-step synthesis of II.TFA, starting from 2-bromo-1-(pyridin-4-yl)ethanone.HBr with benzamidine, was given. II showed IC₅₀ of 0.001 μM against mutant b-Raf (V600E) kinase. The new compds. and compns. comprising I may be used either alone or in combination with at least one addnl. agent for the treatment of a Raf kinase mediated disorder, such as cancer.

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

Serial#: 10/675,927

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

2008:1338861 HCAPLUS Full-text

149:534241

Preparation of radiolabeled aminoquinazolinones for use as radiotracers and imaging agents

Antonios-McCrea, William R.; Auberson, Yves; Bergstroem, Mats; Briard, Emmanuelle; Brinner, Kristin; Levine, Barry Haskeil; Machajewski, Timothy D.; Poon, Daniel

Novartis A.-G., Switz.

PCT Int. Appl., 27pp.

CODEN: PIXXD2

Patent

English

1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2008132211	A1	20081106	WO 2008-EP55244	20080429
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:


OTHER SOURCE(S):

GI

MARPAT 149:534241

US 2007-915144P

P 20070501



AB Title compds. [I; Y = H, alkyl; W = CH₂, NH, NA; A = alkyl; X = H, halo; Ra = (substituted) heterocyclyl bearing a radiolabeled C or F atom], were prepared Thus, [11C]-MeI was added to a mixture of (R)-2-amino-7-[4-fluoro-2-(6-hydroxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one and NaH in DMF followed by heating at 130° for 30 min. to give (R)-2-amino-7-[4-fluoro-2-[6-[11C]-methoxypyridin-2-yl]phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one (unisolated). Tested I inhibited HSP90 with IC₅₀ values in the range of 50-1000 nM in a FIDA assay.

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 63

REFERENCE COUNT:


2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

L31 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:806624 HCAPLUS Full-text
 DOCUMENT NUMBER: 149:128864
 TITLE: Preparation of quinazolines for PDK1 inhibition
 INVENTOR(S): Ramarthy, Savithri; Lin, Xiaodong;
 Subramanian, Sharada; Rico, Alice C.; Wang,
 Xiaojing M.; Jain, Rama; Murray, Jeremy M.; Basham,
 Steven E.; Warne, Robert L.; Shu, Wei; Zhou, Yasheen;
 Dove, Jeffrey; Aikawa, Mina; Amara, Fayman
 PATENT ASSIGNEE(S): Novartis Vaccines & Diagnostics, Inc., USA
 SOURCE: PCT Int. Appl., 355pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008079988	A2	20080703	WO 2007-US88392	20071220
WO 2008079988	A3	20081016		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007336893	A1	20080703	AU 2007-336893	20071220
CA 2673003	A1	20080703	CA 2007-2673003	20071220
KR 2009092287	A	20090831	KR 2009-712780	20071220
EP 2125755	A2	20091202	EP 2007-869660	20071220
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
IN 2009DN03735	A	20100326	IN 2009-DN3735	20090608
MX 2009006627	A	20090812	MX 2009-6627	20090618
CN 101652352	A	20100217	CN 2007-80047581	20090622
NO 2009002725	A	20090922	NO 2009-2725	20090717
PRIORITY APPLN. INFO.:			US 2006-876972P	P 20061222
			US 2007-999170P	P 20071015
			WO 2007-US88392	W 20071220

OTHER SOURCE(S): MARPAT 149:128864
 GI



AB The title compds. I [Ar = (un)substituted (hetero)aryl; R¹ = H, alkyl, halo, etc.; R² = H, alkoxy, alkyl, etc.; R³ = H, halo, CN, etc.; L = a bond, C(O), CONH, O, etc.; A¹ = alkyl, alkoxy, acyl, etc.; with the provisos] that are inhibitors of PDK1, were prepared E.g., a multi-step synthesis of II, starting from 2-amino-3-methoxybenzoic acid, was given. Exemplified compds. I were tested in PDK1 kinase alpha screen assay. One-hundred-forty exemplified compds. I showed IC₅₀'s of less than 25 μM, and of those, 131 showed IC₅₀'s of less than 5 μM. Also provided are pharmaceutical compns. including the compds. I, and methods of treating proliferative diseases, such as cancers, with the compds. or compns.

IC ICM A61K

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L31 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:445316 HCAPLUS Full-text

DOCUMENT NUMBER: 148:449654

TITLE: Preparation of pyrimidinylpyrazolamines as protein kinase inhibitors

INVENTOR(S): Albaugh, Pamela; Chopiuk, Gregory S.; Ding, Qiang; Huang, Shenlin; Liu, Zuosheng; Pan, Shifeng; Ren, Pingda; Wang, Xia; Wang, Xing; Xie, Yongping; Zhang, Chengzhi; Zhang, Qiong; Zhang, Guobao; Poon, Daniel; Kenhowe, Paul; Sendzik, Martin

PATENT ASSIGNEE(S): IRM LLC, Bermuda; Novartis AG

SOURCE: PCT Int. Appl., 251 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008042639	A1	20080410	WO 2007-US79340	20070924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,			


Serial#: 10/675,927

BY, KG, KZ, MD, RU, TJ, TM			
AU 2007305016	Al	20080410	AU 2007-305016 20070924
CA 2663366	Al	20080410	CA 2007-2663366 20070924
EP 2057146	Al	20090513	EP 2007-814982 20070924
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2010505862	T	20100225	JP 2009-531524 20070924
IN 2009DN01777	A	20090522	IN 2009-DN1777 20090317
MX 2009003456	A	20090414	MX 2009-3456 20090331
KR 2009060322	A	20090611	KR 2009-706724 20090401
CN 101522661	A	20090902	CN 2007-80036857 20090402
NO 2009001759	A	20090701	NO 2009-1759 20090504
US 20100029605	Al	20100204	US 2009-444129 20090603
PRIORITY APPLN. INFO.:		US 2006-827873P	P 20061002
		WO 2007-US79340	W 20070924

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:449654; MARPAT 148:449654

GI



AB Title compds. I [A = (un)substituted 5-membered, unsatd. or unsatd., ring containing 1-3 heteroatoms selected from N, (un)substituted NH, O or S; B = (un)substituted 5-6 membered, unsatd. or unsatd., ring containing 0-3 heteroatoms selected from N, (un)substituted NH, O or S; Z = CH or N; R1 = XNR5R6, XOR5, XR5, etc. (X = a bond, alkylene; R5 = H, alkyl, arylalkyl, etc.); R2 = R11, CONR10R11, SO2NR10R11, etc. (R10 = H, alkyl; R11 = aryl, heteroaryl, cycloalkyl, heterocycloalkyl; or R10 and R11, together with the atom they are attached to, can form 5-6 membered ring); R20 = H, alkyl, N(R21)2 (R21 = H or alkyl; or two R21, together with the atom they are attached to, can form 5-6 membered ring)], useful for treating or preventing diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases, were prepared E.g., a multi-step synthesis of II, starting from 4,6-dichloropyrimidine, was given. Compds. I were tested against various kinases. For example, I showed IC50 values in the range of 10 nM to 2 μ M when tested against FGFR3. Pharmaceutical compns. comprising compds. I were also disclosed.

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

Serial#: 10/675,927

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1176211 HCAPLUS Full-text

DOCUMENT NUMBER: 147:469365

TITLE: Preparation of quinazolines for PDK1 inhibition

INVENTOR(S): Ramurthy, Savithra; Lin, Xiadong; Subramanian, Sbarada; Rico, Alice C.; Wang, Xiaojong M.; Jain, Rama; Murray, Jeremy M.; Bashman, Steven E.; Warne, Robert L.; Shu, Wei; Zhou, Yasheen; Dove, Jeffrey; Aikawa, Mina; Amiri, Payman; Wang, Weibo; Jensen, Johanna M.; Wagman, Allan S.; Pfister, Keith B.; Ng, Simon C.

PATENT ASSIGNEE(S): Novartis Vaccines & Diagnostics, Inc., USA

SOURCE: PCT Int. Appl., 390 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007/117607	A2	2007/1018	WO 2007-US8592	20070405
WO 2007/117607	A3	2007/1221		
WO 2007/117607	A9	20080306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007235339	A1	2007/1018	AU 2007-235339	20070405
CA 2648529	A1	2007/1018	CA 2007-2648529	20070405
EP 2004615	A2	20081224	EP 2007-755008	20070405
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009532486	T	20090910	JP 2009-504315	20070405
MX 2008012852	A	20081128	MX 2008-12852	20081006
IN 2008KN04156	A	20090313	IN 2008-KN4156	20081014
KR 2008111114	A	20081222	KR 2008-726508	20081029
CN 101454294	A	20090610	CN 2007-80019502	20081127
US 20100048561	A1	20100225	US 2009-295967	20091102
PRIORITY APPLN. INFO.:			US 2006-790304P	P 20060406
			WO 2007-US8592	W 20070405
OTHER SOURCE(S): MARPAT 147:469365				
GI				



AB The title compds. I [one of W1 or W2 = R1 and the other = LAl; L = a bond, C(O), CONH, O, etc.; A1 = (un)substituted aryl, heteroaryl, heterocyclyl; Y = H, alkyl, halo, CN, NO2 or NH2; R1 = H, alkyl, alkoxy, acyl, etc.; R2, R3 = H, alkyl, alkoxy, acyl, etc.; R4 = (un)substituted aryl, heteroaryl, cycloalkyl, heterocyclyl; with the proviso that are inhibitors of PDK1, were prepared E.g., a multi-step synthesis of 4-[6-ethynyl-8-(1-isopropylpiperidin-4-yloxy)quinazolin-2-ylamino]benzenesulfonamide, starting from 6-bromo-2-chloro-8-methoxyquinazoline, was given. Exemplified compds. I were tested in various assays. For example, I showed an IC50 value of less than or equal to 25 μ M, with respect to inhibition of PDK1. Also provided are pharmaceutical compns. including the compds. I, and methods of treating proliferative diseases, such as cancers, with the compds. or compns.

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L31 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:816899 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:189196

TITLE: Pyrimidine derivatives used as PI-3 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer

INVENTOR(S): Pick, Teresa; Barsanti, Paul; Iwanowicz, Edwin; Fantl, Wendy; Hendryckson, Tom; Knapp, Mark; Meritt, Hanne; Voliva, Charles; Wiesmann, Marion; Xin, Xiaohua; Burger, Matthew; Ni, Zhi-Jie; Pecchi, Sabina; Atallah, Gordana; Bartullis, Sarah; Frazier, Kelly; Smith, Aaron; Verhagen, Joelle; Zhang, Yanchen; Wagman, Allan; Ng, Simon; Pfister, Keith; Poon, Daniel; Louie, Alicia

PATENT ASSIGNEE(S): Novartis A.-G., Switz.

SOURCE: PCT Int. Appl., 258pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007084786	A1	20070726	WO 2007-US1708	20070122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

Serial#: 10/675,927

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM				
AU 2007206048	A1	20070726	AU 2007-206048	20070122
CA 2636993	A1	20070726	CA 2007-2636993	20070122
EP 1984350	A1	20081029	EP 2007-716906	20070122
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,				
BA, HR, MK, RS				
JP 2009527464	T	20090730	JP 2008-551469	20070122
IN 2008DN06263	A	20081024	IN 2008-DN6263	20080717
MX 2008009269	A	20080730	MX 2008-9269	20080718
NO 2008003389	A	20080919	NO 2008-3389	20080801
KR 2008096776	A	20081103	KR 2008-720198	20080819
CN 101389622	A	20090318	CN 2007-80006374	20080822
			US 2006-760789P	P 20060120
			WO 2007-US1708	W 20070122

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 147:189196
GI



AB Phosphatidylinositol (PI) 3-kinase inhibitor compds. I, their pharmaceutically acceptable salts, and prodrugs thereof; compns. of the compds., either alone or in combination with at least one addnl. therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compds., either alone or in combination with at least one addnl. therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. Compds. of formula I wherein is CRA and N; Ra is H, CN, halo, Me, CF3, and sulfonamido; R1 and R3 are independently H, CN, NO2, halo, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted (hetero)aryl, etc.; R2 is H, CN, NO2, halo, OH, amino, (un)substituted alkyl, etc.; R4 is H, halo; and their stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their PI-3 kinase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 and EC50 values of > 1 μM.

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Serial#: 10/675,927

L31 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:175383 HCAPLUS Full-text
DOCUMENT NUMBER: 146:251846
TITLE: Substituted imidazole compounds as KSP inhibitors and
their preparation, pharmaceutical compositions and use
in the treatment of cancers

INVENTOR(S):

Barsanti, Paul A.; Xia, Yi; Wang, Weibo; Mendenhall,
Kris G.; Lagniton, Liana M.; Pamurthy,
Savithri; Phillips, Megan C.; Subramanian,
Sharadha; Boyce, Rustum; Brammeier, Nathan M.;
Constantine, Ryan; Duhl, David; Walter, Annette O.;
Abrams, Tinya J.; Penhove, Paul A.

PATENT ASSIGNEE(S): Novartis Vaccines and Diagnostics Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 101pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070037853	A1	20070215	US 2006-502303	20060809
US 7626040	B2	20091201		
AU 2006279991	A1	20070222	AU 2006-279991	20060809
CA 2618747	A1	20070222	CA 2006-2618747	20060809
WO 2007021794	A1	20070222	WO 2006-US31129	20060809
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1912972	A1	20080423	EP 2006-789653	20060809
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009504664	T	20090205	JP 2008-526175	20060809
IN 2008KN00119	A	20081205	IN 2008-KN119	20080108
MX 2008001411	A	20080623	MX 2008-1411	20080129
CN 101253167	A	20080827	CN 2006-80029347	20080213
KR 2008036611	A	20080428	KR 2008-703946	20080219

PRIORITY APPLN. INFO.:

US 2005-706901P P 20050809
WO 2006-US31129 W 20060809

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:251846; MARPAT 146:251846
GI



AB The invention relates to substituted imidazole compds. of formula I and pharmaceutically acceptable salts, esters or prodrugs thereof, compns. of the derivs. together with pharmaceutically acceptable carriers, and uses of the compds. Compds. of formula I wherein R1 is aminoacyl, acylamino, carboxyl, carboxyl esters, and (un)substituted alkyl with the proviso that substituted alkyl is not substituted with aryl; R2 is H, alkyl and aryl; R3 and R5 are independently H, OH, (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted (hetero)aryl, etc.; R5 is H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; one of R6 and R7 is (un)substituted cycloalkyl, (un)substituted heterocyclyl, and (un)substituted (hetero)aryl and the other one of R6 and R7 is H, halo, and alkyl; R8 is L-A; L is SO, SO2 and (un)substituted C1-5 alkylene; A is (un)substituted (hetero)aryl, (un)substituted heterocyclic, and (un)substituted cycloalkyl; and their pharmaceutically acceptable salts, esters and prodrugs thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their KSP inhibitory activity.

INCL 514326000; 514341000; 514378000; 514397000; 514400000; 546210000;
546272700; 548335500; 548300700; 548247000

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:453877 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:124498

TITLE: 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as
potent CHK-1 inhibitors

AUTHOR(S): Ni, Zhi-Jie; Barsanti, Paul; Brammeier, Nathan;
Diebes, Anthony; Eoon, Daniel J.; Ng, Simon;
Pecchi, Sabina; Pfister, Keith; Kennowe, Paul
A.; Ramurthy, Savithri; Wagman, Allan
S.; Bussiere, Dirksen E.; Le, Vincent; Zhou, Yasheen;
Jansen, Johanna M.; Ma, Sylvia; Gesner, Thomas G.
Chiron Corporation, Emeryville, CA, 94608, USA
Bioorganic & Medicinal Chemistry Letters (2006),
16(12), 3121-3124
CODEN: BMCLE8; ISSN: 0960-894X

CORPORATE SOURCE:
SOURCE:

PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:124498

Serial#: 10/675,927

AB CHK-1 is one of the key enzymes regulating checkpoints in cellular growth cycles. Novel 4-(aminoalkylamino)-3-benzimidazolyl-2-quinolinones were prepared and assayed for their ability to inhibit CHK-1. These compds. are potent cell permeable CHK-1 inhibitors and showed a synergistic effect with a DNA-damaging agent, camptothecin.

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:13616 HCAPLUS Full-text

DOCUMENT NUMBER: 144:108320

TITLE: Preparation of N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer

INVENTOR(S): Wang, Weibo; Barsanti, Paul A.; Xi, Yi; Boyce, Rustum S.; Pecchi, Sabina; Brammeier, Nathan; Phillips, Megan; Mendenhall, Kris; Wayman, Kelly; Lagniton, Liana Marie; Constantine, Ryan; Yang, Hong; Mieuli, Elizabeth; Ramurthy, Savithri; Jazan, Elisa; Sharma, Anu; Rama, Jain; Sabramanian, Shradha; Penbowe, Paul; Bair, Kenneth Walter; Duhl, David; Walter, Annette; Abrams, Tinya; Huh, Kay; Martin, Eric; Knapp, Mark; Le, Vincent

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 294 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002236	A1	20060105	WO 2005-US22062	20050620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SM, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005258135	A1	20060105	AU 2005-258135	20050620
CA 2571002	A1	20060105	CA 2005-2571002	20050620
US 20060009472	A1	20060112	US 2005-158574	20050620
US 7576221	B2	20090818		
EP 1765789	A1	20070328	EP 2005-760871	20050620
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1993331	A	20070704	CN 2005-80026203	20050620
BR 2005010929	A	20070717	BR 2005-10929	20050620
JP 20080503501	T	20080207	JP 2007-516842	20050620

Serial#: 10/675,927

SG 153851	Al	20090729	SG 2009-4294	20050620
MX 2006014909	A	20070228	MX 2006-14909	20061218
IN 2007KN00144	A	20070629	IN 2007-KN144	20070111
KR 2007106961	A	20071106	KR 2007-700979	20070115
ZA 2007000481	A	20081029	ZA 2007-481	20070116
NO 2007000343	A	20070305	NO 2007-343	20070118
US 20090258016	Al	20091015	US 2009-455798	20090605
PRIORITY APPLN. INFO.:			US 2004-580927P	P 20040618
			US 2005-158574	A3 20050620
			WO 2005-US22062	W 20050620

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:108320; MARPAT 144:108320

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = aminoacetyl, acylamino, carboxyl, etc.; R2 = H, alkyl, aryl; R3 = H, CO-A, CS-A, SO-A, SO2-A, SO2NR, where R = H or alkyl; A = H, (un)substituted alkyl, alkoxy, aryl, etc.; or R1 and R3 together form a heterocycle or substituted heterocycle; R4 = H, alkyleneaminoacyl, alkyleneoxyacyl, alkylenehydroxy, etc.; R5 = S(O)q-Al or (un)substituted alkylene-Al, where Al = (un)substituted aryl, heteroaryl, heterocyclic, etc., and q = 1-2; one of R6 or R7 = (un)substituted heterocyclic, aryl or heteroaryl; the other of R6 or R7 = H, halo or alkyl; or R6 and R7 both = H], and their pharmaceutically acceptable salts, are prepared and disclosed as compds. which modulate the activity of kinesin spindle protein (KSP) and are useful for the treatment of cancer. Thus, e.g., II was prepared by conversion of N-Boc-3-formylpyrrolidine to the TMS-enol ether followed by oxidation to the N-Boc-3-formyl-3-hydroxypyrrolidine which underwent reductive amination with III followed by spirocyclization with chloroacetyl chloride and deprotection. Assays for determining activity are described (no data). Therapeutic use of I with addnl. agents useful for the treatment of cancer is claimed.

IC ICM C07D233-54
ICS C07D401-12; C07D405-12; C07D413-12; C07D417-12; A61K031-4174;
A61K031-4178; A61P035-00

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 34, 63

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(12 CITINGS)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L31 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:369277 HCAPLUS Full-text
DOCUMENT NUMBER: 142:430271
TITLE: Preparation of substituted benzazoles as inhibitors of
raf kinase
INVENTOR(S): Ramurthy, Savitri; Subramanian,
Sharadha; Verhagen, Joelle; Foon, Daniel
J.; Hansen, Teresa; Shafer, Cynthia; McBride,
Christopher; Levine, Barry H.; Costales,
Abran; Renhowe, Paul A.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037273	A1	20050428	WO 2004-US34179	20041015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004281151	A1	20050428	AU 2004-281151	20041015
CA 2542653	A1	20050428	CA 2004-2542653	20041015
US 20050192287	A1	20050901	US 2004-967089	20041015
US 7423150	B2	20080909		
EP 1682126	A1	20060726	EP 2004-795357	20041015
EP 1682126	B1	20090701		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1889951	A	20070103	CN 2004-80036199	20041015
JP 2007509058	T	20070412	JP 2006-535367	20041015
AT 435015	T	20090715	AT 2004-795357	20041015
PT 1682126	E	20091002	PT 2004-795357	20041015
ES 2327418	T3	20091029	ES 2004-795357	20041015
MX 2006004236	A	20060628	MX 2006-4236	20060417
KR 2006118472	A	20061123	KR 2006-709081	20060510
IN 2006KN01221	A	20070427	IN 2006-KN1221	20060510
US 20090035309	A1	20090205	US 2008-205028	20080905
PRIORITY APPLN. INFO.:			US 2003-511966P	P 20031016
			US 2004-967089	A3 20041015
			WO 2004-US34179	W 20041015


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:430271; MARPAT 142:430271

GI



I



II

Serial#: 10/675,927

AB Title compds. I [X1, X3 = amino, O, S and at least one of X1 and X3 be N; X2 = NH, alkyl; A1 = alkyl, cycloalkyl, heterocycloalkyl, aryl, etc.; R1 = H, alkyl, alkoxyalkyl, etc.; R2 = H, alkyl; R3-3' = H, halo, OH, etc.; p, q = 0-3] are prepared For instance, N-[4-[[2-[[4-chloro-3-(3-fluoropyridin-4-yl)phenyl]amino]-1-methyl-1H- benzimidazol-5-yl]oxy]pyridin-2-yl]acetamide (II) is prepared in 8 steps from 4-[[4-(methylamino)-3-nitrophenyl]oxy]pyridine-2-carboxylic acid and 3-tert-butylisothiocyanate. Compds. of the invention have a raf kinase inhibitory activity at an IC50 < 10 µM and are useful in the treatment of alone or in combination with at least one adnl. agent for the treatment of a raf kinase mediated disorder, such as cancer.

IC ICM A61K031-4184

ICS A61K031-428; C07D401-12; C07D405-14; C07D401-14; C07D417-12;
C07D409-14; C07D413-14; A61P035-00

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:349005 HCAPLUS Full-text

DOCUMENT NUMBER: 142:411374

TITLE: Preparation of 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and their use as inhibitors of Raf kinase

INVENTOR(S): Ramarthy, Savithri; Renhowe, Paul A.
; Subramanian, Shradha

PATENT ASSIGNEE(S): Chiron Corporation, USA; Novartis Vaccines and Diagnostics, Inc.

SOURCE: U.S. Pat. Appl. Publ., 42 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050085482	A1	20050421	US 2004-966358	20041015
US 7691866	B2	20100406		
AU 2004281154	A1	20050428	AU 2004-281154	20041015
CA 2542329	A1	20050428	CA 2004-2542329	20041015
WO 2005037285	A1	20050428	WO 2004-US34185	20041015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1680122	A1	20060719	EP 2004-795363	20041015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1882345	A	20061220	CN 2004-80030549	20041015
JP 2007509059	T	20070412	JP 2006-535368	20041015


Serial#: 10/675,927

MX 2006003607	A	20060605	MX 2006-3607	20060330
KR 2007029110	A	20070313	KR 2006-707130	20060413
IN 2006KN01069	A	20070420	IN 2006-KN1069	20060425
US 20090317359	A1	20091224	US 2009-554748	20090904
PRIORITY APPLN. INFO.:			US 2003-511851P	P 20031016
			US 2004-966358	A3 20041015
			WO 2004-US34185	W 20041015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:411374; MARPAT 142:411374

GI



AB The title compds. I [X1, X2 = N, CH, provided that at least one of X1 and X2 = N; Y = O, S, CH2, etc.; Z = II, NR6R7, NR5C(:O)R8, NR5C(:S)R8, NR5AA (wherein AA = (un)substituted amino acid); A1 = (un)substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, etc.; A2 = (un)substituted (hetero)aryl; R1 = O or H, and R2 = NR6R7; or R1 is taken together with R2 to form (un)substituted heterocycloalkyl or heteroaryl group; R3 = R31 = H, halo, alkyl, or alkoxy; R4 = H, OH, (un)substituted alkyl; R5 = H, (un)substituted alkyl, alkoxyalkyl, etc.; R6, R7 = H, (un)substituted alkyl, alkoxy, alkoxyalkyl, etc.; or R6 and R7 are taken together to form (un)substituted heterocycloalkyl or heteroaryl; and R8 = (un)substituted alkyl, alkenyl, alkynyl, alkoxy, etc.; X3 is not defined], useful for inhibition of Raf kinase activity in a human or animal, were prepared E.g., a multi-step synthesis of III, starting from 5-hydroxy-2-nitrobenzaldehyde, was given. The exemplified compds. I were shown to have a raf kinase inhibitory activity at an IC50 of less than 5 μ M. The new compds. I may be used either alone or in combination with at least one addnl. agent for the treatment of a Raf kinase mediated disorder, such as cancer. The pharmaceutical compns. comprising the compound I are disclosed.

ICM A61K031-517

ICS A61K031-502; A61K031-498

INCL 514248000; X51-424.9; X51-426.62; X51-426.64; X54-423.5; X54-435.3; X54-428.4; X54-429.3

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L31 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:182868 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:235595

TITLE: Preparation of pyrrole based selective inhibitors of glycogen synthase kinase 3 for treating diabetes and

Serial#: 10/675,927

INVENTOR(S): Desai, Manoj; Ni, Zhi-Jie; Ng, Simon; Pfister, Keith B.; Ramurthy, Savithri; Subramanian, Sharadha; Wagman, Allan S.

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018455	A1	20040304	WO 2003-US26625	20030821
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2496246	A1	20040304	CA 2003-2496246	20030821
AU 2003268184	A1	20040311	AU 2003-268184	20030821
US 20040077707	A1	20040422	US 2003-646625	20030821
US 7250443	B2	20070731		
EP 1537099	A1	20050608	EP 2003-749133	20030821
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1688573	A	20051026	CN 2003-824335	20030821
JP 2006501243	T	20060112	JP 2004-531200	20030821
IN 2005KN00471	A	20060203	IN 2005-KN471	20050321
IN 215544	A1	20080229		
US 20070244109	A1	20071018	US 2007-761937	20070612
US 7671049	B2	20100302		
PRIORITY APPLN. INFO.:			US 2002-405846P	P 20020823
			US 2003-646625	A3 20030821
			WO 2003-US26625	W 20030821
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE			IN LSUS DISPLAY FORMAT	
OTHER SOURCE(S):		MARPAT 140:235595		
GI				



AB New pyrrole based compds. (shown as I; variables defined below; e.g. II), compns. and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compds. and compns. of the invention may be employed alone, or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer. For I: X is N, O, or (un)substituted C; W is absent or -O-, -S-, -S(O)-, -SO₂-, -NH-, -NH-CO-, -NR'CO-, -NHSO₂-, -NR'SO₂-, -CO-, -CO₂-, -CH₂-, -CF₂-, -CHF-, -CONH-, -CONR'-, and -NR'-, where R' is (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo; Al is (un)substituted aryl or heteroaryl; R0 and R0' = H and Me. R1, R2, R3, and R4 = H, hydroxy, and (un)substituted loweralkyl, cycloloweralkyl, cyclicaminoalkyl, alkylaminoalkyl, loweralkoxy, amino, alkylamino, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, aryl and heteroaryl. R5 and R8 = H, halo, and (un)substituted loweralkyl, cycloalkyl, alkoxy, amino, aminoalkoxy, carbonyloxy, aminocarbonyloxy, alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cycloimido, heterocycloimido, amidino, cycloamidino, heterocycloamidino, guanidinyl, aryl, biaryl, heteroaryl, heteroaralkyl, heteroaralkyl, heteroarylheteroaryl, heterocycloalkyl, heterocyclocarbonyloxy, heteroarylcarbonyloxy, and arylsulfonamido. R6 = H, and (un)substituted aryl, heteroaryl, and heterocyclo; R7 = H, hydroxy, halo, carboxy, nitro, amino, amido, amidino, imido, cyano, sulfonyl, methanesulfonyl, and (un)substituted alkyl, alkoxy, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, etc.; addnl. details are given in the claims. Although the methods of preparation are not claimed, example preps. and characterization data are included for hundreds of I. For example, II was prepared in 7 steps starting with esterification of (E)-3-(2,4-dichlorophenyl)-2-propenoic acid with tBuOH, followed by cyclization with p-tolylSO₂CH₂NC to give 4-(2,4-dichlorophenyl)pyrrole-3-carboxylic acid tert-Bu ester, followed by N-alkylation with 3-bromopropylphthalimide, followed by conversion of the phthalimide to the diamine with hydrazine, followed by N-substitution with (6-chloro-3-nitro-2-pyridyl)amine to give 1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)pyrrole-3-carboxylic acid tert-Bu ester, followed by acid hydrolysis and carboxamide formation with (2S)-(+)-2-aminopropan-1-ol to give II. Representative I have GSK3 inhibitory activity <10 μM (specific compds. not mentioned); they exhibit a selectivity of ≥2-fold for GSK3 as compared to another

Serial#: 10/675,927

kinase and more typically they exhibit a selectivity of ≥ 5 -fold. Compds. I were shown to be capable of significantly reducing the potential of glutamate to induce neuronal cell death. In the glucose tolerance test, representative I exhibited good in vitro potency, and when formulated in captisol and administered s.c. to mice (30 mg/kg), exhibited high bioavailability and tissue penetration in vivo. A significant reduction in basal hyperglycemia just prior to the glucose tolerance test, and significantly improved glucose disposal following glucose challenge were observed, comparable to the efficacy obtained with Troglitazone. Also of significance was the observation that insulin levels in treated animals remained lower than in control mice.

IC ICM C07D401-12
ICS C07D521-00; C07D405-14; C07D401-14; C07D453-02; C07D413-14;
C07D487-08; A61K031-4439; A61P003-10
CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 34, 63
OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L31 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:182836 HCAPLUS Full-text
DOCUMENT NUMBER: 140:235711
TITLE: Preparation of benzimidazole quinolinones for
inhibiting a serine/threonine kinase
INVENTOR(S): Barsanti, Paul A.; Bussiere, Dirksen; Harrison,
Stephen D.; Heise, Carla C.; Jansen, Johanna M.;
Jazan, Elisa; Machajewski, Timothy D.; McBride,
Christopher; McCrea, William R.; Ng, Simon; Ni,
Zhi-Jie; Pecchi, Sabina; Pfister, Keith;
Ramurthy, Savithri; Renhowe, Paul A.
; Shafer, Cynthia M.; Silver, Joel B.; Wagman, Allan;
Weismann, Marion
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 570 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018419	A2	20040304	WO 2003-US25990	20030819
WO 2004018419	A3	20040603		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2496164	A1	20040304	CA 2003-2496164	20030819
AU 2003288899	A1	20040311	AU 2003-288899	20030819
AU 2003288899	B2	20090903		
EP 1539754	A2	20050615	EP 2003-781286	20030819
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

Serial#: 10/675,927

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
BR 2003013743	A	20050705
CN 1692112	A	20051102
CN 100526312	C	20090812
JP 2006503919	T	20060202
IN 2005KN00484	A	20060106
AU 2009238373	A1	20091217
PRIORITY APPLN. INFO.:		
		US 2002-405729P P 20020823
		US 2002-426107P P 20021113
		US 2002-426226P P 20021113
		US 2002-426282P P 20021113
		US 2002-428210P P 20021121
		US 2003-460327P P 20030403
		US 2003-460328P P 20030403
		US 2003-460493P P 20030403
		US 2003-478916P P 20030616
		US 2003-484048P P 20030701
		US 2002-426204P P 20021113
		US 2003-460369P P 20030403
		WO 2003-US25990 W 20030819
		US 2003-517915P P 20031107
		AU 2003-290699 A3 20031112

OTHER SOURCE(S): MARPAT 140:235711
GI



AB The title compds. [I and II; A, B, C, and D = C, N; W, X, Y and Z = C, N and at least one of W, X, Y, and Z = N; R1-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or NR9R10 = 5-7 membered ring], useful for inhibiting various enzymes and treating various conditions, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10 μ M with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1 α , Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFR α , and PDGFR β . In

Serial#: 10/675,927

addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFR α , and PDGFR β with IC50 values of less than 1 μ M.

IC ICM C07D

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L31 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:183993 HCAPLUS [Full-text](#)

TITLE: Antidiabetic glycogen synthase kinase 3 inhibitors: In vitro and in vivo activity

AUTHOR(S): Wagman, Allan S.; Harrison, Stephen D.; Johnson, Kirk; Ring, David B.; Bussiere, Dirksen E.; Nuss, John M.; Pfister, K. B.; Goff, Dane; Boyce, Rustum S.; Ramurthy, Savithry; Brown, Sean P.; Renhowe, Paul A.; Subramanian, Sharadha; Zhou, Xiaohui A.

CORPORATE SOURCE: Small Molecule Drug Discovery, Chiron Corporation, Emeryville, CA, 94608-2916, USA

SOURCE: Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003 (2003), MEDI-022. American Chemical Society: Washington, D. C.

CODEN: 69DSA4

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB Glycogen synthase kinase 3 (GSK3) has been proposed to neg. regulate various aspects of insulin signaling. We have generated novel, highly selective, ATP-competitive GSK3 inhibitors and used them to test whether reducing GSK3 activity is sufficient to potentiate insulin action. These small mol. weight inhibitors activate glycogen synthase in a variety of cultured cells and enhance insulin-stimulated glucose transport in skeletal muscles from diabetic rats. Single oral doses of inhibitors lower hyperglycemia and improve glucose disposal following a glucose challenge in diabetic rodents, without causing hypoglycemia or elevating insulin. These results suggest that selective GSK3 inhibitors may be useful in the treatment of type 2 diabetes.

L31 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:42265 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:106699

TITLE: Preparation of (indazolyl)benzimidazoles and analogs as tyrosine and serine/threonine kinase inhibitors

INVENTOR(S): Renhowe, Paul A.; Shafer, Cynthia M.; McBride, Chris; Silver, Joel; Pecchi, Sabina; Machajewski, Tim; Mccrea, Bill; Poon, Daniel; Thomas, Teresa

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 435 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Serial#: 10/675,927

WO 2003004488	A1	20030116	WO 2002-US20844	20020702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002354727	A1	20030121	AU 2002-354727	20020702
EP 1401831	A1	20040331	EP 2002-752132	20020702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004536113	T	20041202	JP 2003-510655	20020702
JP 2010018616	A	20100128	JP 2009-186787	20090811
PRIORITY APPLN. INFO.:			US 2001-302791P	P 20010703
			JP 2003-510655	A3 20020702
			WO 2002-US20844	W 20020702

OTHER SOURCE(S): MARPAT 138:106699
GI



I

AB Title compds. I [wherein Z1-Z4 = C independently C or N; R1 = H, F, Cl, or Br; R2 = H, F, Cl, Br, CN, NO2, or (un)substituted CO2H, NH2, CONH2, NHCONH2, etc.; R3 = H, F, Cl, Br, or (un)substituted alkoxy; R4, R9, and R10 = H; R5 and R8 = independently H, F, Cl, or (un)substituted alkyl, alkoxy, NH2, heterocyclyl, etc.; R6 and R7 = independently H, F, Cl, Br, CF3, CO2H, or (un)substituted alkyl, (heterocyclyl)alkoxy, arylalkoxy, alkoxyalkoxy, (heterocyclyl)heterocyclyl, arylheterocyclyl, heterocycliloxy, aryloxy, NH2, CONH2, etc.; or R5 is absent if Z1 = N; or R6 is absent if Z2 = N; or R7 is absent if Z3 = N; or R8 is absent if Z4 = N; with the proviso that at least one of R1, R2, R3, R5, R6, R7, or R8 ≠ H; and tautomers and pharmaceutically acceptable salts thereof] were prepared as tyrosine and serine/threonine kinase inhibitors. For example, dimerization of indazole-3-carboxylic acid with P03 followed by addition of 1,2-phenylenediamine in toluene gave 3-(1H-benzimidazol-2-yl)-1H-indazole. Seven hundred twenty-eight exemplary compds. were assayed for serine/threonine kinase activity in vitro, and the majority displayed an IC50 value of less than 10 μM with respect to VEGFR1, Flk-1, bFGF, Tie-2, CHK-1, cdc2, GSK-3, NEK-2, and PDGF.

IC ICM C07D403-04
ICS C07D471-04; C07D487-08; C07D473-00; C07D401-14; C07D403-14;
C07D491-04; A61K031-4184; A61P005-50; A61P025-00; A61P025-16;
A61P037-02

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Serial#: 10/675,927

Section cross-reference(s): 1

OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS
RECORD (17 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:814853 HCAPLUS Full-text

DOCUMENT NUMBER: 137:325431

TITLE: Preparation of aminopyrimidines and -pyridines as

glycogen synthase kinase 3 inhibitors

INVENTOR(S): Nuss, John M.; Harrison, Stephen D.; Ring, David B.;

Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.;

Pamurthy, Savithri; Seely, Lynn; Wagman, Allan

S.; Desai, Manjo; Levane, Barry H.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 134 pp., Cont.-in-part of U.S.

6,417,185.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020156087	A1	20021024	US 2001-949035	20010906
US 7045519	B2	20060516		
US 6417185	B1	20020709	US 1999-336038	19990618
US 20030130289	A1	20030710	US 2002-309535	20021203
US 7037918	B2	20060502		
US 20060089369	A1	20060427	US 2005-220400	20050906
US 7425557	B2	20080916		

PRIORITY APPLN. INFO.: US 1998-89978P P 19980619
US 1999-336038 A2 19990618
US 2000-230480P P 20000906
US 1999-336098 A3 19990618
US 2001-949035 A3 20010906

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:325431

GI



Serial#: 10/675,927

AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidiny, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidiny, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acetylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHC2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3 β in a cell free assay with IC50 values of < 1 μ M. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).

IC ICM A61K031-513

ICS A61K031-505; A61K031-506; A61K031-444; C07D043-02; C07D213-63; C07D239-02

INCL 514256000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 306 THERE ARE 306 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2010 ACS on SIN

ACCESSION NUMBER: 2002:185092 HCAPLUS Full-text

DOCUMENT NUMBER: 136:247598

TITLE: Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors

INVENTOR(S): Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manoj; Levine, Barry H.

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020495	A2	20020314	WO 2001-US42081	20010906
WO 2002020495	A3	20020620		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,			

Serial#: 10/675,927


DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001095026	A	20020322	AU 2001-95026	20010906
EP 1317433	A2	20030611	EP 2001-975734	20010906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004514656	T	20040520	JP 2002-525117	20010906
CN 1592743	A	20050309	CN 2001-818425	20010906
CN 100506801	C	20090701		
AU 2001295026	B2	20080403	AU 2001-295026	20010906
IN 2003KN00277	A	20050311	IN 2003-KN277	20030305
KR 816769	B1	20080326	KR 2003-703327	20030306
KR 2008013026	A	20080212	KR 2008-701887	20080124
KR 860827	B1	20080930		

PRIORITY APPLN. INFO.:


US 2000-230480P	P 20000906
WO 2001-US42081	W 20010906
KR 2003-703327	A3 20030306

OTHER SOURCE(S): MARPAT 136:247598

GI



I



II

AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidiny, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidiny, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acetylated by benzotriazolecaboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3 β in a cell free assay with IC50 values of < 1 μ M. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).


Serial#: 10/675,927

IC ICM C07D239-42
 ICS C07D401-12; C07D405-12; C07D403-12; C07D405-14; C07D413-14;
 C07D401-14; C07D213-85; C07D213-75; C07D213-74; C07D213-80;
 A61K031-505; A61P025-28
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS
 RECORD (18 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:811233 HCAPLUS Full-text
 DOCUMENT NUMBER: 132:64265
 TITLE: Preparation of aminopyrimidines and -pyridines as
 glycogen synthase kinase 3 inhibitors
 INVENTOR(S): Nuss, John M.; Harrison, Stephen D.; Ring, David B.;
 Boyce, Rustum S.; Brown, Sean P.; Goff, Dane; Johnson,
 Kirk; Pfister, Keith B.; Ramurthy, Savithry;
 Renhowe, Paul A.; Seely, Lynn;
 Subramanian, Sberadha; Wagman, Allan S.; Zhou,
 Xiaohui A.
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 262 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965897	A1	19991223	WO 1999-US13809	19990618
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9949566	A	20000105	AU 1999-49566	19990618
EP 1087963	A1	20010404	EP 1999-933522	19990618
EP 1087963	B1	20040825		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6489344	B1	20021203	US 1999-336098	19990618
JP 2003527303	T	20030916	JP 2000-554722	19990618
AT 274510	T	20040915	AT 1999-933522	19990618
IN 2000KN00609	A	20050311	IN 2000-KN609	20001207
US 20030130289	A1	20030710	US 2002-309535	20021203
US 7037918	B2	20060502		
PRIORITY APPLN. INFO.:			US 1998-89978P	P 19980619
			US 1999-336098	A3 19990618
			WO 1999-US13809	W 19990618

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 132:64265
 GI



II

AB RZCR2R12CR3R13Z1R5 [I; R = (un)substituted (hetero)aryl; Z = O, NR1, CR1R11; Z1 = O, NR4, CR4R14; R1-R4 = H, OH, NH2, alkyl, alkoxy, etc.; R5 = (un)substituted 2-pyridyl or -pyrimidyl; R11-R14 = H or alkyl] were prepared. Thus, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine which was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to give, after resin cleavage, title compound II. Data for biol. activity of I were given.

IC ICM C07D401-12
ICS C07D403-12; C07D239-48; C07D401-14; C07D405-14; C07D409-14;
C07D417-12; C07D213-74; A61K031-44; A61K031-505

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:218872 HCAPLUS Full-text

DOCUMENT NUMBER: 126:293272

ORIGINAL REFERENCE NO.: 126:56793a,56796a

TITLE: Developing a general strategy for the solid supported synthesis of heterocycles: applications to the generation of molecular diversity and drug discovery

AUTHOR(S): Nuss, John M.; Desai, Manoj C.; Zuckermann, Ronald N.; Singh, Rajinder; Renhove, Paul A.; Goff, Dane A.; Chinn, Jason P.; Wang, Liang; Dorr, Hilary; Brown, Edward G.; Subramanian, Shradha

CORPORATE SOURCE: Chiron Corp., Emeryville, CA, 94608, USA

SOURCE: Pure and Applied Chemistry (1997), 69(3), 447-452

CODEN: PACHAS; ISSN: 0033-4545

PUBLISHER: Blackwell

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB The development of a general strategy for the generation of mol. diversity in the form of novel, non-amide based heterocyclic structures is described with 19 refs. The generation of diverse peptide and peptidomimetic libraries, the automation of these strategies and computational approaches to diversity generation are also discussed. The main focus of this lecture is the progression of these concepts into a strategy for small mol. library generation, and hence the generation of small mol. therapeutic leads.

CC 28-0 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 34

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

SEARCH HISTORY

```

FILE 'HCAPLUS' ENTERED AT 10:48:55 ON 13 APR 2010
E US2003-675927/APPS
L1      1 SEA SPE=ON  ABB=ON  PLU=ON  US2003-675927/APPS
        D SCAN
        SEL RN
L2      TRA PLU=ON  L1 1- RN :    1593 TERMS

FILE 'REGISTRY' ENTERED AT 11:00:13 ON 13 APR 2010
L3      1593 SEA SPE=ON  ABB=ON  PLU=ON  L2
L4      STRUCTURE UPLOADED
        D
L5      50 SEA SSS SAM L4
L6      0 SEA SPE=ON  ABB=ON  PLU=ON  L3 AND L5
L7      5908 SEA SSS FUL L4
L8      1277 SEA SPE=ON  ABB=ON  PLU=ON  L3 AND L7
L9      STRUCTURE UPLOADED
        D
L10     50 SEA SUB=L7 SSS SAM L9
L11     STRUCTURE UPLOADED
        D
L12     50 SEA SUB=L7 SSS SAM L11
L13     1382 SEA SUB=L7 SSS FUL L11

FILE 'HCAPLUS' ENTERED AT 11:26:34 ON 13 APR 2010
L14     33 SEA SPE=ON  ABB=ON  PLU=ON  L13
L15     32 SEA SPE=ON  ABB=ON  PLU=ON  AMIRI P?/AU
L16     40 SEA SPE=ON  ABB=ON  PLU=ON  FANTL W?/AU
L17     1048 SEA SPE=ON  ABB=ON  PLU=ON  LEVINE B?/AU
L18     88 SEA SPE=ON  ABB=ON  PLU=ON  POON D?/AU
L19     26 SEA SPE=ON  ABB=ON  PLU=ON  RAMURTHY S?/AU
L20     42 SEA SPE=ON  ABB=ON  PLU=ON  RENHOWE P?/AU
L21     1408 SEA SPE=ON  ABB=ON  PLU=ON  SUBRAMANIAN S?/AU
L22     286 SEA SPE=ON  ABB=ON  PLU=ON  SUNG L?/AU
L23     5 SEA SPE=ON  ABB=ON  PLU=ON  L15 AND ((L16 OR L17 OR L18 OR L19
        OR L20 OR L21 OR L22))
L24     3 SEA SPE=ON  ABB=ON  PLU=ON  L16 AND ((L17 OR L18 OR L19 OR L20
        OR L21 OR L22))
L25     7 SEA SPE=ON  ABB=ON  PLU=ON  L17 AND ((L18 OR L19 OR L20 OR L21
        OR L22))
L26     8 SEA SPE=ON  ABB=ON  PLU=ON  L18 AND ((L19 OR L20 OR L21 OR
        L22))
L27     15 SEA SPE=ON  ABB=ON  PLU=ON  L19 AND ((L20 OR L21 OR L22))
L28     9 SEA SPE=ON  ABB=ON  PLU=ON  L20 AND ((L21 OR L22))
L29     3 SEA SPE=ON  ABB=ON  PLU=ON  L21 AND L22
L30     23 SEA SPE=ON  ABB=ON  PLU=ON  (L23 OR L24 OR L25 OR L26 OR L27
        OR L28 OR L29)
L31     20 SEA SPE=ON  ABB=ON  PLU=ON  L30 NOT L14

FILE 'REGISTRY' ENTERED AT 13:21:10 ON 13 APR 2010

FILE 'HCAPLUS' ENTERED AT 13:21:13 ON 13 APR 2010
        D STAT QUE L14
        D L14 IBIB ABS HITSTR 1-33


FILE 'HCAPLUS' ENTERED AT 13:23:59 ON 13 APR 2010
        D STAT QUE L31
        D L31 IBIB ABS HITIND HITSTR 1-20

```

Serial#: 10/675,927

=>

Uploading LL4.str



```
chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 8-10
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 5-11 7-8 8-9 8-10
```

G1:O,S

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS
```

Uploading LL11.str

Serial#: 10/675,927



```

chain nodes :
10 11 13 14
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
15
chain bonds :
5-11 8-10 10-13 11-14 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 5-11 7-8 8-9 8-10 10-13 11-14 14-15

```

G1:O,S

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:Atom 14:Atom 15:CLASS

```